
<html lang="en"     class="pb-page"  data-request-id="6b93ecff-b767-4853-b0cc-6d656c52f7a8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2013.56.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/jm301650g;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluations of Novel 7-[7-Amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens(1)" /></meta><meta name="dc.Creator" content="Takashi  Odagiri" /></meta><meta name="dc.Creator" content="Hiroaki  Inagaki" /></meta><meta name="dc.Creator" content="Yuichi  Sugimoto" /></meta><meta name="dc.Creator" content="Masatoshi  Nagamochi" /></meta><meta name="dc.Creator" content="Rie N.  Miyauchi" /></meta><meta name="dc.Creator" content="Junichi  Kuroyanagi" /></meta><meta name="dc.Creator" content="Takahiro  Kitamura" /></meta><meta name="dc.Creator" content="Satoshi  Komoriya" /></meta><meta name="dc.Creator" content="Hisashi  Takahashi" /></meta><meta name="dc.Description" content="Novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]- 8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid 2a and 2b were designed and synthesized to obt..." /></meta><meta name="Description" content="Novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]- 8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid 2a and 2b were designed and synthesized to obt..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 25, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301650g" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301650g" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301650g" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301650g" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluations of Novel 7-[7-Amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301650g" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluations of Novel 7-[7-Amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens(1)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0011.jpeg" /></meta><meta property="og:description" content="Novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]- 8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid 2a and 2b were designed and synthesized to obtain potent antibacterial drugs for the treatment of respiratory tract infections. Among these, compound 2a possessing (S)-configuration for the asymmetrical carbon on the pyrolidine moiety at the C-7 position of the quinolone scaffold exhibited potent in vitro antibacterial activity against respiratory pathogens including Gram-positive (Streptococcus pneumoniae and Staphylococcus aureus), Gram-negative (Haemophilus influenzae and Moraxcella catarrhalis), and atypical strains (Chalmydia pneumoniae and Mycoplasma pneumoniae), as well as multidrug-resistant Streptococcus pneumoniae and quinolone-resistant and methicillin-resistant Staphylococcus aureus). Furthermore, compound 2a showed excellent in vivo activity against the experimental murine pneumonia model due to multidrug resistant Streptococcus pneumoniae (MDRSP) and favorable profiles in preliminary toxicological and nonclinical pharmacokinetic studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301650g"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301650g">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301650g&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301650g&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301650g&amp;href=/doi/10.1021/jm301650g" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1974-1983</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301647t" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301652t" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluations of Novel 7-[7-Amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takashi++Odagiri">Takashi Odagiri</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroaki++Inagaki">Hiroaki Inagaki</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuichi++Sugimoto">Yuichi Sugimoto</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masatoshi++Nagamochi">Masatoshi Nagamochi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rie+N.++Miyauchi">Rie N. Miyauchi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Junichi++Kuroyanagi">Junichi Kuroyanagi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takahiro++Kitamura">Takahiro Kitamura</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Satoshi++Komoriya">Satoshi Komoriya</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hisashi++Takahashi">Hisashi Takahashi</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div><div class="corresp-info"><strong>*</strong>Phone: +81-3-3492-3131. Fax; +81-3-5436-8563. E-mail: <a href="/cdn-cgi/l/email-protection#87e8e3e6e0eef5eea9f3e6ece6f4efeea9e1e5c7e3e6eeeee4efeef4e6e9ecfee8a9e4e8a9edf7"><span class="__cf_email__" data-cfemail="bfd0dbded8d6cdd691cbded4deccd7d691d9ddffdbded6d6dcd7d6ccded1d4c6d091dcd091d5cf">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301650g&amp;href=/doi/10.1021%2Fjm301650g" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1974–1983</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 14, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 November 2012</li><li><span class="item_label"><b>Published</b> online</span>25 February 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301650g" title="DOI URL">https://doi.org/10.1021/jm301650g</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1974%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTakashi%2BOdagiri%252C%2BHiroaki%2BInagaki%252C%2BYuichi%2BSugimoto%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D5%26contentID%3Djm301650g%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluations%2Bof%2BNovel%2B7-%255B7-Amino-7-methyl-5-azaspiro%255B2.4%255Dheptan-5-yl%255D-8-methoxyquinolines%2Bwith%2BPotent%2BAntibacterial%2BActivity%2Bagainst%2BRespiratory%2BPathogens%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1983%26publicationDate%3DMarch%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301650g"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1920</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301650g" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluations of Novel 7-[7-Amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Takashi&quot;,&quot;last_name&quot;:&quot;Odagiri&quot;},{&quot;first_name&quot;:&quot;Hiroaki&quot;,&quot;last_name&quot;:&quot;Inagaki&quot;},{&quot;first_name&quot;:&quot;Yuichi&quot;,&quot;last_name&quot;:&quot;Sugimoto&quot;},{&quot;first_name&quot;:&quot;Masatoshi&quot;,&quot;last_name&quot;:&quot;Nagamochi&quot;},{&quot;first_name&quot;:&quot;Rie&quot;,&quot;last_name&quot;:&quot;N. Miyauchi&quot;},{&quot;first_name&quot;:&quot;Junichi&quot;,&quot;last_name&quot;:&quot;Kuroyanagi&quot;},{&quot;first_name&quot;:&quot;Takahiro&quot;,&quot;last_name&quot;:&quot;Kitamura&quot;},{&quot;first_name&quot;:&quot;Satoshi&quot;,&quot;last_name&quot;:&quot;Komoriya&quot;},{&quot;first_name&quot;:&quot;Hisashi&quot;,&quot;last_name&quot;:&quot;Takahashi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;1974-1983&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301650g&quot;},&quot;abstract&quot;:&quot;Novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]- 8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid 2a and 2b were designed and synthesized to obtain potent antibacterial drugs for the treatment of respiratory tract infections. Among these, compound 2a possessing (S)-configuration for the asymmetrical carbon on the pyrolidine moiety at the C-7 position of the quinolone scaffold exhibited potent in vitro antibacterial activity against respiratory pathogens including Gram-positive (Streptococcus pneumoniae and Staphylococcus aureus), Gram-negative (Haemophilus influenzae and Moraxcella catarrhalis), and atypical strains (Chalmydia pneumoniae and Mycoplasma pneumoniae), as well as multidrug-resistant Streptococcus pneumoniae and quinolone-resistant and methicillin-resistant Staphylococcus aureus). Furthermore, compound 2a showed excellent in vivo activity against the experimental murine pneumonia model due to multidrug resistant Streptococcus pneumoniae (MDRSP) &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301650g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301650g" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301650g&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301650g" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301650g&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301650g" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301650g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301650g&amp;href=/doi/10.1021/jm301650g" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301650g" /></input><a href="/doi/pdf/10.1021/jm301650g" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (818 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301650g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301650g%26sid%3Dliteratum%253Aachs%26pmid%3D23409972%26genre%3Darticle%26aulast%3DOdagiri%26date%3D2013%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluations%2Bof%2BNovel%2B7-%255B7-Amino-7-methyl-5-azaspiro%255B2.4%255Dheptan-5-yl%255D-8-methoxyquinolines%2Bwith%2BPotent%2BAntibacterial%2BActivity%2Bagainst%2BRespiratory%2BPathogens%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D5%26spage%3D1974%26epage%3D1983%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290723" title="Solutions">Solutions</a>,</li><li><a href="/action/doSearch?ConceptID=290860" title="Solution chemistry">Solution chemistry</a>,</li><li><a href="/action/doSearch?ConceptID=291214" title="Bacteria">Bacteria</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jmcmar.2013.56.issue-5/production/jmcmar.2013.56.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0011.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1<i>R</i>,2<i>S</i>)-2-fluorocyclopropyl]- 8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid <b>2a</b> and <b>2b</b> were designed and synthesized to obtain potent antibacterial drugs for the treatment of respiratory tract infections. Among these, compound <b>2a</b> possessing (<i>S</i>)-configuration for the asymmetrical carbon on the pyrolidine moiety at the C-7 position of the quinolone scaffold exhibited potent in vitro antibacterial activity against respiratory pathogens including Gram-positive (<i>Streptococcus pneumoniae</i> and <i>Staphylococcus aureus</i>), Gram-negative (<i>Haemophilus influenzae</i> and <i>Moraxcella catarrhalis</i>), and atypical strains (<i>Chalmydia pneumoniae</i> and <i>Mycoplasma pneumoniae</i>), as well as multidrug-resistant <i>Streptococcus pneumoniae</i> and quinolone-resistant and methicillin-resistant <i>Staphylococcus aureus</i>). Furthermore, compound <b>2a</b> showed excellent in vivo activity against the experimental murine pneumonia model due to multidrug resistant <i>Streptococcus pneumoniae</i> (MDRSP) and favorable profiles in preliminary toxicological and nonclinical pharmacokinetic studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As community-acquired pathogens are exhibiting increasing levels of resistance to β-lactams and macrolides, newer quinolones have emerged as one of the first-line antibacterial drugs for respiratory tract infections in the medical community. Meanwhile, multidrug-resistant <i>Streptococcus pneumoniae</i> (MDRSP) and community-acquired methicillin-resistant <i>Staphylococcus aureus</i> (CA-MRSA) are emerging as key pathogens in community-acquired respiratory infections.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Fluoroquinolones such as levofloxacin (LVFX), gatifloxacin (GFLX), and moxifloxacin (MFLX) are beneficial for the empirical treatment of respiratory infections in the community because of their extended antibacterial spectra, including atypical pathogens, with preferable pharmacokinetic (PK) and safety profiles;<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> however, the antibacterial activity of these newer quinolones are not potent enough, and bacteria resistance such as quinolone-resistant <i>S. pneumoniae</i> and CA-MRSA to these drugs will be problematic in the near future.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> On the other hand, clinical adverse events (e.g., torsades de pointes, or fatal liver injury) by some quinolones have been reported.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Thus, the new respiratory quinolone providing both improved activity against respiratory pathogens including MDRSP and a good safety profile is keenly required.</div><div class="NLM_p">As previously reported,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> compound <b>1</b> showed potent activity against respiratory pathogens including penicillin-resistant <i>S. pneumoniae</i> (PRSP), together with a superior safety profile similar to levofloxacin (LVFX). However, the results of the in vitro metabolic study revealed that compound <b>1</b> exerted mechanism-based inhibition (MBI) of cytochrome (CYP) 3A4. CYP3A4 is the most abundant CYP isozyme that accepts a great number of medicines as substrates. Although beneficial combination therapy utilizing CYP3A4 inhibition has been reported, clinical drug–drug interaction (DDI) due to CYP3A4 inhibition often resulted in serious adverse events.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Therefore, we judged compound <b>1</b> to be inappropriate as a new candidate for further development.</div><div class="NLM_p">To solve the MBI problem, we focused on the chemical structure at the C-7 pyrrolidine substituent of compound <b>1</b>. According to the report by Silverman,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> the chemical structure like the cyclopropylmethylamine unit may have a risk to inactivate the enzyme monoamine oxidase (MAO) and the inactivation begins with the formation of iminium intermediate. That is to say, the conversion to the structure that cannot form an iminium intermediate may prevent the exertion of MBI. On the other hand, trovafloxacin is reported to show numerous cases of hepatotoxicity, which limits its clinical usefulness. It possesses two substructural elements that have the potential to generate reactive intermediates: a cyclopropylamine moiety and a difluoroanilino system. Evidence has been reported that trovafloxacin-induced hepatotoxicity may be mediated through oxidation of the cyclopropylamine substructure to reactive intermediates that may form covalent adducts to hepatic proteins, resulting in damage to liver tissue.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Therefore, we planned to introduce a methyl group onto the carbon atom at the root of the C7-amino moiety of compound <b>1</b>, thereby aiming to avoid the formation of the reactive intermediate.</div><div class="NLM_p">In this article, we describe the details of the synthesis, in vitro and in vivo antibacterial activities, safety profile, and pharmacokinetic profile of the designed compound <b>2a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86641" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86641" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, we envisioned synthesizing the desired 7-substituted 8-methoxyquinolone derivative <b>2a</b> by aromatic nucleophilic substitution reaction from amine <b>3a</b> and 6,7-difluoro-1-[(1<i>R</i>,2<i>S</i>)-2-fluorocyclopropan-1-yl]-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid BF<sub>2</sub> chelate (<b>4</b>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">The synthesis of <b>2</b> is illustrated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Amine <span class="smallcaps smallerCapital">dl</span>-<b>6</b> was prepared by the Strecker reaction of <b>5</b>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Hydrogenation with Raney Ni and the removal of the <i>tert</i>-butyl group under an acidic condition gave diaminocarboxylic acid <span class="smallcaps smallerCapital">dl</span>-<b>7</b>. Whne <span class="smallcaps smallerCapital">dl</span>-<b>7</b> was heated with 1,1,1,3,3,3-hexamethyldisilazane in acetonitrile (MeCN), the desired cyclization was accomplished. The remaining amino moiety was protected by di-<i>tert</i>-butyl dicarbonate (Boc<sub>2</sub>O) to provide lactam <span class="smallcaps smallerCapital">dl</span>-<b>8</b>. Treatment of <span class="smallcaps smallerCapital">dl</span>-<b>8</b> with sodium hydride (NaH) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) followed by a reaction with benzyl bromide (BnBr) provided benzylamide <span class="smallcaps smallerCapital">dl</span>-<b>9</b>. This racemic <b>9</b> was separated into the two enantiomers (+)-<b>9</b> and (−)-<b>9</b> by column chromatography with Chiralpak AD. After the temporary removal of <i>tert</i>-butoxycarbonyl groups of (+)-<b>9</b> and (−)-<b>9</b>, the amide moieties were reduced by lithium aluminum hydride (LiAlH<sub>4</sub>). Then the primary amino groups were protected again by Boc<sub>2</sub>O to give benzylamines (+)-<b>10</b> and (−)-<b>10</b>. The benzyl groups were removed by catalytic hydrogenolysis. The resultant crudes and quinolonecarboxylic acid BF<sub>2</sub> chelate <b>4</b> were heated with triethylamine in dimethyl sulfoxide (DMSO), followed by dechelation and deprotection to give compounds <b>2a</b> and <b>2b</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaCN, NH<sub>3</sub> aq, NH<sub>4</sub>Cl, NH<sub>3</sub>/MeOH; (b) H<sub>2</sub>, Raney Ni/EtOH; (c) concentrated aqueous HCl; (d) 1,1,1,3,3,3-hexamethyldisilazane/MeCN; (e) Boc<sub>2</sub>O/1.4-dioxane; (f) BnBr, NaH/DMF; (g) Chiralpak AD; (h) TFA/CH<sub>2</sub>Cl<sub>2</sub>; (i) LiAlH<sub>4</sub>/THF; (j) Boc<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub>; (k) H<sub>2</sub>, Pd–C/MeOH; (l) <b>4</b>, Et<sub>3</sub>N/DMSO; (m) Et<sub>3</sub>N/80% aqueous EtOH; (n) concentrated aqueous HCl.</p></p></figure><div class="NLM_p">The absolute configurations of <b>2a</b> and <b>2b</b> were determined by an alternative synthesis (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Alkylation of compound <b>11</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> which was synthesized from (<i>R</i>)-phenylethylamine, with use of lithium hexamethyldisilazide (LHMDS), followed by the treatment with tetrabutylammonium fluoride (TBAF) provided alcohol <b>13</b> as a diastereomixture. After the conversion of the primary alcohol of <b>13</b> to the benzenesulfonyloxy group, the cyclization was performed by treatment with sodium hexamethyldisilazide (NaHMDS). Compound <b>14</b> was obtained as prisms, and the absolute configuration was determined to be 7<i>S</i> by X-ray crystallographic analysis (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Phenylethylamine <b>16</b> was prepared by multistep reactions (removal of <i>tert</i>-butyl ester, Curtius rearrangement, acidic hydrolysis, reduction with sodium bis(2-methoxyethoxy)aluminum hydride, and formation of <i>tert</i>-butyl carbamate). After the phenylethyl group of <b>16</b> was removed by catalytic hydrogenolysis, the resultant secondary amine was reacted with BF<sub>2</sub> chelate <b>4</b> followed by the above-mentioned method to give the target compound <b>2</b>. The analytical data of <b>2</b> corresponded with those of <b>2a</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) LiHMDS/THF; (b) TBAF/THF; (c) PhSO<sub>2</sub>Cl, Et<sub>3</sub>N, DMAP/CH<sub>2</sub>Cl<sub>2</sub>; (d) NaHMDS/THF; (e) TFA/CH<sub>2</sub>Cl<sub>2</sub>; (f) diphenylphosphoryl azide, Et<sub>3</sub>N/toluene; (g) 6 N aqueous HCl/1,4-dioxane; (h) sodium bis(2-methoxyethoxy)aluminum hydride/toluene; (i) Boc<sub>2</sub>O/toluene; (j) H<sub>2</sub>, Pd–C/MeOH; (k) <b>4</b>, Et<sub>3</sub>N/DMSO; (l) Et<sub>3</sub>N/80% aqueous EtOH; (m) concentrated aqueous HCl.</p></p></figure><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The minimum inhibitory concentrations (MICs) of <b>2a</b> and <b>2b</b> against several representative Gram-positive and Gram-negative bacteria are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, along with the data for levofloxacin, moxifloxacin, ciprofloxacin, and the previously reported compound <b>1</b> for comparison. The synthesized compounds <b>2a</b> and <b>2b</b> exhibited a broad antibacterial spectrum against Gram-positive and Gram-negative bacteria. A novel quinolone <b>2a</b>, which has the (7<i>S</i>)-amino group of the C-7 substituent, exhibited about 4 to >16 times better activity against Gram-positive bacteria compared with the activity of LVFX, although activities of <b>2a</b> against some bacteria were slightly inferior to those of <b>1</b>. Particularly, <b>2a</b> was more potent than an existing respiratory quinolone, moxifloxacin, against MDRSP and levofloxacin-resistant MRSA strains. Against Gram-negative bacteria except <i>Pseudomonas aeruginosa</i>, the activity of <b>2a</b> was comparable to those of other quinolones tested. For example, <b>2a</b> showed potent activities against <i>Haemophilus influenzae</i> and <i>Moraxcella catarrhalis</i>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antibacterial Activities MIC (μg/mL) of Compounds <b>2a</b> and <b>2b</b> and Reference Quinolones against Gram-Positive and Gram-Negative Bacteria<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">compd</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">organism</th><th class="colsep0 rowsep0" align="center" char="."><b>2a</b></th><th class="colsep0 rowsep0" align="center" char="."><b>2b</b></th><th class="colsep0 rowsep0" align="center" char=".">LVFX</th><th class="colsep0 rowsep0" align="center" char=".">CPFX</th><th class="colsep0 rowsep0" align="center" char=".">MFLX</th><th class="colsep0 rowsep0" align="center" char="."><b>1</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. aureus</i> FDA 209-P</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. aureus</i> 870307<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">1.56</td><td class="colsep0 rowsep0" align="char" char=".">>6.25</td><td class="colsep0 rowsep0" align="char" char=".">>6.25</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. epidermidis</i> 56500</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. pneumoniae</i> J24<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. pneumoniae</i> 104835<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>6.25</td><td class="colsep0 rowsep0" align="char" char=".">>6.25</td><td class="colsep0 rowsep0" align="char" char=".">3.13</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>S. pyogenes</i> G-36</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">1.56</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>E. faecalis</i> ATCC 19433</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>B. subtilis</i> IID 685</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">1.56</td><td class="colsep0 rowsep0" align="char" char=".">3.12</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>E. coli</i> NIHJ</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char="."><0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K. pneumoniae</i> TYPE 1</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>H. influenzae</i> ATCC49247</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char="."><0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>M(B). catarrhalis</i> ATCC25238</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>P. aeruginosa</i> PAO-1</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Antibacterial activities were determined using a standard microbroth dilution method. Abbreviations are as follows: LVFX, levofloxacin; CPFX, ciprofloxacin; MFLX, moxifloxacin.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Levofloxacin-resistant and methicillin-resistant <i>S. aureus</i> (levofloxacin-r-MRSA).</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Penicillin-susceptible <i>S. pneumoniae</i> (PSSP).</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Multidrug-resistant <i>S. pneumoniae</i> (MDRSP, quinolone-resistant and penicillin-resistant strains).</p></div></div></div><div class="NLM_p">Next, the activity of <b>2a</b> and representative respiratory quinolones against atypical organisms are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. A newer quinolone <b>2a</b> exhibited potent antibacterial activity against <i>Mycoplasma pneumoniae</i> and <i>Chlamydophilia pneumoniae</i> strains. The activity of <b>2a</b> was comparable with those of moxifloxacin and gemifloxacin and was 4–10 times higher than that of levofloxacin.</div><div class="NLM_p">Finally, the MICs against clinically isolated levofloxacin-intermediate and -resistant <i>Streptococcus pneumoniae</i> of compound <b>2a</b> and reference antibacterial agents are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Compound <b>2a</b> showed more potent activity than the other quinolone antibacterial agents (levofloxacin, ciprofloxacin, or moxifloxacin) and the other categories of drugs (azythromycin, clarithromycin, or amoxicillin) that were used generally in the clinic as antibacterials for the treatment of respiratory tract infections. The MIC<sub>90</sub> of <b>2a</b> was 1 μg/mL, equal to that of garenoxacin. Thus, <b>2a</b> exhibited potent and well balanced antibacterial activity against representative respiratory pathogens, including atypical strains and MDRSP.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antibacterial Activities MIC (μg/mL) of <b>2a</b> and Reference Quinolones against Atypical Organisms <i>Mycoplasma pneumoniae</i> and <i>Chlamydophilia pneumoniae</i><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">compd</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">organism</th><th class="colsep0 rowsep0" align="center" char="."><b>2a</b></th><th class="colsep0 rowsep0" align="center" char=".">LVFX</th><th class="colsep0 rowsep0" align="center" char=".">MFLX</th><th class="colsep0 rowsep0" align="center" char=".">GRNX</th><th class="colsep0 rowsep0" align="center" char=".">GMFX</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>M. pneumoniae</i> 18-1</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>M. pneumoniae</i> ATCC 29085</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C. pneumoniae</i> AR-39</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td><td class="colsep0 rowsep0" align="char" char=".">0.063</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C. pneumoniae</i> CM-1</td><td class="colsep0 rowsep0" align="char" char=".">0.063</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.063</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Antibacterial activities of <i>M. pneumoniae</i> and <i>C. pneumoniae</i> strains were determined using a standard microbroth dilution method and standard recommended techniques, respectively. Abbreviations are as follows: LVFX, levofloxacin; MFLX, moxifloxacin; GRNX, garenoxacin; GMFX, gemifloxacin.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antibacterial Activities MIC (μg/mL) of <b>2a</b> and Reference Drugs against Clinical Isolates of Levofloxacin-Intermediate and -Resistant <i>Streptococcus pneumoniae</i><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">MIC (μg/mL)<a class="ref internalNav" href="#t3fn3" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">range</th><th class="colsep0 rowsep0" align="center">MIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">MIC<sub>80</sub></th><th class="colsep0 rowsep0" align="center">MIC<sub>90</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">Organism<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a> (No. of Strains): LVFX-Intermediate and -Resistant <i>S. pneumoniae</i> (14)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="left">0.25–2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LVFX</td><td class="colsep0 rowsep0" align="left">4–32</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CPFX</td><td class="colsep0 rowsep0" align="left">8–32</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MFLX</td><td class="colsep0 rowsep0" align="left">0.25–4</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GRNX</td><td class="colsep0 rowsep0" align="left">0.06–1</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZM</td><td class="colsep0 rowsep0" align="left">0.12 to >32</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAM</td><td class="colsep0 rowsep0" align="left">0.06 to >32</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>32</td><td class="colsep0 rowsep0" align="left">>32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMPC</td><td class="colsep0 rowsep0" align="left">0.03–4</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PCG</td><td class="colsep0 rowsep0" align="left">0.03–8</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Antibacterial Aactivities were determined using a standard microbroth dilution method. Abbreviations are as follows: LVFX, levofloxacin; CPFX, ciprofloxacin; MFLX, moxifloxacin; GRNX, garenoxacin; AZM, azythromycin; CAM, clarithromycin; AMPC, amoxicillin; PCG, benzylpenicillin.</p></div><div class="footnote" id="t3fn3"><sup>b</sup><p class="last">MIC<sub>50</sub> = MIC at which 50% of isolates are inhibited. MIC<sub>80</sub> = MIC at which 80% of isolates are inhibited. MIC<sub>90</sub> = MIC at which 90% of isolates are inhibited.</p></div><div class="footnote" id="t3fn2"><sup>c</sup><p class="last">The strains were collected by the Levofloxacin Surveillance Group from patients in Japan in 2004.</p></div></div></div><div class="NLM_p">The potential inhibitory effects of compounds <b>1</b> and <b>2a</b> on a mechanism-based inhibition (MBI) of CYP3A4 were investigated using the general procedure described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The results are illustrated in Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. Compound <b>1</b> inhibited the activity of CYP3A4 for 1′-hydroxylation of midazolam dose-dependently; however, <b>2a</b> did not show an inhibitory effect on the MBI of CYP3A4 over the range of concentrations tested. According to these experimental findings, introduction of the methyl group into the geminal position of the 7-amino group on the cyclopropylmethylamine system is effective to reduce the MBI potential. Meanwhile, compound <b>2a</b> did not exhibit any inhibitory effects on the enzymatic activities of other human CYP isoforms over the range of concentrations tested.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mechanism-based inhibition against CYP3A4 by <b>1</b>. Shown are effects of preincubation of CYP3A4 with <b>1</b> for 1′-hydroxylation of midazolam in pooled human liver microsomal system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanism-based inhibition against CYP3A4 by <b>2a</b>. Shown are effects of preincubation of CYP3A4 with <b>2a</b> for 1′-hydroxylation of midazolam in pooled human liver microsomal system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> shows effects on human ether-a-go-go-related gene (hERG) potassium current in hERG transfected CHO-K1 cells. Compounds that inhibit hERG potassium channels have been shown to prolong the QT interval of electrocardiogram in man and increase the risk of fatal cardiac arrhythmia.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b>2a</b> at a dose 30 and 100 μM had no effect on hERG currents. Comparative studies using other quinolones indicated a potential of <b>2a</b> for hERG current that is lower than those of moxifloxacin and compound <b>1</b>. The grade of compound <b>2a</b> was approximately equal to that of levofloxacin, which is known not to cause QT prolongation syndrome at clinical dosage.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effects on hERG Potassium Current in hERG Transfected CHO-K1 Cells<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">% inhibition</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">30 μM</th><th class="colsep0 rowsep0" align="center" char=".">100 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LVFX</td><td class="colsep0 rowsep0" align="char" char=".">–0.9</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MFLX</td><td class="colsep0 rowsep0" align="char" char=".">21.5</td><td class="colsep0 rowsep0" align="char" char=".">42.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">14.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Abbreviations are as follows: LVFX, levofloxacin; MFLX, moxifloxacin.</p></div></div></div><div class="NLM_p">The apparent partition coefficients (<i>P</i>′),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> the solubility to water,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and in vitro plasma protein binding ratios in human of <b>2a</b>, <b>1</b> (as free base substance), and levofloxacin are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Introduction of a methyl group into the geminal position of the 7-amino group on the C7-substituent significantly increased the <i>P</i>′ of parent compound <b>1</b>. The <i>P</i>′ of <b>2a</b> was 2 times higher than that of <b>1</b>, while the solubility in water of <b>2a</b> was slightly improved. On the other hand, the protein binding ratio of <b>2a</b> was almost the same as the value of levofloxacin.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Physicochemical Properties and in Vitro Protein Binding Ratios of <b>1</b>, <b>2a</b>, LVFX, and MFLX</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>2a</b></th><th class="colsep0 rowsep0" align="center"><b>1</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">LVFX<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">MFLX<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>P</i>′<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">19.2</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">53.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (μg/mL)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">620</td><td class="colsep0 rowsep0" align="left">446</td><td class="colsep0 rowsep0" align="left">>11900</td><td class="colsep0 rowsep0" align="left">777</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding ratio (%)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">34.7</td><td class="colsep0 rowsep0" align="left">41.8</td><td class="colsep0 rowsep0" align="left">32.2<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">47.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">The physicochemical parameters (apparent partition coefficient and aqueous solubility) of <b>1</b> and moxifloxacin were assessed by using a free base quinolone compound.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Abbreviation are as follows: LVFX, levofloxacin; MFLX, moxifloxacin.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Apparent partition coefficient, CHCl<sub>3</sub>/0.1 M phosphate buffer (pH 7.4).</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Aqueous solubility.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">In vitro human plasma protein binding ratios of the quinolones were measured by an ultrafiltration method at 5 μg/mL compounds. The data were expressed as the mean values ± SD of three experiments.</p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last">The value was examined at 10 μg/mL.</p></div></div></div><div class="NLM_p">The pharmacokinetic profiles of <b>2a</b>, <b>1</b>, levofloxacin, and moxifloxacin after single oral administration to rats are displayed in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Compound <b>2a</b> exhibited higher peak plasma concentration (<i>C</i><sub>max</sub>) and area under the time–concentration curve (AUC) than those of <b>1</b>. Compound <b>2a</b> also exhibited a favorable profile of distribution. It was distributed to the lung, a major target organ, very effectively; AUC<sub>(lung)</sub>/AUC<sub>(serum)</sub> ratio (<i>K</i><sub>p</sub>) of compound <b>2a</b> was higher than the value of existing respiratory quinolone, moxifloxacin.</div><div class="NLM_p">The pharmacokinetic profiles of compound <b>2a</b> and reference quinolones after oral or intravenous administration to monkeys are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>. After single oral administration, the <i>C</i><sub>max</sub> and AUC values of <b>2a</b> were higher than those of the other quinolones tested. Similarly, <b>2a</b> administered intravenously further showed a high AUC value. The bioavailability of compound <b>2a</b> was about 70% in monkeys. Compound <b>2a</b> was thus expected to exhibit a high plasma concentration and a good distribution to lung in humans, thereby furnishing superior efficacy for the respiratory infections. Moreover, above 60% of an intact <b>2a</b> was excreted in the urine. Taken together with the profile of pharmacokinetics and the antibacterial activity, compound <b>2a</b> will be expected to show excellent efficacy against urinary tract infections.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters of <b>2a</b> and Reference Quinolones in Rats after an Oral Dose of 5 mg/kg (<i>n</i> = 3)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">PK parameter/route: po</th><th class="colsep0 rowsep0" align="center"><b>2a</b></th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center">LVFX</th><th class="colsep0 rowsep0" align="center">MFLX<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serum</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="left">1.22</td><td class="colsep0 rowsep0" align="left">0.816</td><td class="colsep0 rowsep0" align="left">1.47</td><td class="colsep0 rowsep0" align="left">1.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC<sub>0–8h</sub> (μg·h/mL)</td><td class="colsep0 rowsep0" align="left">3.08</td><td class="colsep0 rowsep0" align="left">1.59</td><td class="colsep0 rowsep0" align="left">3.41</td><td class="colsep0 rowsep0" align="left">4.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">AUC<sub>0–8h</sub> (μg·h/mL)</td><td class="colsep0 rowsep0" align="left">13.7</td><td class="colsep0 rowsep0" align="left">6.77</td><td class="colsep0 rowsep0" align="left">5.57</td><td class="colsep0 rowsep0" align="left">15.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>p</sub> <a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">AUC<sub>0–8h</sub> (μg·h/mL)</td><td class="colsep0 rowsep0" align="left">32.1</td><td class="colsep0 rowsep0" align="left">15.0</td><td class="colsep0 rowsep0" align="left">16.4</td><td class="colsep0 rowsep0" align="left">24.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>p</sub> <a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">9.4</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">AUC<sub>0–8h</sub> (μg·h/mL)</td><td class="colsep0 rowsep0" align="left">27.8</td><td class="colsep0 rowsep0" align="left">19.3</td><td class="colsep0 rowsep0" align="left">19.3</td><td class="colsep0 rowsep0" align="left">30.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>p</sub> <a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">12.2</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">urinary recovery<sub>0–24h</sub> (%)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">32.0</td><td class="colsep0 rowsep0" align="left">23.1</td><td class="colsep0 rowsep0" align="left">80.0</td><td class="colsep0 rowsep0" align="left">25.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Animal: 7-week-old male Crj:CD rats.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last"><i>K</i><sub>p</sub> values are tissue/serum concentration ratio.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">The values were calculated by using the concentrations of unchanged quinolones.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Moxifloxacin hydrochloride hydrate was administered.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters of <b>2a</b> and Reference Quinolones in Monkeys after a Dose of 5 mg/kg (<i>n</i> = 3)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter</th><th class="colsep0 rowsep0" align="center"><b>2a</b></th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center">LVFX</th><th class="colsep0 rowsep0" align="center">MFLX<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">Route: po</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serum</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="left">2.20</td><td class="colsep0 rowsep0" align="left">1.27</td><td class="colsep0 rowsep0" align="left">1.92</td><td class="colsep0 rowsep0" align="left">1.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–24h</sub> (μg·h/mL)</td><td class="colsep0 rowsep0" align="left">16.9</td><td class="colsep0 rowsep0" align="left">9.45</td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="left">6.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">urinary recovery<sub>0–24h</sub> (%)<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">61.3</td><td class="colsep0 rowsep0" align="left">41.0</td><td class="colsep0 rowsep0" align="left">73.9</td><td class="colsep0 rowsep0" align="left">8.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (%)</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">route: iv</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serum</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>5min</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="left">3.66</td><td class="colsep0 rowsep0" align="left">4.75</td><td class="colsep0 rowsep0" align="left">4.17<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">2.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–8h</sub> (μg·h/mL)</td><td class="colsep0 rowsep0" align="left">23.8</td><td class="colsep0 rowsep0" align="left">19.4</td><td class="colsep0 rowsep0" align="left">15.5<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">10.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2α</sub> (h)</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">3.2<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">urinary recovery<sub>0–24h</sub> (%)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">69.8</td><td class="colsep0 rowsep0" align="left">50.7</td><td class="colsep0 rowsep0" align="left">80.7<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">11.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Animal: female cynomolgus monkeys.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Moxifloxacin hydrochloride hydrate was administered.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">The values were calculated by using the concentrations of unchanged quinolones.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">These values result from the division of data for 10 mg/kg intravenous administration by levofloxacin.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">Those values are the results for a 10 mg/kg intravenous administration.</p></div></div></div><div class="NLM_p">The results of the intravenous single-dose toxicity study and the micronucleus test are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>. An approximate lethal dose in mice was greater than 100 mg/kg. Compound <b>2a</b> showed negative responses in the micronucleus induction at a dose of 150 mg/kg in mice.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Intravenous Single-Dose Toxicity and Micronuclei-Forming Toxicity of <b>2a</b> in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">dose (mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">50</th><th class="colsep0 rowsep0" align="center">100</th><th class="colsep0 rowsep0" align="center">150</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">intravenous single-dosetoxicity/mortality<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0/5</td><td class="colsep0 rowsep0" align="left">0/5</td><td class="colsep0 rowsep0" align="left">1/5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">micronuclei-forming toxicity test/result<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">negative</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Mortality = (the number of dead mice)/(the number of tested mice).</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Using the bone marrow of surviving animals in the intravenous single-dose toxicity test.</p></div></div></div><div class="NLM_p">The therapeutic efficacies of compound <b>2a</b> in experimental murine pneumonia models due to quinolone-resistant (QR) or -sensitive (QS) penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) are compared with the efficacies of moxifloxacin and compound <b>1</b> in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. The therapeutic efficacy of subcutaneously administrated <b>2a</b> was superior to that of moxifloxacin, while the one in oral administration was comparable to that of compound <b>1</b>, although possessing 2-fold more potency in vitro compared with <b>2a</b>. The comparison with GRNX has been previously reported.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Therapeutic effects on pneumococcal pneumonia (QR-PRSP) in mice. Animals were CBA/JNCrj mice (<i>n</i> = 4). Bacteria were <i>S. pneumoniae</i> (QR-PRSP). Test drugs were administered subcutaneously twice a day.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Therapeutic effects on pneumococcal pneumonia (QS-PRSP) in mice. Animals were CBA/JNCrj mice (<i>n</i> = 4). Bacteria were <i>S. pneumoniae</i> (QR-PRSP). Test drugs were administered subcutaneously twice a day.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>2a</b>, 6-fluoro-8-methoxyquinolone possessing the (7<i>S</i>)-7-amino-7-methyl-5-azabicyclo[2.4]heptan-5-yl group at the C-7 position of the scaffold, was designed, synthesized, and evaluated. Compound <b>2a</b> exhibited about 4- to 8-fold better antibacterial activity in vitro against Gram-positive bacteria compared with the activity of LVFX. Compound <b>2a</b> also showed excellent in vivo antibacterial activity against <i>Streptococcus pneumoniae</i> infection in mice, which was supported and rationalized by a good pharmacokinetic profile. In addition, compound <b>2a</b> did not exert mechanism-based inhibition on CYP3A4, which was a serious setback of compound <b>1</b>.</div><div class="NLM_p last">Thus, compound <b>2a</b> has been selected for further evaluation as the promising candidate for treating community-acquired pneumonia.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General</h3><div class="NLM_p last">All melting points were taken on a Yamato MP-500D melting point apparatus and are uncorrected. Optical rotations were measured in a 0.5 dm cell at 25 °C at 589 nm with a HORIBA SEPA-300 polarimeter. <sup>1</sup>H NMR spectra were determined on a JEOL JNM-EX400 spectrometer. Chemical shifts are reported in parts per million relative to tetramethylsilane or sodium 2,2-dimethyl-2-silapentane-5-sulfonate as internal standards. Signficant <sup>1</sup>H NMR data are tabulated in the following order: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling constant(s) in hertz. High-resolution mass spectra were obtained on a JEOL JMS-700 mass spectrometer under electron impact ionization conditions (EI), electron spray ionization conditions (ESI), or fast atom bombardment ionization conditions (FAB). The high-resolution mass spectra were recorded on a JEOL JMS-100LP spectrometer. Elemental analyses are indicated only by the symbols of the elements; analytical results were within 0.4% of the theoretical values. Purities of ≥95% were determined by elemental analysis (all tested compounds). Column chromatography refers to flash column chromatography conducted on Merck silica gel 60, 230–400 mesh ASTM. Thin-layer chromatography (TLC) was performed with Merck silica gel 60 F254 TLC plates, and compound visualization was effected with a 5% solution of molybdophosphoric acid in ethanol, UV lamp, iodine, or Wako ninhydrin spray.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vitro Antibacterial Activity</h3><div class="NLM_p last">The MICs of the compounds tested in this study were determined by the 2-fold microdilution method using Mueller–Hinton broth (Difco Laboratories, Detroit, MI) with an inoculum size of approximately 10<sup>5</sup> CFU per well. The MIC was defined as the lowest concentration that prevented visible bacterial growth after incubation at 35 °C for 18 h.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Efficacy against <i>S. pneumoniae</i> Infection in Mice</h3><div class="NLM_p last">Three-week-old male CBA/JNCrlj mice (4 mice/group) were used. The bacteria used for infection were quinolone-resistant <i>S. pneumoniae</i> 104835 (penicillin-resistant, QR-PRSP) and quinolone-sensitive <i>S. pneumoniae</i> 033806 (penicillin-resistant, QS-PRSP), both of which were inoculated by nasal drop. One day after the infection, drugs were administered subcutaneously or orally twice a day. The number of bacteria in the lungs was examined on the day after the final administration of drug. The lungs were removed aseptically and weighed, and then the viable bacterial counts were determined. The detection limit was ≥2.30 log<sub>10</sub> CFU/g of lung.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Single Intravenous Dose Toxicity</h3><div class="NLM_p last">The test compounds were dissolved in 0.1 N NaOH in saline at different concentrations. The solution was administered intravenously to male Slc:ddY mice, 6 weeks of age at a dose level of 50, 100, and 150 mg/kg (10 mL/kg, 0.2 mL/min). The number of dead mice was counted on day 7.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Bone Marrow Micronucleus Test</h3><div class="NLM_p last">The test compounds were dissolved in 0.1 N NaOH in saline at different concentrations. The solution was administered intravenously to male Slc:ddY mice, 6 weeks of age at a dose level of 50, 100, and 150 mg/kg (10 mL/kg, 0.2 mL/min). At 24 and 48 h after dosing of the compounds, approximately 5 μL of peripheral blood was collected from a tail blood vessel of each mice. The blood was dropped onto an acridine orange coated glass slide and covered immediately with a coverslip. For each animal, 1000 reticulocytes were examined for micronuclei by fluorescence microscopy, and the frequency of micronucleated reticulocytes (MNRET) was expressed as a percentage. Statistical analysis was performed by the Kastenbaum and Bowman method.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Pharmacokinetic Studies</h3><div class="NLM_p last">Seven-week-old male Crj:CD rats (<i>n</i> = 4) were used. The animals were administered drug samples in a single intravenous dose (5 mg/kg) as an aqueous solution. The concentrations of the compounds were determined by a microbiological assay (agar well dilution method) using <i>B. subtilis</i> ATCC 6051. The mean values of the four rats were shown.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> X-ray Crystallographic Analysis of <b>14</b></h3><div class="NLM_p last">A colorless prism-shaped crystal was formed from AcOEt: C<sub>20</sub>H<sub>27</sub>NO<sub>3</sub>; FW = 329.44; sample dimensions, 0.40 mm × 0.30 mm × 0.34 mm. The lattice parameters and intensities were measured on a Rigaku AFC7R diffractometer (Cu Kα radiation, λ = 1.541 78 Å, graphite monochromator, ω–2θ scans, 2θ<sub>max</sub> = 120.1°): orthorhombic, space group <i>P</i>2<sub>1</sub>2<sub>1</sub><i>2</i><sub>1</sub>; <i>a</i> = 16.396(2) Å, <i>b</i> = 17.122(2) Å, <i>c</i> = 6.800(1) Å, <i>V</i> = 1908.9(5) Å<sup>3</sup>, <i>Z</i> = 4; <i>D</i><sub>calcd</sub> = 1.15 g/cm<sup>3</sup>; <i>F</i><sub>000</sub> = 712; μ = 6.09 cm<sup>–1</sup>. The structure was solved by direct methods with the program Sir92.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The final cycle of full-matrix least-squares refinement was based on 1665 observed reflections and 245 variable parameters and converged at <i>R</i> = 0.063 (Rw = 0.191).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 1-(1,2-Diamino-1-methylethyl)-1-cyclopropanecarboxylic Acid Dihydrochloride (<b>7</b>)</h3><div class="NLM_p last">To a solution of <b>5</b> (9.21 g, 50.0 mmol) in 7 N NH<sub>3</sub>–MeOH (300 mL) were added aqueous NH<sub>3</sub> (28%, 90 mL), ammonium chloride (53.5 g, 1.00 mol), and sodium cyanide (4.90 g, 100 mmol) at 0 °C, and the mixture was stirred at ambient temperature for 18 h. The mixture was concentrated in vacuo. Water (100 mL) was added to the residue, and then the aqueous solution was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give <b>6</b> (10.15 g) as a pale brown oil. To a solution of <b>6</b> (1.12 g, 5.30 mmol) in EtOH (50 mL) was added Raney nickel catalyst (about 50%, 10 mL), and the mixture was stirred at ambient temperature for 6 h under hydrogen atmosphere. The resultant suspension was filtered through Celite, and the filtrate was concentrated in vacuo. The residue was dissolved in concentrated aqueous HCl (5 mL), and the mixture was stirred at ambient temperature for 0.5 h. After the mixture was diluted with water, the resultant solution was concentrated in vacuo. The resultant residue was mixed with EtOH and concentrated in vacuo (2×) to give <b>7</b> (0.82 g, 65%) as a yellow amorphous product. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 1.20–1.26 (1H, m), 1.28 (3H, s), 1.32–1.43 (2H, m), 1.58–1.62 (1H, m), 3.46 (1H, d, <i>J</i> = 13.4 Hz), 3.80 (1H, d, <i>J</i> = 13.4 Hz). High-resolution MS (ESI) calcd for C<sub>7</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub>: 159.1134. Found: 159.1125.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>tert</i>-Butyl (7-Methyl-4-oxo-5-azaspiro[2.4]hept-7-yl)carbamate (<b>8</b>)</h3><div class="NLM_p last">To a solution of <b>7</b> (800 mg, 3.46 mmol) in 70 mL of CH<sub>3</sub>CN was added 1,1,1,3,3,3-hexamethyldisilazane (7.38 mL, 34.6 mmol) under nitrogen atmosphere, and then the mixture was heated to reflux for 4 h. After the mixture was cooled at ambient temperature, MeOH (70 mL) was added. The resultant solution was concentrated in vacuo. The residue was mixed with Boc<sub>2</sub>O (1.53 g, 7.00 mmol) and 1,4-dioxane (20 mL), and the mixture was stirred for 5 h at ambient temperature. Water was added, and the aqueous solution was extracted with CHCl<sub>3</sub> (2×). The combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was treated with light petroleum ether and the solid was collected by filtration to give <b>8</b> (502 mg, 60%) as a colorless powder, mp 221–223 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.77–0.82 (1H, m), 0.94–1.04 (2H, m), 1.16–1.23 (1H, m), 1.28 (3H, s), 1.43 (9H, s), 3.29 (1H, d, <i>J</i> = 10.3 Hz), 4.12 (1H, m), 4.60 (1H, br s), 5.82 (1H, br s). High-resolution MS (ESI) calcd for C<sub>12</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub>: 241.1552. Found: 241.1538. Anal. Calcd for C<sub>12</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>: C 59.88, H 8.39, N 11.66. Found: C 59.80, H 8.43, N 11.74.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>tert</i>-Butyl (5-Benzyl-7-methyl-4-oxo-5-azaspiro[2.4]hept-7-yl)carbamate (<b>9</b>)</h3><div class="NLM_p last">To a solution of <b>8</b> (3.12 g, 13.0 mmol) in 65 mL of DMF on an ice bath was added NaH (55% mineral oil dispersion, 566 mg, 13.0 mmol) carefully. After the mixture was stirred for 40 min at the same temperature, BnBr (1.85 mL, 15.6 mmol) was added dropwise and the mixture was stirred for 1.5 h at ambient temperature. The reaction mixture was diluted with 300 mL of AcOEt and washed with water (2×) and brine. The organic solution was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The resultant residue was purified by silica gel column chromatography, eluting with hexane/EtOAc = 4:1 to yield <b>9</b> (4.20 g, 98%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.76–0.81 (1H, m), 0.93–1.06 (2H, m), 1.21–1.29 (4H, m), 1.37 (9H, s), 3.14 (1H, d, <i>J</i> = 10.3 Hz), 3.92–3.98 (1H, m), 4.44, 4.56 (each 1H, ABq, <i>J</i> = 14.9 Hz), 4.56 (1H, br s), 7.22–7.33 (5H, m). High-resolution MS (ESI) calcd for C<sub>19</sub>H<sub>27</sub>N<sub>2</sub>O<sub>3</sub>: 331.2022. Found: 331.2020.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (−)-<i>tert</i>-Butyl (5-Benzyl-7-methyl-4-oxo-5-azaspiro[2.4]hept-7-yl)carbamate ((−)-<b>9</b>) and (+)-<i>tert</i>-Butyl (5-Benzyl-7-methyl-4-oxo-5-azaspiro[2.4]hept-7-yl)carbamate ((+)-<b>9</b>)</h3><div class="NLM_p last">An amount of 2.25 g of racemic <b>9</b> was separated into its enantiomers by semipreparative HPLC by using a Chiralpak AD column (Daicel Chemical Industries, Ltd.; 250 mm × 20 mm, 5 μm; flow, 20 mL/min; solvents, hexane/isopropanol 90:10; 50 mg/run; UV detection at 254 nm) to give (−)-<b>9</b> (997 mg, 44%, <i>t</i><sub>R</sub> = 7.0 min) and (+)-<b>9</b> (957 mg, 43%, <i>t</i><sub>R</sub> = 11.3 min) as a colorless powder, respectively. (−)-<b>9</b>: mp 109–111 °C. [α]<sub class="stack">D</sub><sup class="stack">25</sup> −113.9° (<i>c</i> 0.180, CHCl<sub>3</sub>). Anal. Calcd for C<sub>19</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>: C 69.09, H 7.93, N 8.48. Found: C 68.80, H 7.99, N 8.51. (+)-<b>9</b>; mp 108–110 °C. [α]<sub class="stack">D</sub><sup class="stack">25</sup> +108.8° (<i>c</i> 0.249, CHCl<sub>3</sub>). Anal. Calcd for C<sub>19</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>: C 69.09, H 7.93, N 8.48. Found: C 68.99, H 8.01, N, 8.48.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (−)-<i>tert</i>-Butyl (5-Benzyl-7-methyl-5-azaspiro[2.4]hept-7-yl)carbamate ((−)-<b>10</b>)</h3><div class="NLM_p last">To a solution of (−)-<b>9</b> (950 mg, 2.88 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added trifluoroacetic acid (7.5 mL) at ambient temperature. The mixture was stirred for 40 min and then concentrated in vacuo. The resultant residue was mixed with toluene and concentrated in vacuo (2×). After saturated aqueous NaHCO<sub>3</sub> was added, the aqueous layer was extracted with CHCl<sub>3</sub> (2×). The combined organic solution was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. To the solution of the residue in THF (30 mL) was added LiAlH<sub>4</sub> (218 mg, 5.75 mmol) at 0 °C, and the mixture was stirred for 1 h at same temperature. After addition of LiAlH<sub>4</sub> (109 mg, 2.87 mmol), the mixture was stirred for 3 h at ambient temperature and stirred at 0 °C again. To the mixture, water (0.31 mL), 15 wt % aqueous NaOH (0.31 mL), and water (0.93 mL) were added dropwise. The resultant mixture was stirred at ambient temperature for 14 h and dried over anhydrous MgSO<sub>4</sub>. The suspension was filtered through Celite, and the filtrate was concentrated in vacuo. The residue was mixed with Boc<sub>2</sub>O (1.26 g, 5.75 mmol) and CH<sub>2</sub>Cl<sub>2</sub> (15 mL), and the mixture was stirred for 20 h at ambient temperature and then concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with CHCl<sub>3</sub>/MeOH/triethylamine = 95:5:1 to yield (−)-<b>10</b> (586 mg, 64%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.40–0.45 (1H, m), 0.50–0.55 (1H, m), 0.63–0.69 (1H, m), 0.80–0.85 (1H, m), 1.20 (3H, s), 1.43 (9H, s), 2.44 (1H, d, <i>J</i> = 8.8 Hz), 2.59 (1H, d, <i>J</i> = 9.5 Hz), 2.83 (1H, d, <i>J</i> = 8.8 Hz), 3.33 (1H, m), 3.57 (1H, d, <i>J</i> = 13.2 Hz), 3.68 (1H, d, <i>J</i> = 13.2 Hz), 4.75 (1H, br s), 7.20–7.37 (5H, m). High-resolution MS (ESI) calcd for C<sub>19</sub>H<sub>29</sub>N<sub>2</sub>O<sub>2</sub>: 317.2229. Found: 317.2253. [α]<sub class="stack">D</sub><sup class="stack">25</sup> −63.6° (<i>c</i> 0.129, CHCl<sub>3</sub>).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 7-(7-Amino-7-methyl-5-azaspiro[2.4]hept-5-yl)-6-fluoro-1-[(1<i>R</i>,2<i>S</i>)-2-fluorocyclopropyl]-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (<b>2a</b>)</h3><div class="NLM_p last">To a solution of (−)-<b>10</b> (581 mg, 1.84 mmol) in MeOH (40 mL) was added 10% Pd/C (M, 290 mg, containing 50% water), and the mixture was stirred for 5 h at ambient temperature under hydrogen atmosphere. The catalyst was filtered off, and the filtrate was concentrated in vacuo. The residue was mixed with <b>4</b> (663 mg, 1.84 mmol), triethylamine (0.795 mL, 5.52 mmol), and DMSO (5 mL), and the mixture was stirred at 40 °C for 14 h. To this solution were added 80% aqueous EtOH (50 mL) and triethylamine (5 mL), and the resultant mixture was heated to reflux for 2 h and then concentrated in vacuo to give the residue, which was diluted with AcOEt. The organic solution was washed with 10% aqueous citric acid solution, water (2×) and brine. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. To the residue was added 10 mL of concentrated aqueous HCl at 0 °C, and the mixture was stirred for 20 min at ambient temperature. The aqueous solution was washed with CHCl<sub>3</sub> and made alkaline with saturated aqueous NaOH at 0 °C. The pH of the solution was adjusted to 7.4 with concentrated aqueous HCl and then diluted aqueous HCl. The resultant solution was extracted with CHCl<sub>3</sub> (2×) and CHCl<sub>3</sub>/MeOH = 9:1. The combined organic solution was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude product was recrystallized from EtOH to yield <b>2a</b> (644 mg, 84%) as a pale pinkish powder, mp 198–200 °C. <sup>1</sup>H NMR (0.1 N NaOD/D<sub>2</sub>O): δ 0.49–0.56 (2H, m), 0.67–0.76 (2H, m), 1.12 (3H, s), 1.43–1.64 (2H, m), 3.56 (3H, s), 3.59–3.71 (4H, m), 3.99–4.04 (1H, m), 4.80–5.03 (1H, m), 7.65 (1H, d, <i>J</i> = 13.9 Hz), 8.45 (1H, s). [α]<sub class="stack">D</sub><sup class="stack">25</sup> +40.8° (<i>c</i> 0.147, 0.1 N aqueous NaOH). Anal. Calcd for C<sub>21</sub>H<sub>23</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>·0.75EtOH·0.5H<sub>2</sub>O: C 58.37, H 6.20, F 8.20, N 9.08. Found: C 58.23, H 5.99, F 8.09, N 9.02.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (+)-<i>tert</i>-Butyl (5-Benzyl-7-methyl-5-azaspiro[2.4]hept-7-yl)carbamate ((+)-<b>10</b>)</h3><div class="NLM_p last">With the procedures as described for (−)-<b>10</b>, the title compound was prepared in 69% yield from (+)-<b>9</b> as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.40–0.45 (1H, m), 0.50–0.55 (1H, m), 0.63–0.69 (1H, m), 0.80–0.85 (1H, m), 1.20 (3H, s), 1.43 (9H, s), 2.44 (1H, d, <i>J</i> = 8.8 Hz), 2.59 (1H, d, <i>J</i> = 9.5 Hz), 2.83 (1H, d, <i>J</i> = 8.8 Hz), 3.33 (1H, m), 3.57 (1H, d, <i>J</i> = 13.2 Hz), 3.68 (1H, d, <i>J</i> = 13.2 Hz), 4.75 (1H, br s), 7.20–7.37 (5H, m). High-resolution MS (ESI) calcd for C<sub>19</sub>H<sub>29</sub>N<sub>2</sub>O<sub>2</sub>: 317.2229. Found: 317.2249. [α]<sub class="stack">D</sub><sup class="stack">25</sup> +76.2° (<i>c</i> 0.290, CHCl<sub>3</sub>).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 7-(7-Amino-7-methyl-5-azaspiro[2.4]hept-5-yl)-6-fluoro-1-[(1<i>R</i>,2<i>S</i>)-2-fluorocyclopropyl]-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (<b>2b</b>)</h3><div class="NLM_p last">With the procedures as described for <b>2a</b>, the title compound was prepared in 78% yield from (+)-<b>10</b> as a pale pinkish powder, mp 212–214 °C. <sup>1</sup>H NMR (0.1 N NaOD/D<sub>2</sub>O): δ 0.52 (2H, m), 0.73 (2H, m), 1.07 (3H, s), 1.42–1.64 (2H, m), 3.45 (1H, d, <i>J</i> = 10.3 Hz), 3.52–3.56 (1H, m), 3.55 (3H, s), 3.73 (1H, dd, <i>J</i> = 2.2, 10.0 Hz), 3.85 (1H, d, J = 9.0 Hz), 3.99–4.04 (1H, m), 4.82–5.02 (1H, m), 7.64 (1H, d, <i>J</i> = 14.4 Hz), 8.45 (1H, s). [α]<sub class="stack">D</sub><sup class="stack">25</sup> +128.8° (<i>c</i> 0.163, 0.1 N aqueous NaOH). Anal. Calcd for C<sub>21</sub>H<sub>23</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>·1.0EtOH·0.5H<sub>2</sub>O: C 58.22, H 6.37, F 8.01, N 8.86. Found: C 58.02, H 6.13, F 8.05, N 9.02.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>tert</i>-Butyl (3<i>S</i>)-4-(2-Hydroxyethyl)-3-methyl-5-oxo-1-[(<i>R</i>)-1-phenylethyl]pyrrolidine-3-carboxylate (<b>13</b>)</h3><div class="NLM_p last">Under nitrogen atmosphere, to a solution of <b>11</b> (30.0 g, 98.9 mmol) and <b>12</b> (36.8 g, 129 mmol) in anhydrous THF (288 mL) was added 1 M LiHMDS/THF (129 mL) dropwise at −4 °C. After the mixture was stirred at 2 °C for 3.5 h, saturated aqueous NH<sub>4</sub>Cl and AcOEt were added. The separated organic solution was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. To a solution of the residue in THF (450 mL) on an ice bath was added 1 M TBAF/THF (148 mL) dropwise, and the mixture was stirred for 2 h at ambient temperature. After concentration in vacuo, AcOEt and 10% aqueous NaHCO<sub>3</sub> were added to the mixture. The organic solution was washed with 10% aqueous citric acid and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography, eluting with hexane/AcOEt = 1:1 to yield diastereomixture <b>13</b> (29.1 g, 85%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.28 (3H, s), 1.40 (9H, s), 1.51–1.53 (1H, m), 1.53 (3H, d, <i>J</i> = 7.1 Hz), 1.78–1.94 (2H, m), 2.90–3.08 (2H, m), 3.67–3.75 (1H, m), 3.80–3.91 (1H, m), 4.85–4.89 (1H, m), 5.43–5.53 (1H, m), 7.27–7.37 (5H, m). High-resolution MS (ESI) calcd for C<sub>20</sub>H<sub>30</sub>NO<sub>4</sub>: 348.2175. Found: 348.2177.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>tert</i>-Butyl (7<i>S</i>)-7-Methyl-4-oxo-5-[(<i>R</i>)-1-phenylethyl]-5-azaspiro[2.4]heptan-7-carboxylate (<b>14</b>)</h3><div class="NLM_p last">To a solution of <b>13</b> (29.1 g, 83.9 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (280 mL) on an ice bath were added TEA (15.2 mL, 109 mmol), benzenesulfonyl chloride (11.8 mL, 92.3 mmol), and DMAP (1.02 g, 8.39 mmol). The mixture was stirred at ambient temperature for 19 h and diluted with AcOEt. This solution was washed with saturated aqueous NH<sub>4</sub>Cl, 1 N aqueous HCl, saturated aqueous NaHCO<sub>3</sub>, and brine. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. To a solution of the residue in anhydrous THF (470 mL) on an ice bath was added 1 M NaHMDS/THF (109 mL) under nitrogen atmosphere, and the mixture was stirred at ambient temperature for 1 h. Aqueous saturated NH<sub>4</sub>Cl was added to the mixture, and the resultant solution was extracted with AcOEt (2×). The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The resultant residue was purified by silica gel column chromatography, eluting with hexane/AcOEt = 3:1 to yield <b>14</b> (24.6 g, 89%) as a colorless crystal, mp 55–57 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.72–0.77 (1H, m), 0.85–0.90 (1H, m), 1.04–1.13 (2H, m), 1.18 (3H, s), 1.32 (9H, s), 1.54 (3H, d, <i>J</i> = 7.1 Hz), 3.08 (1H, d, <i>J</i> = 9.8 Hz), 3.53 (1H, d, <i>J</i> = 7.1 Hz), 5.52 (1H, q, <i>J</i> = 7.1 Hz), 7.26–7.34 (5H, m). High-resolution MS (FAB) calcd for C<sub>20</sub>H<sub>28</sub>NO<sub>3</sub>: 330.2069. Found: 330.2069. [α]<sub class="stack">D</sub><sup class="stack">25</sup> +122.1° (<i>c</i> 0.517, CHCl<sub>3</sub>). Anal. Calcd for C<sub>20</sub>H<sub>27</sub>NO<sub>3</sub>: C 72.92, H 8.26, N 4.25. Found: C 72.64, H 8.27, N 4.06.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (7<i>S</i>)-7-(<i>tert</i>-Butoxycarbonylamino)-7-methyl-5-[(<i>R</i>)-1-phenylethyl]-5-azaspiro[2.4]heptane (<b>16</b>)</h3><div class="NLM_p last">To a solution of <b>14</b> (24.5 g, 74.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (120 mL) on an ice bath was added trifluoroacetic acid (120 mL), and the mixture was stirred at ambient temperature for 2 h and concentrated in vacuo. The residue was mixed with toluene, and the solution was concentrated in vacuo. After the residue was dissolved in 1 N aqueous NaOH at 0 °C, the aqueous solution was washed with AcOEt and acidified with concentrated aqueous HCl under ice-cooling. The mixture was extracted with CHCl<sub>3</sub> (2×), and the combined organic solution was washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. To a solution of the residue in toluene (200 mL) were added triethylamine (20.7 mL, 149 mmol) and diphenylphosphoryl azide (17.6 mL, 81.8 mmol) at ambient temperature. The mixture was heated to reflux for 1 h and then concentrated in vacuo. The residue was mixed with 1,4-dioxane (180 mL), water (90 mL), and concentrated aqueous HCl (90 mL), and the mixture was stirred at 50 °C for 1 h. Water (200 mL) was added to the mixture, and the resultant solution was washed with AcOEt and made alkaline with 10 N aqueous NaOH at 0 °C and extracted with toluene (2×). The combined organic solution was washed with brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. To a solution of the residue in toluene (82 mL) was added Red-Al (65% w/w in toluene, 77.6 mL, 259 mmol) dropwise over 15 min, and the mixture was stirred at 80 °C for 10 min. After the mixture was cooled to 0 °C, 25 wt % aqueous NaOH (158 mL) was dropped into the mixture, which was extracted with toluene. To the organic solution which was washed with brine was added Boc<sub>2</sub>O (15.6 g, 71.2 mmol), and the mixture was stirred at ambient temperature for 3 h and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with hexane/AcOEt = 3:1 to yield <b>16</b> (18.0 g, 73%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.37–0.49 (2H, m), 0.62–0.68 (1H, m), 0.77–0.82 (1H, m), 1.20 (3H, s), 1.32 (3H, d, <i>J</i> = 6.6 Hz), 1.44 (9H, s), 2.46 (2H, dd, <i>J</i> = 33.2, 9.3 Hz), 2.68 (1H, d, <i>J</i> = 8.8 Hz), 3.27 (1H, q, <i>J</i> = 6.6 Hz), 3.31–3.34 (1H, m), 4.71 (1H, s), 7.19–7.34 (5H, m). High-resolution MS (ESI) calcd for C<sub>20</sub>H<sub>31</sub>N<sub>2</sub>O<sub>2</sub>: 331.2385. Found: 331.2406. [α]<sub class="stack">D</sub><sup class="stack">25</sup> −23.817° (<i>c</i> 0.786, CHCl<sub>3</sub>).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 7-[(7<i>S</i>)-7-Amino-7-methyl-5-azaspiro[2.4]hept-5-yl]-6-fluoro-1-[(1<i>R</i>,2<i>S</i>)-2-fluorocyclopropyl]-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (<b>2</b>)</h3><div class="NLM_p last">To a solution of <b>16</b> (18.0 g, 54.5 mmol) in MeOH (180 mL) was added 10% Pd/C (M, 9.0 g, containing 50% water), and the mixture was stirred at ambient temperature for 18 h and then at 40 °C for 5.5 h under hydrogen atmosphere. The catalyst was filtered off, and the filtrate was concentrated in vacuo, followed by the procedures as described for <b>2a</b>. The title compound was prepared in 79% yield from <b>16</b> as a pale pinkish powder. The analytical data of this compound corresponded with those of compound <b>2a</b>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/jm301650g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Crystallographic details for <b>14</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301650g/suppl_file/jm301650g_si_001.pdf">jm301650g_si_001.pdf (46.92 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm301650g" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takashi Odagiri</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#46292227212f342f6832272d27352e2f6820240622272f2f252e2f3527282d3f29682529682c36"><span class="__cf_email__" data-cfemail="29464d484e405b40075d4842485a4140074f4b694d4840404a41405a4847425046074a46074359">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroaki Inagaki</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuichi Sugimoto</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masatoshi Nagamochi</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rie N. Miyauchi</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junichi Kuroyanagi</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takahiro Kitamura</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoshi Komoriya</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hisashi Takahashi</span> - <span class="hlFld-Affiliation affiliation">R&D
Division, Daiichi Sankyo Co., Ltd., 1-2-58
Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d163e3274-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Kiyoshi Takasuna and Koichi Goto for the safety assessment. And we thank Dr. Masaya Tachibana for the MBI assay. In particular, we thank Megumi Chiba, Dr. Ryo Okumura, and Dr. Yuichi Kurosaka for the biological tests. We also thank Hidetaka Sakurai for the X-ray crystal analyses.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00707" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00707" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Komoriya, S.; Inagaki, H.; Sugimoto, Y.; Nagamochi, M.; Miyauchi, R.; Kuroyanagi, J.; Kitamura, T.; Hoshino, K.; Murakami, Y.; Tachibana, M.; Imamura, Y.; Takahashi, H.; Takemura, M.</span><span> </span><span class="NLM_article-title">DC-159a, a New Generation of Respiratory Quinolone: Design, Synthesis, and Biological Evaluation</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Society for Microbiology</span>: <span class="NLM_publisher-loc">Washington, DC</span>; Abstract F1-0477.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+Komoriya&author=H.+Inagaki&author=Y.+Sugimoto&author=M.+Nagamochi&author=R.+Miyauchi&author=J.+Kuroyanagi&author=T.+Kitamura&author=K.+Hoshino&author=Y.+Murakami&author=M.+Tachibana&author=Y.+Imamura&author=H.+Takahashi&author=M.+Takemura&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKomoriya%26aufirst%3DS.%26atitle%3DDC-159a%252C%2520a%2520New%2520Generation%2520of%2520Respiratory%2520Quinolone%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2006%26pub%3DAmerican%2520Society%2520for%2520Microbiology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Fridkin, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hageman, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanza, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Como-Sabetti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jernigan, J. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynfield, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, M. M.</span><span> </span><span class="NLM_article-title">Active bacterial core surveillance program of the emerging infections program network. Methicillin-resistant <i>Staphylococcus aureus</i> disease in three communities</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1436</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1056%2FNEJMoa043252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=15814879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVWltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1436-1444&issue=14&author=S.+K.+Fridkinauthor=J.+C.+Hagemanauthor=M.+Morrisonauthor=L.+T.+Sanzaauthor=K.+Como-Sabettiauthor=J.+A+Jerniganauthor=K.+Harrimanauthor=L.+H.+Harrisonauthor=R.+Lynfieldauthor=M.+M.+Farley&title=Active+bacterial+core+surveillance+program+of+the+emerging+infections+program+network.+Methicillin-resistant+Staphylococcus+aureus+disease+in+three+communities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Methicillin-resistant Staphylococcus aureus disease in three communities</span></div><div class="casAuthors">Fridkin, Scott K.; Hageman, Jeffrey C.; Morrison, Melissa; Sanza, Laurie Thomson; Como-Sabetti, Kathryn; Jernigan, John A.; Harriman, Kathleen; Harrison, Lee H.; Lynfield, Ruth; Farley, Monica M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1436-1444</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in patients who do not have the established risk factors.  The national burden and clin. effect of this novel presentation of MRSA disease are unclear.  METHODS: We evaluated MRSA infections in patients identified from population-based surveillance in Baltimore and Atlanta and from hospital-lab.-based sentinel surveillance of 12 hospitals in Minnesota.  Information was obtained by interviewing patients and by reviewing their medical records.  Infections were classified as community-acquired MRSA disease if no established risk factors were identified.  RESULTS: From 2001 through 2002, 1647 cases of community-acquired MRSA infection were reported, representing between 8 and 20 percent of all MRSA isolates.  The annual disease incidence varied according to site (25.7 cases per 100,000 population in Atlanta vs. 18.0 per 100,000 in Baltimore) and was significantly higher among persons less than two years old than among those who were two years of age or older (relative risk, 1.51; 95 percent confidence interval, 1.19 to 1.92) and among blacks than among whites in Atlanta (age-adjusted relative risk, 2.74; 95 percent confidence interval, 2.44 to 3.07). Six percent of cases were invasive, and 77 percent involved skin and soft tissue.  The infecting strain of MRSA was often (73 percent) resistant to prescribed antimicrobial agents.  Among patients with skin or soft-tissue infections, therapy to which the infecting strain was resistant did not appear to be assocd. with adverse patient-reported outcomes.  Overall, 23 percent of patients were hospitalized for the MRSA infection.  CONCLUSIONS: Community-assocd. MRSA infections are now a common and serious problem.  These infections usually involve the skin, esp. among children, and hospitalization is common.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKjhK3hwB6PbVg90H21EOLACvtfcHk0lg3MRcjUOMejg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVWltr0%253D&md5=7d0e2634a3c0693cc3fc04afbdf25ac0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043252%26sid%3Dliteratum%253Aachs%26aulast%3DFridkin%26aufirst%3DS.%2BK.%26aulast%3DHageman%26aufirst%3DJ.%2BC.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DSanza%26aufirst%3DL.%2BT.%26aulast%3DComo-Sabetti%26aufirst%3DK.%26aulast%3DJernigan%26aufirst%3DJ.%2BA%26aulast%3DHarriman%26aufirst%3DK.%26aulast%3DHarrison%26aufirst%3DL.%2BH.%26aulast%3DLynfield%26aufirst%3DR.%26aulast%3DFarley%26aufirst%3DM.%2BM.%26atitle%3DActive%2520bacterial%2520core%2520surveillance%2520program%2520of%2520the%2520emerging%2520infections%2520program%2520network.%2520Methicillin-resistant%2520Staphylococcus%2520aureus%2520disease%2520in%2520three%2520communities%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D14%26spage%3D1436%26epage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Fuller, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGeer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, D. E.</span><span> </span><span class="NLM_article-title">Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management</span> <span class="citation_source-journal">Eur. J. Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1007%2Fs10096-005-0059-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=16344922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FgsV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=780-788&author=J.+D.+Fullerauthor=A.+McGeerauthor=D.+E.+Low&title=Drug-resistant+pneumococcal+pneumonia%3A+clinical+relevance+and+approach+to+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management</span></div><div class="casAuthors">Fuller J D; McGeer A; Low D E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">780-8</span>
        ISSN:<span class="NLM_cas:issn">0934-9723</span>.
    </div><div class="casAbstract">Community-acquired pneumonia is the most common infectious disease that causes death, with Streptococcus pneumoniae remaining the leading causative pathogen.  The worldwide incidence of infections caused by pneumococci resistant to penicillin, macrolides, and other antimicrobial agents has increased at an alarming rate during the past 2 decades.  Yet, these agents are still used as first-line empirical therapy in the outpatient setting.  There are several reasons for this, including the infrequency of making a pathogen-specific diagnosis, the failure of studies to demonstrate the relevance of resistance, and the infrequency with which clinicians recognize clinical failures.  Despite this, there is mounting evidence that supports the practice of using high doses of some antimicrobial agents, a more active antimicrobial agent within a class, or switching to another class of antimicrobial agents when a patient is identified as being at an increased risk of infection with a resistant pneumococcus.  There is now information that will allow the physician to identify not only the patient at risk for infection with a resistant pneumococcus but also the antimicrobial class and, in some cases, the agent within the class to which the organism is more likely to be resistant.  This will allow clinicians to better define optimal therapy for patients with community-acquired pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgh1WC97YUkzEwO064Z95rfW6udTcc2eY5ZrTkuQ6WHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FgsV2isQ%253D%253D&md5=43605afe9cf317d8ef997d43b952694c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs10096-005-0059-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10096-005-0059-x%26sid%3Dliteratum%253Aachs%26aulast%3DFuller%26aufirst%3DJ.%2BD.%26aulast%3DMcGeer%26aufirst%3DA.%26aulast%3DLow%26aufirst%3DD.%2BE.%26atitle%3DDrug-resistant%2520pneumococcal%2520pneumonia%253A%2520clinical%2520relevance%2520and%2520approach%2520to%2520management%26jtitle%3DEur.%2520J.%2520Clin.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D24%26spage%3D780%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_contrib-group">Shams, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, M. E,</span><span> </span><span class="NLM_article-title">Guide to selection of fluoroquinolones in patients with lower respiratory tract infections</span> <span class="citation_source-journal">Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=949-991&issue=7&author=W.+E.+Shamsauthor=M.+E%2C+Evans&title=Guide+to+selection+of+fluoroquinolones+in+patients+with+lower+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShams%26aufirst%3DW.%2BE.%26aulast%3DEvans%26aufirst%3DM.%2BE%252C%26atitle%3DGuide%2520to%2520selection%2520of%2520fluoroquinolones%2520in%2520patients%2520with%2520lower%2520respiratory%2520tract%2520infections%26jtitle%3DDrugs.%26date%3D2005%26volume%3D65%26issue%3D7%26spage%3D949%26epage%3D991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_contrib-group">Zhanelaaa, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontaine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schurek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noreddin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoban, D. J.</span><span> </span><span class="NLM_article-title">A review of new fluoroquinolones: focus on their use in respiratory tract infections</span> <span class="citation_source-journal">Treat. Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F00151829-200605060-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=17154673" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=437-465&author=G.+G.+Zhanelaaaauthor=S.+Fontaineauthor=H.+Adamauthor=K.+Schurekauthor=M.+Mayerauthor=A.+M.+Noreddinauthor=A.+S.+Ginauthor=E.+Rubinsteinauthor=D.+J.+Hoban&title=A+review+of+new+fluoroquinolones%3A+focus+on+their+use+in+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.2165%2F00151829-200605060-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00151829-200605060-00009%26sid%3Dliteratum%253Aachs%26aulast%3DZhanelaaa%26aufirst%3DG.%2BG.%26aulast%3DFontaine%26aufirst%3DS.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DSchurek%26aufirst%3DK.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DNoreddin%26aufirst%3DA.%2BM.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DRubinstein%26aufirst%3DE.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26atitle%3DA%2520review%2520of%2520new%2520fluoroquinolones%253A%2520focus%2520on%2520their%2520use%2520in%2520respiratory%2520tract%2520infections%26jtitle%3DTreat.%2520Respir.%2520Med.%26date%3D2006%26volume%3D5%26spage%3D437%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimoto, T.</span><span> </span><span class="NLM_article-title">The history of the development and changes of quinolone antibacterial agents</span> <span class="citation_source-journal">Jpn. J. Hist. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ksFeisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=161-179&issue=2&author=H.+Takahashiauthor=I.+Hayakawaauthor=T.+Akimoto&title=The+history+of+the+development+and+changes+of+quinolone+antibacterial+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The history of the development and changes of quinolone antibacterial agents</span></div><div class="casAuthors">Takahashi Hisashi; Hayakawa Isao; Akimoto Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Yakushigaku zasshi</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-79</span>
        ISSN:<span class="NLM_cas:issn">0285-2314</span>.
    </div><div class="casAbstract">The quinolones, especially the new quinolones (the 6-fluoroquinolones), are the synthetic antibacterial agents to rival the Beta-lactam and the macrolide antibacterials for impact in clinical usage in the antibacterial therapeutic field.  They have a broad antibacterial spectrum of activity against Gram-positive, Gram-negative and mycobacterial pathogens as well as anaerobes.  Further, they show good-to-moderate oral absorption and tissue penetration with favorable pharmacokinetics in humans resulting in high clinical efficacy in the treatment of many kinds of infections.  They also exhibit excellent safety profiles as well as those of oral Beta-lactam antibiotics.  The bacterial effects of quinolones inhibit the function of bacterial DNA gyrase and topoisomerase IV.  The history of the development of the quinolones originated from nalidixic acid (NA), developed in 1962.  In addition, the breakthrough in the drug design for the scaffold and the basic side chains have allowed improvements to be made to the first new quinolone, norfloxacin (NFLX), patented in 1978.  Although currently more than 10,000 compounds have been already synthesized in the world, only two percent of them were developed and tested in clinical studies.  Furthermore, out of all these compounds, only twenty have been successfully launched into the market.  In this paper, the history of the development and changes of the quinolones are described from the first quinolone, NA, via, the first new quinolone (6-fluorinated quinolone) NFLX, to the latest extended-spectrum quinolone antibacterial agents against multi-drug resistant bacterial infections.  NA has only modest activity against Gram-negative bacteria and low oral absorption, therefore a suitable candidate for treatment of systemic infections (UTIs) is required.  Since the original discovery of NA, a series of quinolones, which are referred to as the old quinolones, have been developed leading to the first new quinolone, NFLX, with moderate improvements in over all properties starting in 1962 through and continuing throughout the 1970's.  Especially, the drug design for pipemidic acid (PPA) indicated one of the important breakthroughs that lead to NFLX.  The introduction of a piperazinyl group, which ia a basic moiety at the C7-position of the quinolone nuclei, improved activity against Gram-negative organisms broadening the spectrum to include Pseudomonas aeruginosa.  PPA also showed soem activity against Gram-positive bac teria.  The basic piperazine ring, which can form the zwitterionic natrure with the carboxylic acid at the C3-position, has subsequently been shown to increase the ability of the drugs to penetrate the bacterial cells resulting in enhanced activity.  Further, the zwitterionic forms resulted in significant tissue penetration in the pharmacokinetics.  On the other hand, the first compound with a fluorine atom at the C6-position of the related quinolone scaffold was flumequine and the compound indicated that activity against Gram-positive bacteria could be improved in the old quinolones.  The addition of a flourine atom at the C6-position is essential for the inhibition of target enzymes.  The results show the poten antibacterial activity and the penetration of the quinolone molecule into the bacterial cells and human tissue.  The real breakthrough came with the combination of these two features in NFLX, a 6-fluorinated quinolone having a piperazinyl group at the C7-position, NFLX features significant differences from the old quinolones in the activities and pharmacokinetics in humans, resulting in high clinical efficacy in the treatment of many kinds of infections including RTIs.Consequently, those great discoveries are rapidly superseded by even better compounds and NFLX proved to be just the beginning of a highly successful period of research into the modifications of the new quinolone antibacterials.  Simce the chemical structure and important features of NFLX had become apparent in 1978, many compounds were patented in the next three years, several of which reached the market.  Among the drugs, ofloxacin (OFLX) and ciprofloxacin (CPFX) are recognized as superior in several respects to the oral beta-lactam antibiotics as an antibacterial agent.  With a focus on OFLX and CPFX, numerous research groups entered the antibacterial therapeutic field, triggering intense competition in the search to find newer, more effective quinolones.  After NFLX was introduced in the market, while resulting by the end of today, eleven kinds of other new quinolones launched in Japan.  They are enoxacin (ENX), OFLX, CPFX, lomefloxacin (LFLX), fleroxacin (FRLX), tosufloxacin (TFLX), levofloxacin (LVFX), sparfloxacin (SPFX), gatifloxacin (GFLX), prulifloxacin (PULX) and also pazufloxacin (PZFX).  The advantages of these compounds, e.g., LVFX, SPFX and GFLX, are that their spectrum includes Gram-positive bacteria species as well as Gram-negative bacteria and they improve bioavailability results when a daily dose is administered for systemic infections including RTIs.  However, unexpected adverse reactions, such as the CNS reaction, the drug-drug interaction, phototoxicity, hepatotoxicity and cardiotoxicity such as the QTc interval prolongation of ECG, have been reported in the clinical evaluations or the post-marketing surveillance of several new quinolones.  Moreover, the adverse reactions of arthropathy (the joint toxicity) predicated from studies in juvenile animals have never materialized in clinical use.  Therefore, no drugs other than NFLX have yet been approved for pediatric use.  Fortunately, the newer quinolones are being developed and tested to reduce these adverse reactions on the basis of recent studies.  On the other hand, multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphycolocci (MRCNS), penicillin-resistant Streptococcus pneumoniae (PRSP) and vancomycin-resistant enterococci (VRE) have been a serious problem in the medical community.  Recently, the new quinolone antibacterials are highly successful class of antibacterial therapeutic field, however, the increased isolation of quinolone-resistant bacteria above them has become a normal outcome.  These problems of multi-drug resistance have been the driving force for the development of newer quinolones.  The next gereration of quinolone antibacterial agents will be potent against multi-drug resistant bacteria, such as MRSA, and provide a lower rate of emergence in resistance.  Further, they should have favorable safety profiles to reduce the adverse reactions.  The future of quinolones as the ultimate in pharmaceuticals must be handled cautiously if they are to realize their potential in the medical community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8vA5u365FSnT4ugvCDgnZfW6udTcc2eZzi35J7FC-5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ksFeisw%253D%253D&md5=d54979b47150eb3872992253b3569850</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAkimoto%26aufirst%3DT.%26atitle%3DThe%2520history%2520of%2520the%2520development%2520and%2520changes%2520of%2520quinolone%2520antibacterial%2520agents%26jtitle%3DJpn.%2520J.%2520Hist.%2520Pharm.%26date%3D2003%26volume%3D38%26issue%3D2%26spage%3D161%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_contrib-group">Fuller, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low., D. E.</span><span> </span><span class="NLM_article-title">A review of <i>Streptococcus pneumoniae</i> infection treatment failures associated with fluoroquinolone resistance</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1086%2F430829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=15937772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ptVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=118-121&author=J.+D.+Fullerauthor=D.+E.+Low.&title=A+review+of+Streptococcus+pneumoniae+infection+treatment+failures+associated+with+fluoroquinolone+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance</span></div><div class="casAuthors">Fuller Jeffrey D; Low Donald E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We reviewed all of the published reports of cases of fluoroquinolone treatment failures for respiratory tract infection due to fluoroquinolone-resistant Streptococcus pneumoniae.  There were 20 ciprofloxacin and levofloxacin treatment failures reported.  Physicians should be aware, when treating pneumococcal respiratory tract infections in older patients with a fluoroquinolone, that clinical failures might occur, especially for patients with comorbid illnesses and a history of recent fluoroquinolone use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAcAREMijQLrqxQ2mb9Pu8fW6udTcc2eZzi35J7FC-5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ptVWmsw%253D%253D&md5=f7451bde71559f2f18dea4f852afc4e1</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1086%2F430829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F430829%26sid%3Dliteratum%253Aachs%26aulast%3DFuller%26aufirst%3DJ.%2BD.%26aulast%3DLow.%26aufirst%3DD.%2BE.%26atitle%3DA%2520review%2520of%2520Streptococcus%2520pneumoniae%2520infection%2520treatment%2520failures%2520associated%2520with%2520fluoroquinolone%2520resistance%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D41%26spage%3D118%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_contrib-group">Hoffman-Roberts, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C. Babcock,  E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitropoulos, I. F.</span><span> </span><span class="NLM_article-title">Investigational new drugs for the treatment of resistant pneumococcal infections</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=973-995&issue=8&author=H.+L.+Hoffman-Robertsauthor=+E.+C.+Babcockauthor=I.+F.+Mitropoulos&title=Investigational+new+drugs+for+the+treatment+of+resistant+pneumococcal+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman-Roberts%26aufirst%3DH.%2BL.%26aulast%3DC.%2BBabcock%26aufirst%3DE.%26aulast%3DMitropoulos%26aufirst%3DI.%2BF.%26atitle%3DInvestigational%2520new%2520drugs%2520for%2520the%2520treatment%2520of%2520resistant%2520pneumococcal%2520infections%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2005%26volume%3D14%26issue%3D8%26spage%3D973%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motola, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F11531850-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=20297862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls12murk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=303-314&issue=4&author=E.+Poluzziauthor=E.+Raschiauthor=D.+Motolaauthor=U.+Morettiauthor=F.+De+Ponti&title=Antimicrobials+and+the+risk+of+torsades+de+pointes%3A+the+contribution+from+data+mining+of+the+US+FDA+Adverse+Event+Reporting+System"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System</span></div><div class="casAuthors">Poluzzi, Elisabetta; Raschi, Emanuel; Motola, Domenico; Moretti, Ugo; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-314</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">Background: Drug-induced torsades de pointes (TdP) is a complex regulatory and clin. problem due to the rarity of this sometimes fatal adverse event.  In this context, the US FDA Adverse Event Reporting System (AERS) is an important source of information, which can be applied to the anal. of TdP liability of marketed drugs.  Objective: To critically evaluate the risk of antimicrobial-induced TdP by detecting alert signals in the AERS, on the basis of both quant. and qual. analyses.  Methods: Reports of TdP from Jan. 2004 through Dec. 2008 were retrieved from the public version of the AERS.  The abs. no. of cases and reporting odds ratio as a measure of disproportionality were evaluated for each antimicrobial drug (quant. approach).  A list of drugs with suspected TdP liability (provided by the Arizona Center of Education and Research on Therapeutics [CERT]) was used as a ref. to define signals.  In a further anal., to refine signal detection, we identified TdP cases without co-medications listed by Arizona CERT (qual. approach).  Results: Over the 5-yr period, 374 reports of TdP were retrieved: 28 anti-bacterials, 8 antifungals, 1 antileprosy and 26 antivirals were involved.  Antimicrobials more frequently reported were levofloxacin (55) and moxifloxacin (37) among the antibacterials, fluconazole (47) and voriconazole (17) among the antifungals, and lamivudine (8) and nelfinavir (6) among the antivirals.  A significant disproportionality was obsd. for 17 compds., including several macrolides, fluoroquinolones, linezolid, triazole antifungals, caspofungin, indinavir and nelfinavir.  With the qual. approach, we identified the following addnl. drugs or fixed dose combinations, characterized by at least two TdP cases without co-medications listed by Arizona CERT: ceftriaxone, piperacillin/tazobactam, cotrimoxazole, metronidazole, ribavirin, lamivudine and lopinavir/ritonavir.  Discussion: Disproportionality for macrolides, fluoroquinolones and most of the azole antifungals should be viewed as 'expected' according to Arizona CERT list.  By contrast, signals were generated by linezolid, caspofungin, posaconazole, indinavir and nelfinavir.  Drugs detected only by the qual. approach should be further investigated by increasing the sensitivity of the method, e.g. by searching also for the TdP surrogate marker, prolongation of the QT interval.  Conclusions: The freely available version of the FDA AERS database represents an important source to detect signals of TdP.  In particular, our anal. generated five signals among antimicrobials for which further investigations and active surveillance are warranted.  These signals should be considered in evaluating the benefit-risk profile of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkddzQ8GgdLVg90H21EOLACvtfcHk0lj_Ikklk7E4PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls12murk%253D&md5=68a94e209a7f51d386fd8f202df500c0</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.2165%2F11531850-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11531850-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DMotola%26aufirst%3DD.%26aulast%3DMoretti%26aufirst%3DU.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DAntimicrobials%2520and%2520the%2520risk%2520of%2520torsades%2520de%2520pointes%253A%2520the%2520contribution%2520from%2520data%2520mining%2520of%2520the%2520US%2520FDA%2520Adverse%2520Event%2520Reporting%2520System%26jtitle%3DDrug%2520Saf.%26date%3D2010%26volume%3D33%26issue%3D4%26spage%3D303%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_contrib-group">Falagas, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafailidis, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosmarakis, E. S.</span><span> </span><span class="NLM_article-title">Arrhythmias associated with fluoroquinolone therapy</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1016%2Fj.ijantimicag.2006.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=17241772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=374-379&issue=4&author=M.+E.+Falagasauthor=P.+I.+Rafailidisauthor=E.+S.+Rosmarakis&title=Arrhythmias+associated+with+fluoroquinolone+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Arrhythmias associated with fluoroquinolone therapy</span></div><div class="casAuthors">Falagas, Matthew E.; Rafailidis, Petros I.; Rosmarakis, Evangelos S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">374-379</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fluoroquinolones are widely used and well tolerated antibacterial agents.  However, prolongation of the QT interval is an adverse effect assocd. with the use of fluoroquinolones.  According to the available case reports and clin. studies, moxifloxacin carries the greatest risk of QT prolongation from all available quinolones in clin. practice and it should be used with caution in patients with predisposing factors for Torsades de pointes (Tdp).  Although gemifloxacin, levofloxacin and ofloxacin are assocd. with a lower risk of QT prolongation compared with moxifloxacin, they should also be used with caution in patients with risk factors for QT prolongation.  Ciprofloxacin appears to be assocd. with the lowest risk for QT prolongation and the lowest rate of Tdp.  The overall risk of Tdp is small with the use of fluoroquinolones.  Clinicians can minimise that risk by avoiding prescriptions of multiple medications assocd. with QT interval prolongation, esp. in high-risk patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJyMt602Wu_7Vg90H21EOLACvtfcHk0lgI8OGq0piPBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislehs7Y%253D&md5=39aab28223fa27b61898ec823b3f5771</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2006.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2006.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DFalagas%26aufirst%3DM.%2BE.%26aulast%3DRafailidis%26aufirst%3DP.%2BI.%26aulast%3DRosmarakis%26aufirst%3DE.%2BS.%26atitle%3DArrhythmias%2520associated%2520with%2520fluoroquinolone%2520therapy%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2007%26volume%3D29%26issue%3D4%26spage%3D374%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_contrib-group">Owens, R. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrose, P. G.</span><span> </span><span class="NLM_article-title">Torsades de pointes associated with fluoroquinolones</span> <span class="citation_source-journal">Pharmacotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=663-668&issue=5&author=R.+C.+Owensauthor=P.+G.+Ambrose&title=Torsades+de+pointes+associated+with+fluoroquinolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DR.%2BC.%26aulast%3DAmbrose%26aufirst%3DP.%2BG.%26atitle%3DTorsades%2520de%2520pointes%2520associated%2520with%2520fluoroquinolones%26jtitle%3DPharmacotherapy%26date%3D2002%26volume%3D22%26issue%3D5%26spage%3D663%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_contrib-group">Mehlhorn, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. A.</span><span> </span><span class="NLM_article-title">Safety concerns with fluoroquinolones</span> <span class="citation_source-journal">Ann Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1859</span><span class="NLM_x">–</span> <span class="NLM_lpage">1866</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2007&pages=1859-1866&issue=11&author=A.+J.+Mehlhornauthor=D.+A.+Brown&title=Safety+concerns+with+fluoroquinolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMehlhorn%26aufirst%3DA.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BA.%26atitle%3DSafety%2520concerns%2520with%2520fluoroquinolones%26jtitle%3DAnn%2520Pharmacother.%26date%3D2007%26volume%3D41%26issue%3D11%26spage%3D1859%26epage%3D1866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_contrib-group">Sprandel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodvold, K. A.</span><span> </span><span class="NLM_article-title">Safety and tolerability of fluoroquinolones</span> <span class="citation_source-journal">Clin Cornerstone</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S29</span><span class="NLM_x">–</span> <span class="NLM_lpage">S36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=S29-S36&issue=Suppl.+3&author=K.+A.+Sprandelauthor=K.+A.+Rodvold&title=Safety+and+tolerability+of+fluoroquinolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSprandel%26aufirst%3DK.%2BA.%26aulast%3DRodvold%26aufirst%3DK.%2BA.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520fluoroquinolones%26jtitle%3DClin%2520Cornerstone%26date%3D2003%26issue%3DSuppl.%25203%26spage%3DS29%26epage%3DS36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Kawakami, K.; Ohki, H.; Kimura, K.; Tanaka, M.; Takemura, M.; Sato, K.; Takahashi, H.; Hayakawa, I.</span><span> </span><span class="NLM_article-title">DK-507k, a New 8-Methoxyquinolones: Synthesis and Biological Evaluation of 7-[(3-Amino-4-substituted)pyrrolidine-1-yl] Derivatives</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Society for Microbiology</span>: <span class="NLM_publisher-loc">Washington, DC</span>; Abstract F-546.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=K.+Kawakami&author=H.+Ohki&author=K.+Kimura&author=M.+Tanaka&author=M.+Takemura&author=K.+Sato&author=H.+Takahashi&author=I.+Hayakawa&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKawakami%26aufirst%3DK.%26atitle%3DDK-507k%252C%2520a%2520New%25208-Methoxyquinolones%253A%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25207-%255B%25283-Amino-4-substituted%2529pyrrolidine-1-yl%255D%2520Derivatives%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2001%26pub%3DAmerican%2520Society%2520for%2520Microbiology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Dresser, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, D. G.</span><span> </span><span class="NLM_article-title">Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 #A4 inhibition</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F00003088-200038010-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=10668858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2000&pages=41-57&author=G.+K.+Dresserauthor=J.+D.+Spenceauthor=D.+G.+Bailey&title=Pharmacokinetic-pharmacodynamic+consequences+and+clinical+relevance+of+cytochrome+P450+%23A4+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition</span></div><div class="casAuthors">Dresser, George K.; Spence, J. David; Bailey, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-57</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 162 refs.  Drug interactions occur when the efficacy or toxicity of a medication is changed by administration of another substance.  Pharmacokinetic interactions often occur as a result of a change in drug metab.  Cytochrome P 450 (CYP) 3A4 oxidizes a broad spectrum of drugs by a no. of metabolic processes.  The location of CYP3A4 in the small bowel and liver permits an effect on both presystemic and systemic drug disposition.  Some interactions with CYP3A4 inhibitors may also involve inhibition of P-glycoprotein.  Clin. important CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir and grapefruit juice.  Torsades de pointes, a life-threatening ventricular arrhythmia assocd. with QT prolongation, can occur when these inhibitors are coadministered with terfenadine, astemizole, cisapride or pimozide.  Rhabdomyolysis has been assocd. with the coadministration of some 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors ("statins") and CYP3A4 inhibitors.  Symptomatic hypotension may occur when CYP3A4 inhibitors are given with some dihydropyridine calcium antagonists, as well with the phosphodiesterase inhibitor sildenafil.  Excessive sedation can result from concomitant administration of benzodiazepine (midazolam, triazolam, alprazolam or diazepam) or nonbenzodiazepine (zopiclone and buspirone) hypnosedatives with CYP3A4 inhibitors.  Ataxia can occur with carbamazepine, and ergotism with ergotamine, following the addn. of a CYP3A4 inhibitor.  Beneficial drug interactions can occur.  Administration of a CYP3A4 inhibitor with cyclosporin may allow redn. of the dosage and cost of the immunosuppressant.  Certain HIV protease inhibitors, e.g. saquinavir, have low oral bioavailability that can be profoundly increased by the addn. of ritonavir.  The clin. importance of any drug interaction depends on factors that are drug-, patient- and administration-related.  Generally, a doubling or more in plasma drug concn. has the potential for enhanced adverse or beneficial drug response.  Less pronounced pharmacokinetic interactions may still be clin. important for drugs with a steep concn.-response relation or narrow therapeutic index.  In most cases, the extent of drug interaction varies markedly among individuals; this is likely to be dependent on interindividual differences in CYP3A4 tissue content, pre-existing medical conditions and, possibly, age.  Interactions may occur under single dose conditions or only at steady state.  The pharmacodynamic consequences may or may not closely follow pharmacokinetic changes.  Drug interactions may be most apparent when patients are stabilized on the affected drug and the CYP3A4 inhibitor is then added to the regimen.  Temporal relationships between the administration of the drug and CYP3A4 inhibitor may be important in detg. the extent of the interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowhzNIdr3F67Vg90H21EOLACvtfcHk0lhfpTSXFOlSaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2kurw%253D&md5=c879e684a067e66a2c0436bdfc53cd64</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.2165%2F00003088-200038010-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200038010-00003%26sid%3Dliteratum%253Aachs%26aulast%3DDresser%26aufirst%3DG.%2BK.%26aulast%3DSpence%26aufirst%3DJ.%2BD.%26aulast%3DBailey%26aufirst%3DD.%2BG.%26atitle%3DPharmacokinetic-pharmacodynamic%2520consequences%2520and%2520clinical%2520relevance%2520of%2520cytochrome%2520P450%2520%2523A4%2520inhibition%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2000%26volume%3D38%26spage%3D41%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions</span> <span class="citation_source-journal">Curr Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2174%2F138920007780866807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=17584015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=407-447&issue=5&author=A.+S.+Kalgutkarauthor=R.+S.+Obachauthor=T.+S.+Maurer&title=Mechanism-based+inactivation+of+cytochrome+P450+enzymes%3A+chemical+mechanisms%2C+structure%E2%80%93activity+relationships+and+relationship+to+clinical+drug%E2%80%93drug+interactions+and+idiosyncratic+adverse+drug+reactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions</span></div><div class="casAuthors">Kalgutkar, Amit S.; Obach, R. Scott; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-447</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 constitute a superfamily of heme-contg. enzymes that catalyze the oxidative biotransformation of structurally diverse xenobiotics including drugs.  Inhibition of P 450 enzymes is by far the most common mechanism which can lead to DDIs.  P 450 inhibition can be categorized as reversible (competitive or non-competitive) or irreversible (mechanism-based inactivation).  Mechanism-based P 450 inactivation usually involves bioactivation of the xenobiotic to a reactive intermediate, which covalently modifies an active site amino acid residue and/or coordinates to the heme prosthetic group.  Covalent modification of P 450 enzymes can also lead to hapten formation and can in some cases trigger an autoimmune response resulting in toxicol. consequences.  Compared to reversible inhibition, irreversible inhibition more frequently results in unfavorable DDIs as the inactivated P 450 enzyme has to be replaced by newly synthesized protein.  For these reasons, most drug metab. groups within pharmaceutical companies have well-established screening paradigms to assess mechanism-based inactivation of major human P 450 enzymes by new chem. entities followed by indepth mechanistic studies to elucidate the mechanism of P 450 inactivation when a pos. finding is discerned.  A deeper understanding of the process leading to enzyme inactivation by drug candidates can lead to rational chem. intervention strategies to circumvent the P 450 inactivation/bioactivation liability.  Apart from structure-activity relationship studies, methodol. to predict the magnitude of in vivo metabolic DDIs using in vitro P 450 inactivation data and predicted human pharmacokinetics of the candidate drug also exists and can be utilized to project the extent of clin. DDIs against P 450 enzyme-specific substrates.  In this review, a comprehensive anal. of the biochem. basis and known structure-activity relationships for P 450 inactivation by xenobiotics is described.  In addn., the current state-of-the-art of the methodol. used in predicting the magnitude of DDIs using in vitro P 450 inactivation data and human pharmacokinetic parameters is discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV8akoVDkMzrVg90H21EOLACvtfcHk0lhfpTSXFOlSaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D&md5=f2ee4172b6165268710c10dcc32fecb4</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.2174%2F138920007780866807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866807%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520chemical%2520mechanisms%252C%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520relationship%2520to%2520clinical%2520drug%25E2%2580%2593drug%2520interactions%2520and%2520idiosyncratic%2520adverse%2520drug%2520reactions%26jtitle%3DCurr%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26issue%3D5%26spage%3D407%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_contrib-group">Thompson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidolf, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claesson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolgos, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenna, J. G.</span><span> </span><span class="NLM_article-title">Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development</span> <span class="citation_source-journal">Chem.-Biol. Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1016%2Fj.cbi.2010.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=21074519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVyiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2011&pages=65-71&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=R.+Weaverauthor=L.+Weidolfauthor=I.+Wilsonauthor=A.+Claessonauthor=K.+Pageauthor=H.+Dolgosauthor=J.+G.+Kenna&title=Risk+assessment+and+mitigation+strategies+for+reactive+metabolites+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weaver, Richard; Weidolf, Lars; Wilson, Ian; Claesson, Alf; Page, Ken; Dolgos, Hugues; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug toxicity is a leading cause of attrition of candidate drugs during drug development as well as of withdrawal of drugs post-licensing due to adverse drug reactions in man.  These adverse drug reactions cause a broad range of clin. severe conditions including both highly reproducible and dose dependent toxicities as well as relatively infrequent and idiosyncratic adverse events.  The underlying risk factors can be split into two groups: (1) drug-related and (2) patient-related.  The drug-related risk factors include metabolic factors that det. the propensity of a mol. to form toxic reactive metabolites (RMs), and the RM and non-RM mediated mechanisms which cause cell and tissue injury.  Patient related risk factors may vary markedly between individuals, and encompass genetic and non-genetic processes, e.g. environmental, that influence the disposition of drugs and their metabolites, the nature of the adverse responses elicited and the resulting biol. consequences.  We describe a new strategy, which builds upon the strategies used currently within numerous pharmaceutical companies to avoid and minimize RM formation during drug discovery, and that is intended to reduce the likelihood that candidate drugs will cause toxicity in the human population.  The new strategy addresses drug-related safety hazards, but not patient-related risk factors.  A common target organ of toxicity is the liver and to decrease the likelihood that candidate drugs will cause liver toxicity (both non-idiosyncratic and idiosyncratic), we propose use of an in vitro Hepatic Liability Panel alongside in vitro methods for the detection of RMs.  This will enable design and selection of compds. in discovery that have reduced propensity to cause liver toxicity.  In vitro Hepatic Liability is assessed using toxicity assays that quantify: CYP 450 dependent and CYP 450 independent cell toxicity; mitochondrial impairment; and inhibition of the Bile Salt Export Pump.  Prior to progression into development, a Hepatotoxicity Hazard Matrix combines data from the Hepatic Liability Panel with the Estd. RM Body Burden.  The latter is defined as the level of covalent binding of radiolabeled drug to human hepatocyte proteins in vitro adjusted for the predicted human dose.  We exemplify the potential value of this approach by consideration of the thiazolidinedione class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAv1YMcAPyUrVg90H21EOLACvtfcHk0lhfpTSXFOlSaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVyiu7c%253D&md5=54ef4b6d98e18d3b7d3ae75ad0d6c114</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2010.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2010.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DClaesson%26aufirst%3DA.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DRisk%2520assessment%2520and%2520mitigation%2520strategies%2520for%2520reactive%2520metabolites%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2011%26volume%3D192%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_contrib-group">Omar, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. P.</span><span> </span><span class="NLM_article-title">FDA adverse event reports on strain-associated rhabdomyolysis</span> <span class="citation_source-journal">Anal. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1345%2Faph.1A289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=11847951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2002&pages=288-295&author=M.+A.+Omarauthor=J.+P.+Wilson&title=FDA+adverse+event+reports+on+strain-associated+rhabdomyolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">FDA adverse event reports on statin-associated rhabdomyolysis</span></div><div class="casAuthors">Omar, Mohamed A.; Wilson, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-295</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1060-0280</span>.
    
            (<span class="NLM_cas:orgname">Harvey Whitney Books Co.</span>)
        </div><div class="casAbstract">The aim of this study was to det. the no. of cases of statin-assocd. rhabdomyolysis reported to the Food and Drug Administration for 6 statins and to profile the cases.  This was a retrospective anal. of all domestic and foreign reports of statin-assocd. rhabdomyolysis between Nov. 1997 and Mar. 2000 was conducted.  Outcome measures included the total no. of reports (initial plus follow-up), the no. of unique cases, age, gender, percentages of report codes and role codes, and frequencies of concomitant interacting drugs that may have pptd. rhabdomyolysis, outcomes codes, and report source codes.  There were 871 reports of statin-assocd. rhabdomyolysis in the 29-mo time frame examd., representing 601 cases.  The following no. of cases were assocd. with each of the individual statins: simvastatin, 215 (35.8%); cerivastatin, 192 (31.9%); atorvastatin, 73 (12.2%); pravastatin, 71 (11.8%); lovastatin, 40 (6.7%); and fluvastatin, 10 (1.7%).  Drugs that may have interacted with the statins were present in the following no. of cases: mibefradil (n = 99), fibrates (n = 80), cyclosporine (n = 51), macrolide antibiotics (n = 42), warfarin (n = 33), digoxin (n = 26), and azole antifungals (n = 12).  The reports of 62.1% of cases were classified as expedited.  Statins were designated as the primary suspect in 72.0% of the cases.  Death was listed as the outcome in 38 cases.  The majority of reports (n = 556) were from health professionals.  Compared with the other statins, simvastatin and cerivastatin were implicated in a relatively higher no. of reports.  Because of the various limitations of a spontaneous reporting-system database, caution is urged when interpreting the relative no. of cases reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSlPH9OWymc7Vg90H21EOLACvtfcHk0lho7SPiZuehLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFOjtLg%253D&md5=3822b4283e0e0fd1daeb1837afdf1e10</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1345%2Faph.1A289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1A289%26sid%3Dliteratum%253Aachs%26aulast%3DOmar%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DJ.%2BP.%26atitle%3DFDA%2520adverse%2520event%2520reports%2520on%2520strain-associated%2520rhabdomyolysis%26jtitle%3DAnal.%2520Pharmacother.%26date%3D2002%26volume%3D36%26spage%3D288%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_contrib-group">Utrehit, J.</span><span> </span><span class="NLM_article-title">Idiosyncratic drug reactions: past, present, and future</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=84-92&issue=1&author=J.+Utrehit&title=Idiosyncratic+drug+reactions%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUtrehit%26aufirst%3DJ.%26atitle%3DIdiosyncratic%2520drug%2520reactions%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26issue%3D1%26spage%3D84%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Silverman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrillo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. T.</span><span> </span><span class="NLM_article-title">Mechanism-based enzyme inactivation via a diactivated cyclopropane intermediate</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2982</span><span class="NLM_x">–</span> <span class="NLM_lpage">2983</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00060a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=2982-2983&author=R.+B.+Silvermanauthor=C.+Z.+Dingauthor=J.+L.+Borrilloauthor=J.+T.+Chang&title=Mechanism-based+enzyme+inactivation+via+a+diactivated+cyclopropane+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fja00060a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00060a059%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26aulast%3DBorrillo%26aufirst%3DJ.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BT.%26atitle%3DMechanism-based%2520enzyme%2520inactivation%2520via%2520a%2520diactivated%2520cyclopropane%2520intermediate%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D2982%26epage%3D2983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Borlak, J.</span><span> </span><span class="NLM_article-title">Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity—molecular mechanisms and lessons for pharmacotoxicity</span> <span class="citation_source-journal">Hum. Exp. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">2–3</span><span class="NLM_x">) </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1177%2F0960327109105767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=19713375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kitb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=119-121&issue=2%E2%80%933&author=J.+Borlak&title=Trovafloxacin%3A+a+case+study+of+idiosyncratic+or+iatrogenic+liver+toxicity%E2%80%94molecular+mechanisms+and+lessons+for+pharmacotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity molecular mechanisms and lessons for pharmacotoxicity</span></div><div class="casAuthors">Borlak, J.</div><div class="citationInfo"><span class="NLM_cas:title">Human & Experimental Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">119-121</span>CODEN:
                <span class="NLM_cas:coden">HETOEA</span>;
        ISSN:<span class="NLM_cas:issn">0960-3271</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The genomic responses to hepatocyte toxicity assocd. with trovafloxacin, and which kinds of metabolic pathways are perturbed were examd. using DNA microarrays.  It was shown that the drug inhibits mammalian and bacterial topoisomerases.  In addn., hepatic nuclear factor-4α expression was severely reduced by this drug.  It can be concluded that primary human hepatocyte culture studies supplied significant data on a mechanism of idiosyncratic liver toxicity, and may have been used to predict the excessive hepatotoxicity of trovafloxacin, and of other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJdB41P7edpbVg90H21EOLACvtfcHk0lho7SPiZuehLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kitb3E&md5=c4c20158bf7ba99186b48d174a334bd1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F0960327109105767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0960327109105767%26sid%3Dliteratum%253Aachs%26aulast%3DBorlak%26aufirst%3DJ.%26atitle%3DTrovafloxacin%253A%2520a%2520case%2520study%2520of%2520idiosyncratic%2520or%2520iatrogenic%2520liver%2520toxicity%25E2%2580%2594molecular%2520mechanisms%2520and%2520lessons%2520for%2520pharmacotoxicity%26jtitle%3DHum.%2520Exp.%2520Toxicol.%26date%3D2009%26volume%3D28%26issue%3D2%25E2%2580%25933%26spage%3D119%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kawakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemura, M.</span><span> </span><span class="NLM_article-title">Studies on 8-methoxyquinolones: synthesis and antibacterial activity of 7-(3-amino-4-substituted)pyrrolidinyl derivatives</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1667</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2000&pages=1667-1672&issue=11&author=K.+Kawakamiauthor=H.+Takahashiauthor=H.+Ohkiauthor=K.+Kimuraauthor=S.+Miyauchiauthor=R.+Miyauchiauthor=M.+Takemura&title=Studies+on+8-methoxyquinolones%3A+synthesis+and+antibacterial+activity+of+7-%283-amino-4-substituted%29pyrrolidinyl+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKawakami%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DOhki%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DMiyauchi%26aufirst%3DS.%26aulast%3DMiyauchi%26aufirst%3DR.%26aulast%3DTakemura%26aufirst%3DM.%26atitle%3DStudies%2520on%25208-methoxyquinolones%253A%2520synthesis%2520and%2520antibacterial%2520activity%2520of%25207-%25283-amino-4-substituted%2529pyrrolidinyl%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2000%26volume%3D48%26issue%3D11%26spage%3D1667%26epage%3D1672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cornforth, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornforth, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, K. K.</span> <span class="citation_source-journal">J. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_fpage">2539</span><span class="NLM_x">–</span> <span class="NLM_lpage">2547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cornforth%2C+J.+W.%3B+Cornforth%2C+R.+H.%3B+Mathew%2C+K.+K.J.+Chem.+Soc.+1959%2C+2539%E2%80%932547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCornforth%26aufirst%3DJ.%2BW.%26aulast%3DCornforth%26aufirst%3DR.%2BH.%26aulast%3DMathew%26aufirst%3DK.%2BK.%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1959%26spage%3D2539%26epage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="note"><p class="first last">Compound <b>11</b> (or starting material) was prepared by our method described in PCT Int. Appl. WO2006123792 A1, <span class="NLM_year">2006</span>. <sup>1</sup>H NMR (CDCl<sub>3</sub>), δ ppm: 1.34 (12H, s), 1.52 (3H, d, <i>J</i> = 7.10 Hz), 2.27 (1H, d, <i>J</i> = 17.0 Hz), 2.93 (1H, d, <i>J</i> = 17.0 Hz), 3.05 (1H, d, <i>J</i> = 10.1 Hz), 3.32 (1H, d, <i>J</i> = 10.1 Hz), 5.50 (1H, q, <i>J</i> = 7.1 Hz), 7.23–7.38 (5H, m).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_contrib-group">Murayama, N.; Tachibana, M.; Takao, A.; Okazaki, O.; Sudo, K.</span><span> </span><span class="NLM_article-title">DC-159a, a New Generation Respiratory Quinolone: Pharmacokinetics in Rats and Monkeys</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Society for Microbiology</span>: <span class="NLM_publisher-loc">Washington, DC</span>; Abstract F1-0477.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=N.+Murayama&author=M.+Tachibana&author=A.+Takao&author=O.+Okazaki&author=K.+Sudo&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurayama%26aufirst%3DN.%26atitle%3DDC-159a%252C%2520a%2520New%2520Generation%2520Respiratory%2520Quinolone%253A%2520Pharmacokinetics%2520in%2520Rats%2520and%2520Monkeys%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2006%26pub%3DAmerican%2520Society%2520for%2520Microbiology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><div class="note"><p class="first last">Experimental reference of mechanism-based inhibition is as follows: </p></div><span class="NLM_contrib-group">Madan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usuki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs</span> <span class="citation_source-journal">Drugs Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot1Ortb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2002&pages=217-294&author=A.+Madanauthor=E.+Usukiauthor=L.+A.+Burtonauthor=B.+W.+Ogilvieauthor=A.+Parkinson&title=In+vitro+approaches+for+studying+the+inhibition+of+drug-metabolizing+enzymes+and+identifying+the+drug-metabolizing+enzymes+responsible+for+the+metabolism+of+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs</span></div><div class="casAuthors">Madan, Ajay; Usuki, Etsuko; Burton, L. Alayne; Ogilvie, Brian W.; Parkinson, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drugs and the Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">Drug-Drug Interactions</span>),
    <span class="NLM_cas:pages">217-294</span>CODEN:
                <span class="NLM_cas:coden">DPHSDS</span>;
        ISSN:<span class="NLM_cas:issn">0360-2583</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review on the in vitro systems for studying the inhibition of drug-metabolizing enzymes and the identification of drug-metabolizing enzymes involved in the metab. of a drug.  Various exptl. designs, their advantages and pitfalls, and extrapolation of in vitro data to the clin. situation are also discussed.  Particular focus is given to cytochrome P 450 enzymes, because most of the clin. relevant pharmacokinetic drug interactions are, in one way or another, related to P 450 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopsTSmwbgSYLVg90H21EOLACvtfcHk0lg78US8mPAokA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot1Ortb0%253D&md5=07f2d67ac696ad5a6607bd483c307732</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DUsuki%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%2BA.%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520approaches%2520for%2520studying%2520the%2520inhibition%2520of%2520drug-metabolizing%2520enzymes%2520and%2520identifying%2520the%2520drug-metabolizing%2520enzymes%2520responsible%2520for%2520the%2520metabolism%2520of%2520drugs%26jtitle%3DDrugs%2520Pharm.%2520Sci.%26date%3D2002%26volume%3D116%26spage%3D217%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_contrib-group">Ponte, M. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Girolamo, G.</span><span> </span><span class="NLM_article-title">Mechanisms of drug induced QT interval prolongation</span> <span class="citation_source-journal">Curr Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2174%2F157488610789869247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=20210718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFeqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=44-53&issue=1&author=M.+L+Ponteauthor=G.+A.+Kellerauthor=G.+Di+Girolamo&title=Mechanisms+of+drug+induced+QT+interval+prolongation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug induced QT interval prolongation</span></div><div class="casAuthors">Ponte, Marcelo Luis; Keller, Guillermo Alberto; Di Girolamo, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-53</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The long QT syndrome (LQTS) is characterized by a prolonged QT interval, as well as a propensity to develop syncope and sudden cardiac death caused by the malignant polymorphic ventricular arrhythmia called torsades de pointes (TdP).  The QT interval is measured from the onset of the QRS complex to the end of the T wave and can be affected by both ventricular conduction velocities as well as by the velocity of repolarization.  In most cases, QT prolongation is caused by factors that prolong the duration of the action potential, mainly by delaying the repolarization phase 3.  The mol. mechanism is partially known.  There are two well described mechanisms: blocking of the ion channel cavity of HERG; or causing an abnormal protein trafficking required for the location of HERG subunits in cell membrane.  Both of them impair the IKr current.  However the blockade of ion channels is not the only condition to generate TdP.  Other factors may play an important role, e.g. myocardium heterogeneity, drug-drug interaction, genetic polymorphism, and electrolyte disturbances.  Several drugs had been subject of withdrawal because QT-prolongation and arrhythmia.  Understanding of processes involved in drug-induced QT prolongation is needed for the study and prevention of life-threatening arrhythmias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqey6q8MXCoe7Vg90H21EOLACvtfcHk0lg78US8mPAokA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFeqtbg%253D&md5=2e7a05d5105cb97776197407fe09996a</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.2174%2F157488610789869247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488610789869247%26sid%3Dliteratum%253Aachs%26aulast%3DPonte%26aufirst%3DM.%2BL%26aulast%3DKeller%26aufirst%3DG.%2BA.%26aulast%3DDi%2BGirolamo%26aufirst%3DG.%26atitle%3DMechanisms%2520of%2520drug%2520induced%2520QT%2520interval%2520prolongation%26jtitle%3DCurr%2520Drug%2520Saf.%26date%3D2010%26volume%3D5%26issue%3D1%26spage%3D44%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_contrib-group">Lagrutta, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepakova, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2174%2F156802608785700016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=18782006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1102-1112&issue=13&author=A.+A.+Lagruttaauthor=E.+S.+Trepakovaauthor=J.+J.+Salata&title=The+hERG+channel+and+risk+of+drug-acquired+cardiac+arrhythmia%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview</span></div><div class="casAuthors">Lagrutta, Armando A.; Trepakova, Elena S.; Salata, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1102-1112</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the assocd. risk of ventricular arrhythmia and fibrillation.  The mol. characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation.  The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to det. structure-activity relations (SAR) within chem. series.  More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chem. series is a viable strategy to reduce or eliminate hERG activity.  Despite a crit. need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoixN90Myu6bVg90H21EOLACvtfcHk0ljgrPJCiIL3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsrjK&md5=31c03ae1d1c67bf8f85d804c7b2fe2d2</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.2174%2F156802608785700016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785700016%26sid%3Dliteratum%253Aachs%26aulast%3DLagrutta%26aufirst%3DA.%2BA.%26aulast%3DTrepakova%26aufirst%3DE.%2BS.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520hERG%2520channel%2520and%2520risk%2520of%2520drug-acquired%2520cardiac%2520arrhythmia%253A%2520an%2520overview%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D13%26spage%3D1102%26epage%3D1112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_contrib-group">Liu, H. H.</span><span> </span><span class="NLM_article-title">Safety profile of the fluoroquinolones: focus on levofloxacin</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F11536360-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=20397737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslejt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=353-369&issue=5&author=H.+H.+Liu&title=Safety+profile+of+the+fluoroquinolones%3A+focus+on+levofloxacin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of the fluoroquinolones: focus on levofloxacin</span></div><div class="casAuthors">Liu, Hans H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-369</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  The fluoroquinolone class of antibacterial agents are among the most frequently prescribed drugs, with utility in a broad range of bacterial infections.  Although very useful agents, the fluoroquinolones as a class are assocd. with a no. of adverse events, some with considerable clin. significance.  In the past 15-20 years, tolerability concerns have led to restrictions on the use of the fluoroquinolones and, in some instances, the withdrawal of agents from the market.  This review focuses on the safety and tolerability of levofloxacin, a third-generation fluoroquinolone, relative to other fluoroquinolones.  A literature search was performed of the MEDLINE database encompassing the dates 1980-2009, using as keywords the drug names levofloxacin and concurrently marketed fluoroquinolones combined with the words 'safety', 'adverse effect' or 'adverse drug reaction', or the name of the specific adverse effect.  Adverse events commonly assocd. with the fluoroquinolones include gastrointestinal and CNS toxicity (most frequently headache and dizziness), as well as other adverse events including ECG abnormalities (for example QT interval prolongation), disrupted glucose metab., phototoxicity, tendon and joint disorders, hypersensitivity and skin disorders, and hepatic toxicity.  Package inserts for the fluoroquinolones in Europe and the US contain warnings regarding these risks.  US package inserts also carry 'black-box' warnings regarding the risk of tendon rupture and joint disorders with these agents; however, there is a substantial body of evidence to indicate that there are marked differences in the tolerability profiles of the individual agents within the fluoroquinolone class.  These differences may be explained, at least in part, by structural differences: all fluoroquinolones share a basic quinolone core, with differences in specific side chains underlying the adverse event relationships.  Furthermore, many of the fluoroquinolone-assocd. adverse effects and toxicities occur more frequently in patients with pre-existing risk factors, or in certain subpopulations.  Notably, package inserts for the fluoroquinolones carry warnings regarding use in the elderly, paediatric patients and patients with preexisting, or factors predisposing to, seizure disorders.  Because of this, many adverse reactions with these agents could be prevented by improving patient screening and education.  The recent withdrawal of gatifloxacin due to dysglycemia makes it timely to review the safety and tolerability of the individual agents in this class.  Overall, it appears that levofloxacin is relatively well tolerated, with low rates of clin. important adverse events such as CNS toxicity, cardiovascular toxicity and dysglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgeZYFPvQVk7Vg90H21EOLACvtfcHk0ljgrPJCiIL3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslejt7k%253D&md5=6832db269b694276ba5fd46d1ace7d72</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.2165%2F11536360-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11536360-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%2BH.%26atitle%3DSafety%2520profile%2520of%2520the%2520fluoroquinolones%253A%2520focus%2520on%2520levofloxacin%26jtitle%3DDrug%2520Saf.%26date%3D2010%26volume%3D33%26issue%3D5%26spage%3D353%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><div class="note"><p class="first last">Experimental reference of hERG patch clamp assay is as follows:</p></div><span class="NLM_contrib-group">Bischoff, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Netzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongs, O.</span><span> </span><span class="NLM_article-title">Effects of fluoroquinolones on HERG currents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1016%2FS0014-2999%2800%2900693-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=11040340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlKjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=341-343&author=U.+Bischoffauthor=C.+Schmidtauthor=R.+Netzerauthor=O.+Pongs&title=Effects+of+fluoroquinolones+on+HERG+currents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fluoroquinolones on HERG currents</span></div><div class="casAuthors">Bischoff, U.; Schmidt, C.; Netzer, R.; Pongs, O.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-343</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">We have investigated the effects of four fluoroquinolones on the human ether-a-go-go-related gene (HERG) mediated K+ currents to evaluate their potential to induce QT-prolongation.  HERG currents were measured from stably transfected Chinese hamster ovary (CHO) cells by means of the patch-clamp technique.  Bath application of sparfloxacin, moxifloxacin and grepafloxacin produced an inhibition of HERG outward currents at -40 mV with EC50 of 13.5±0.8, 41.2±2.0 and 37.5±3.3 μg/mL, resp.  Current inhibitions were reversible after washout of the compds.  By contrast, ciprofloxacin at concns. of up to 100 μg/mL did not effect HERG outward currents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou4sWoRGGOsrVg90H21EOLACvtfcHk0ljgrPJCiIL3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlKjtbg%253D&md5=205d18afe8d9b1d9bba4873fc7913e41</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2800%2900693-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252800%252900693-2%26sid%3Dliteratum%253Aachs%26aulast%3DBischoff%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DNetzer%26aufirst%3DR.%26aulast%3DPongs%26aufirst%3DO.%26atitle%3DEffects%2520of%2520fluoroquinolones%2520on%2520HERG%2520currents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D406%26spage%3D341%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Atarashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span> </span><span class="NLM_article-title">Fluorocyclopropyl quinolones. 1. Synthesis and Structure–ctivity Relationships of 1-(2-fluorocyclopropyl)-3-pyridonecarboxylic acid antibacterial agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3444</span><span class="NLM_x">–</span> <span class="NLM_lpage">3448</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00074a027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3444-3448&author=S.+Atarashiauthor=M.+Imamuraauthor=Y.+Kimuraauthor=A.+Yoshidaauthor=I.+Hayakawa&title=Fluorocyclopropyl+quinolones.+1.+Synthesis+and+Structure%E2%80%93ctivity+Relationships+of+1-%282-fluorocyclopropyl%29-3-pyridonecarboxylic+acid+antibacterial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm00074a027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00074a027%26sid%3Dliteratum%253Aachs%26aulast%3DAtarashi%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DA.%26aulast%3DHayakawa%26aufirst%3DI.%26atitle%3DFluorocyclopropyl%2520quinolones.%25201.%2520Synthesis%2520and%2520Structure%25E2%2580%2593ctivity%2520Relationships%2520of%25201-%25282-fluorocyclopropyl%2529-3-pyridonecarboxylic%2520acid%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3444%26epage%3D3448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atarashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsuhiro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span> </span><span class="NLM_article-title">Fluorocyclopropyl quinolones. 2. Synthesis and stereochemical structure–activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">3344</span><span class="NLM_x">–</span> <span class="NLM_lpage">3352</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00046a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=3344-3352&author=Y.+Kimuraauthor=S.+Atarashiauthor=K.+Katsuhiroauthor=K.+Satoauthor=I.+Hayakawa&title=Fluorocyclopropyl+quinolones.+2.+Synthesis+and+stereochemical+structure%E2%80%93activity+relationships+of+chiral+7-%287-amino-5-azaspiro%5B2.4%5Dheptan-5-yl%29-1-%282-fluorocyclopropyl%29quinolone+antibacterial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm00046a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00046a019%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DAtarashi%26aufirst%3DS.%26aulast%3DKatsuhiro%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DHayakawa%26aufirst%3DI.%26atitle%3DFluorocyclopropyl%2520quinolones.%25202.%2520Synthesis%2520and%2520stereochemical%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520chiral%25207-%25287-amino-5-azaspiro%255B2.4%255Dheptan-5-yl%2529-1-%25282-fluorocyclopropyl%2529quinolone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D3344%26epage%3D3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Hoshino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okumura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otani, T.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=65-76&issue=1&author=K.+Hoshinoauthor=K.+Inoueauthor=Y.+Murakamiauthor=Y.+Kurosakaauthor=K.+Nambaauthor=Y.+Kashimotoauthor=S.+Uoyamaauthor=R.+Okumuraauthor=S.+Higuchiauthor=T.+Otani&title=In+vitro+and+in+vivo+antibacterial+activities+of+DC-159a%2C+a+new+fluoroquinolone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DKurosaka%26aufirst%3DY.%26aulast%3DNamba%26aufirst%3DK.%26aulast%3DKashimoto%26aufirst%3DY.%26aulast%3DUoyama%26aufirst%3DS.%26aulast%3DOkumura%26aufirst%3DR.%26aulast%3DHiguchi%26aufirst%3DS.%26aulast%3DOtani%26aufirst%3DT.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antibacterial%2520activities%2520of%2520DC-159a%252C%2520a%2520new%2520fluoroquinolone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D1%26spage%3D65%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><div class="note"><p class="first last">SIR92: </p></div><span class="NLM_contrib-group">Altomare, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burla, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascarano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacovazzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagliard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polidori, G.</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1107%2FS002188989400021X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SIR92%3A+Altomare%2C+A.%3B+Burla%2C+M.+C.%3B+Camalli%2C+M.%3B+Cascarano%2C+M.%3B+Giacovazzo%2C+C.%3B+Guagliard%2C+A.%3B+Polidori%2C+G.J.+Appl.+Crystallogr.+1994%2C+27%2C+435%E2%80%93435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS002188989400021X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS002188989400021X%26sid%3Dliteratum%253Aachs%26aulast%3DAltomare%26aufirst%3DA.%26aulast%3DBurla%26aufirst%3DM.%2BC.%26aulast%3DCamalli%26aufirst%3DM.%26aulast%3DCascarano%26aufirst%3DM.%26aulast%3DGiacovazzo%26aufirst%3DC.%26aulast%3DGuagliard%26aufirst%3DA.%26aulast%3DPolidori%26aufirst%3DG.%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1994%26volume%3D27%26spage%3D435%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':[],'ref16':['cit16a','cit16b'],'ref17':['cit17a','cit17b'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Takashi Odagiri, Hiroaki Inagaki, Masatoshi Nagamochi, Takahiro Kitamura, Satoshi Komoriya, <span class="NLM_string-name hlFld-ContribAuthor">Hisashi Takahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel 7-[(3aS,7aS)-3a-Aminohexahydropyrano[3,4-c]pyrrol-2(3H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (16)
                                     , 7234-7244. <a href="https://doi.org/10.1021/acs.jmedchem.8b00644" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00644</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00644%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B7-%25255B%2525283aS%25252C7aS%252529-3a-Aminohexahydropyrano%25255B3%25252C4-c%25255Dpyrrol-2%2525283H%252529-yl%25255D-8-methoxyquinolines%252Bwith%252BPotent%252BAntibacterial%252BActivity%252Bagainst%252BRespiratory%252BPathogens%26aulast%3DOdagiri%26aufirst%3DTakashi%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24042018%26date%3D08082018%26date%3D31072018%26volume%3D61%26issue%3D16%26spage%3D7234%26epage%3D7244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory S.  Bisacchi</span>  . </span><span class="cited-content_cbyCitation_article-title">Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (12)
                                     , 4874-4882. <a href="https://doi.org/10.1021/jm501881c" title="DOI URL">https://doi.org/10.1021/jm501881c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501881c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501881c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOrigins%252Bof%252Bthe%252BQuinolone%252BClass%252Bof%252BAntibacterials%25253A%252BAn%252BExpanded%252B%2525E2%252580%25259CDiscovery%252BStory%2525E2%252580%25259D%26aulast%3DBisacchi%26aufirst%3DGregory%2BS.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D04122014%26date%3D12032015%26date%3D25062015%26date%3D04032015%26volume%3D58%26issue%3D12%26spage%3D4874%26epage%3D4882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">F  Cools</span>, <span class="hlFld-ContribAuthor ">P  Delputte</span>, <span class="hlFld-ContribAuthor ">P  Cos</span>. </span><span class="cited-content_cbyCitation_article-title">The search for novel treatment strategies for
              Streptococcus pneumoniae
              infections. </span><span class="cited-content_cbyCitation_journal-name">FEMS Microbiology Reviews</span><span> <strong>2021,</strong> <em>70 </em><a href="https://doi.org/10.1093/femsre/fuaa072" title="DOI URL">https://doi.org/10.1093/femsre/fuaa072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/femsre/fuaa072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Ffemsre%2Ffuaa072%26sid%3Dliteratum%253Aachs%26jtitle%3DFEMS%2520Microbiology%2520Reviews%26atitle%3DThe%252Bsearch%252Bfor%252Bnovel%252Btreatment%252Bstrategies%252Bfor%252BStreptococcus%252Bpneumoniae%252Binfections%26aulast%3DCools%26aufirst%3DF%26date%3D2021%26date%3D2021%26volume%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lenka  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Roman  Fišera</span>, <span class="hlFld-ContribAuthor ">Barbora  Gaálová</span>, <span class="hlFld-ContribAuthor ">Kamila  Koči</span>, <span class="hlFld-ContribAuthor ">Helena  Bujdáková</span>, <span class="hlFld-ContribAuthor ">Mária  Mečiarová</span>, <span class="hlFld-ContribAuthor ">Renáta  Górová</span>, <span class="hlFld-ContribAuthor ">Helena  Jurdáková</span>, <span class="hlFld-ContribAuthor ">Radovan  Šebesta</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Chiral 3,4-Disubstituted Pyrrolidines with Antibacterial Properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (17)
                                     , 2565-2575. <a href="https://doi.org/10.1002/ejoc.202000235" title="DOI URL">https://doi.org/10.1002/ejoc.202000235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202000235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202000235%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BChiral%252B3%25252C4-Disubstituted%252BPyrrolidines%252Bwith%252BAntibacterial%252BProperties%26aulast%3DRodriguez%26aufirst%3DLenka%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D17%26spage%3D2565%26epage%3D2575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yafeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Tian</span>, <span class="hlFld-ContribAuthor ">Kexin  Su</span>, <span class="hlFld-ContribAuthor ">Peigen  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Guo</span>, <span class="hlFld-ContribAuthor ">Baohua  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodium(
              iii
              )-catalyzed [3 + 3] annulation reactions of
              N
              -nitrosoanilines and cyclopropenones: an approach to functionalized 4-quinolones. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (24)
                                     , 3973-3977. <a href="https://doi.org/10.1039/C9QO01250H" title="DOI URL">https://doi.org/10.1039/C9QO01250H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO01250H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO01250H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DRhodium%252528%252Biii%252B%252529-catalyzed%252B%25255B3%252B%25252B%252B3%25255D%252Bannulation%252Breactions%252Bof%252BN%252B-nitrosoanilines%252Band%252Bcyclopropenones%25253A%252Ban%252Bapproach%252Bto%252Bfunctionalized%252B4-quinolones%26aulast%3DLiu%26aufirst%3DYafeng%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D24%26spage%3D3973%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Komoriya</span>, <span class="hlFld-ContribAuthor ">Takashi  Odagiri</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Inagaki</span>, <span class="hlFld-ContribAuthor ">Masatoshi  Nagamochi</span>, <span class="hlFld-ContribAuthor ">Rie  Miyauchi</span>, <span class="hlFld-ContribAuthor ">Ken-ichi  Yoshida</span>, <span class="hlFld-ContribAuthor ">Takahiro  Kitamura</span>, <span class="hlFld-ContribAuthor ">Hisashi  Takahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel 7-[(1R,5S)-1-Amino-5-fluoro-3-azabicyclo[3.3.0]octan-3-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropane]-8-(methoxy or methyl)quinolones. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2019,</strong> <em>67 </em>
                                    (1)
                                     , 47-58. <a href="https://doi.org/10.1248/cpb.c18-00671" title="DOI URL">https://doi.org/10.1248/cpb.c18-00671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c18-00671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c18-00671%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDiscovery%252Bof%252BNovel%252B7-%25255B%2525281R%25252C5S%252529-1-Amino-5-fluoro-3-azabicyclo%25255B3.3.0%25255Doctan-3-yl%25255D-6-fluoro-1-%25255B%2525281R%25252C2S%252529-2-fluorocyclopropane%25255D-8-%252528methoxy%252Bor%252Bmethyl%252529quinolones%26aulast%3DKomoriya%26aufirst%3DSatoshi%26date%3D2019%26volume%3D67%26issue%3D1%26spage%3D47%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chuan  Gao</span>, <span class="hlFld-ContribAuthor ">Yi-Lei  Fan</span>, <span class="hlFld-ContribAuthor ">Feng  Zhao</span>, <span class="hlFld-ContribAuthor ">Qing-Cheng  Ren</span>, <span class="hlFld-ContribAuthor ">Xiang  Wu</span>, <span class="hlFld-ContribAuthor ">Le  Chang</span>, <span class="hlFld-ContribAuthor ">Feng  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 1081-1095. <a href="https://doi.org/10.1016/j.ejmech.2018.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DQuinolone%252Bderivatives%252Band%252Btheir%252Bactivities%252Bagainst%252Bmethicillin-resistant%252BStaphylococcus%252Baureus%252B%252528MRSA%252529%26aulast%3DGao%26aufirst%3DChuan%26date%3D2018%26volume%3D157%26spage%3D1081%26epage%3D1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Gao</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Qing  Miao</span>, <span class="hlFld-ContribAuthor ">Long  Ma</span>, <span class="hlFld-ContribAuthor ">Guangming  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of quinolone-based derivatives and their activities against Escherichia coli. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 1223-1248. <a href="https://doi.org/10.1016/j.ejmech.2018.08.095" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.095%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bof%252Bquinolone-based%252Bderivatives%252Band%252Btheir%252Bactivities%252Bagainst%252BEscherichia%252Bcoli%26aulast%3DGao%26aufirst%3DFeng%26date%3D2018%26volume%3D157%26spage%3D1223%26epage%3D1248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keigo  Yamashika</span>, <span class="hlFld-ContribAuthor ">Suguru  Morishitabara</span>, <span class="hlFld-ContribAuthor ">Shigeyuki  Yamada</span>, <span class="hlFld-ContribAuthor ">Toshio  Kubota</span>, <span class="hlFld-ContribAuthor ">Tsutomu  Konno</span>. </span><span class="cited-content_cbyCitation_article-title">An asymmetric tertiary carbon center with a tetrafluoroethylene (–CF 2 CF 2 –) fragment: Novel construction method and application in a chiral liquid crystalline molecule. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2018,</strong> <em>207 </em>, 24-37. <a href="https://doi.org/10.1016/j.jfluchem.2017.12.013" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2017.12.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2017.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2017.12.013%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DAn%252Basymmetric%252Btertiary%252Bcarbon%252Bcenter%252Bwith%252Ba%252Btetrafluoroethylene%252B%252528%2525E2%252580%252593CF%252B2%252BCF%252B2%252B%2525E2%252580%252593%252529%252Bfragment%25253A%252BNovel%252Bconstruction%252Bmethod%252Band%252Bapplication%252Bin%252Ba%252Bchiral%252Bliquid%252Bcrystalline%252Bmolecule%26aulast%3DYamashika%26aufirst%3DKeigo%26date%3D2018%26volume%3D207%26spage%3D24%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takashi  Odagiri</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Inagaki</span>, <span class="hlFld-ContribAuthor ">Takahiro  Kitamura</span>, <span class="hlFld-ContribAuthor ">Satoshi  Komoriya</span>, <span class="hlFld-ContribAuthor ">Hisashi  Takahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel 8-Methoxyquinolones Bearing Fused Pyrrolidinyl Moieties at the C-7 Position with Potent Antibacterial Activity Against Respiratory Pathogens. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2018,</strong> <em>96 </em>
                                    (5)
                                     , 858. <a href="https://doi.org/10.3987/COM-18-13889" title="DOI URL">https://doi.org/10.3987/COM-18-13889</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-18-13889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-18-13889%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B8-Methoxyquinolones%252BBearing%252BFused%252BPyrrolidinyl%252BMoieties%252Bat%252Bthe%252BC-7%252BPosition%252Bwith%252BPotent%252BAntibacterial%252BActivity%252BAgainst%252BRespiratory%252BPathogens%26aulast%3DOdagiri%26aufirst%3DTakashi%26date%3D2018%26volume%3D96%26issue%3D5%26spage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meltem  Menteşe</span>, <span class="hlFld-ContribAuthor ">Fatih Şaban  Beriş</span>, <span class="hlFld-ContribAuthor ">Neslihan  Demirbaş</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Some New Ciprofloxacin Hybrids as Potential Antimicrobial Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2017,</strong> <em>54 </em>
                                    (6)
                                     , 2996-3007. <a href="https://doi.org/10.1002/jhet.2907" title="DOI URL">https://doi.org/10.1002/jhet.2907</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.2907%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BSome%252BNew%252BCiprofloxacin%252BHybrids%252Bas%252BPotential%252BAntimicrobial%252BAgents%26aulast%3DMente%25C5%259Fe%26aufirst%3DMeltem%26date%3D2017%26date%3D2017%26volume%3D54%26issue%3D6%26spage%3D2996%26epage%3D3007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akiko  Watanabe</span>, <span class="hlFld-ContribAuthor ">Hideo  Takakusa</span>, <span class="hlFld-ContribAuthor ">Takako  Kimura</span>, <span class="hlFld-ContribAuthor ">Shin-ichi  Inoue</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Kusuhara</span>, <span class="hlFld-ContribAuthor ">Osamu  Ando</span>. </span><span class="cited-content_cbyCitation_article-title">Difference in Mechanism-Based Inhibition of Cytochrome P450 3A4 and 3A5 by a Series of Fluoroquinolone Antibacterial Agents. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2017,</strong> <em>45 </em>
                                    (3)
                                     , 336-341. <a href="https://doi.org/10.1124/dmd.116.073783" title="DOI URL">https://doi.org/10.1124/dmd.116.073783</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.116.073783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.116.073783%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DDifference%252Bin%252BMechanism-Based%252BInhibition%252Bof%252BCytochrome%252BP450%252B3A4%252Band%252B3A5%252Bby%252Ba%252BSeries%252Bof%252BFluoroquinolone%252BAntibacterial%252BAgents%26aulast%3DWatanabe%26aufirst%3DAkiko%26date%3D2017%26date%3D2016%26volume%3D45%26issue%3D3%26spage%3D336%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charles M.  Marson</span>. </span><span class="cited-content_cbyCitation_article-title">Saturated Heterocycles with Applications in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 13-33. <a href="https://doi.org/10.1016/bs.aihch.2016.03.004" title="DOI URL">https://doi.org/10.1016/bs.aihch.2016.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2016.03.004%26sid%3Dliteratum%253Aachs%26atitle%3DSaturated%252BHeterocycles%252Bwith%252BApplications%252Bin%252BMedicinal%252BChemistry%26aulast%3DMarson%26aufirst%3DCharles%2BM.%26date%3D2017%26spage%3D13%26epage%3D33%26pub%3DElsevier%26atitle%3DHeterocyclic%252BChemistry%252Bin%252Bthe%252B21st%252BCentury%252B-%252BA%252BTribute%252Bto%252BAlan%252BKatritzky%26date%3D2017%26volume%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongmei  Meng</span>, <span class="hlFld-ContribAuthor ">Yongzhen  Tang</span>, <span class="hlFld-ContribAuthor ">Junfa  Wei</span>, <span class="hlFld-ContribAuthor ">Xianying  Shi</span>, <span class="hlFld-ContribAuthor ">Mingyu  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed remote (δ) C(sp
              3
              )–H bond amination: a practical strategy to construct pyrrolidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2017,</strong> <em>53 </em>
                                    (42)
                                     , 5744-5747. <a href="https://doi.org/10.1039/C7CC02624B" title="DOI URL">https://doi.org/10.1039/C7CC02624B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CC02624B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CC02624B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCopper-catalyzed%252Bremote%252B%252528%2525CE%2525B4%252529%252BC%252528sp%252B3%252B%252529%2525E2%252580%252593H%252Bbond%252Bamination%25253A%252Ba%252Bpractical%252Bstrategy%252Bto%252Bconstruct%252Bpyrrolidine%252Bderivatives%26aulast%3DMeng%26aufirst%3DDongmei%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D42%26spage%3D5744%26epage%3D5747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Watanabe</span>, <span class="hlFld-ContribAuthor ">H.  Takakusa</span>, <span class="hlFld-ContribAuthor ">T.  Kimura</span>, <span class="hlFld-ContribAuthor ">S.-i.  Inoue</span>, <span class="hlFld-ContribAuthor ">H.  Kusuhara</span>, <span class="hlFld-ContribAuthor ">O.  Ando</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2016,</strong> <em>44 </em>
                                    (10)
                                     , 1608-1616. <a href="https://doi.org/10.1124/dmd.116.071654" title="DOI URL">https://doi.org/10.1124/dmd.116.071654</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.116.071654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.116.071654%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DAnalysis%252Bof%252BMechanism-Based%252BInhibition%252Bof%252BCYP%252B3A4%252Bby%252Ba%252BSeries%252Bof%252BFluoroquinolone%252BAntibacterial%252BAgents%26aulast%3DWatanabe%26aufirst%3DA.%26date%3D2016%26date%3D2016%26volume%3D44%26issue%3D10%26spage%3D1608%26epage%3D1616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ondřej  Píša</span>, <span class="hlFld-ContribAuthor ">Stanislav  Rádl</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4-Quinolones:
              N
              ,
              O
              -Bis­(trimethylsilyl)acetamide-Mediated Cyclization with Cleavage of Aromatic C-O Bond. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>2016 </em>
                                    (13)
                                     , 2336-2350. <a href="https://doi.org/10.1002/ejoc.201600178" title="DOI URL">https://doi.org/10.1002/ejoc.201600178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201600178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201600178%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B4-Quinolones%25253A%252BN%252B%25252C%252BO%252B-Bis%2525C2%2525AD%252528trimethylsilyl%252529acetamide-Mediated%252BCyclization%252Bwith%252BCleavage%252Bof%252BAromatic%252BC-O%252BBond%26aulast%3DP%25C3%25AD%25C5%25A1a%26aufirst%3DOnd%25C5%2599ej%26date%3D2016%26date%3D2016%26volume%3D2016%26issue%3D13%26spage%3D2336%26epage%3D2350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Zhang</span>, <span class="hlFld-ContribAuthor ">Dinesh  Addla</span>, <span class="hlFld-ContribAuthor ">Jeyakkumar  Ponmani</span>, <span class="hlFld-ContribAuthor ">Ao  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Xie</span>, <span class="hlFld-ContribAuthor ">Ya-Nan  Wang</span>, <span class="hlFld-ContribAuthor ">Shao-Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Rong-Xia  Geng</span>, <span class="hlFld-ContribAuthor ">Gui-Xin  Cai</span>, <span class="hlFld-ContribAuthor ">Shuo  Li</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>111 </em>, 160-182. <a href="https://doi.org/10.1016/j.ejmech.2016.01.052" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.01.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.01.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.01.052%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bmembrane%252Bactive%252Bbenzimidazole%252Bquinolones-based%252Btopoisomerase%252Binhibitors%252Bas%252Bpotential%252BDNA-binding%252Bantimicrobial%252Bagents%26aulast%3DZhang%26aufirst%3DLing%26date%3D2016%26volume%3D111%26spage%3D160%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenji  Itoh</span>, <span class="hlFld-ContribAuthor ">Yasuhiro  Kuramoto</span>, <span class="hlFld-ContribAuthor ">Hirotaka  Amano</span>, <span class="hlFld-ContribAuthor ">Daichi  Kazamori</span>, <span class="hlFld-ContribAuthor ">Akira  Yazaki</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>103 </em>, 354-360. <a href="https://doi.org/10.1016/j.ejmech.2015.08.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.08.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.08.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BWQ-3810%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252B7-%2525283-alkylaminoazetidin-1-yl%252529fluoro-quinolones%252Bas%252Borally%252Bactive%252Bantibacterial%252Bagents%26aulast%3DItoh%26aufirst%3DKenji%26date%3D2015%26volume%3D103%26spage%3D354%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raed A.  Al-Qawasmeh</span>, <span class="hlFld-ContribAuthor ">Mohammed M.  Abadleh</span>, <span class="hlFld-ContribAuthor ">Jalal A.  Zahra</span>, <span class="hlFld-ContribAuthor ">Mustafa M.  El-Abadelah</span>, <span class="hlFld-ContribAuthor ">Rabab  Albashiti</span>, <span class="hlFld-ContribAuthor ">Franca  Zani</span>, <span class="hlFld-ContribAuthor ">Matteo  Incerti</span>, <span class="hlFld-ContribAuthor ">Paola  Vicini</span>. </span><span class="cited-content_cbyCitation_article-title">Design synthesis and antibacterial activity studies of new thiadiazoloquinolone compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2014,</strong> <em>29 </em>
                                    (6)
                                     , 777-785. <a href="https://doi.org/10.3109/14756366.2013.855925" title="DOI URL">https://doi.org/10.3109/14756366.2013.855925</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/14756366.2013.855925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F14756366.2013.855925%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bsynthesis%252Band%252Bantibacterial%252Bactivity%252Bstudies%252Bof%252Bnew%252Bthiadiazoloquinolone%252Bcompounds%26aulast%3DAl-Qawasmeh%26aufirst%3DRaed%2BA.%26date%3D2014%26date%3D2014%26volume%3D29%26issue%3D6%26spage%3D777%26epage%3D785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Berlutti</span>, <span class="hlFld-ContribAuthor ">Alessandra  Frioni</span>, <span class="hlFld-ContribAuthor ">Tiziana  Natalizi</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Pantanella</span>, <span class="hlFld-ContribAuthor ">Piera  Valenti</span>. </span><span class="cited-content_cbyCitation_article-title">Influence of sub-inhibitory antibiotics and flow condition on Staphylococcus aureus ATCC 6538 biofilm development and biofilm growth rate: BioTimer assay as a study model. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Antibiotics</span><span> <strong>2014,</strong> <em>67 </em>
                                    (11)
                                     , 763-769. <a href="https://doi.org/10.1038/ja.2014.66" title="DOI URL">https://doi.org/10.1038/ja.2014.66</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ja.2014.66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fja.2014.66%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Antibiotics%26atitle%3DInfluence%252Bof%252Bsub-inhibitory%252Bantibiotics%252Band%252Bflow%252Bcondition%252Bon%252BStaphylococcus%252Baureus%252BATCC%252B6538%252Bbiofilm%252Bdevelopment%252Band%252Bbiofilm%252Bgrowth%252Brate%25253A%252BBioTimer%252Bassay%252Bas%252Ba%252Bstudy%252Bmodel%26aulast%3DBerlutti%26aufirst%3DFrancesca%26date%3D2014%26date%3D2014%26volume%3D67%26issue%3D11%26spage%3D763%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Szymon  Klossowski</span>, <span class="hlFld-ContribAuthor ">Anna  Brodzka</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Zysk</span>, <span class="hlFld-ContribAuthor ">Ryszard  Ostaszewski</span>. </span><span class="cited-content_cbyCitation_article-title">Chemoenzymatic synthesis and application of a new, easily chiral auxiliary for the synthesis of peptidomimetics via an Ugi reaction. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron: Asymmetry</span><span> <strong>2014,</strong> <em>25 </em>
                                    (5)
                                     , 435-442. <a href="https://doi.org/10.1016/j.tetasy.2014.01.016" title="DOI URL">https://doi.org/10.1016/j.tetasy.2014.01.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetasy.2014.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetasy.2014.01.016%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%253A%2520Asymmetry%26atitle%3DChemoenzymatic%252Bsynthesis%252Band%252Bapplication%252Bof%252Ba%252Bnew%25252C%252Beasily%252Bchiral%252Bauxiliary%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bpeptidomimetics%252Bvia%252Ban%252BUgi%252Breaction%26aulast%3DKlossowski%26aufirst%3DSzymon%26date%3D2014%26volume%3D25%26issue%3D5%26spage%3D435%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0011.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaCN, NH<sub>3</sub> aq, NH<sub>4</sub>Cl, NH<sub>3</sub>/MeOH; (b) H<sub>2</sub>, Raney Ni/EtOH; (c) concentrated aqueous HCl; (d) 1,1,1,3,3,3-hexamethyldisilazane/MeCN; (e) Boc<sub>2</sub>O/1.4-dioxane; (f) BnBr, NaH/DMF; (g) Chiralpak AD; (h) TFA/CH<sub>2</sub>Cl<sub>2</sub>; (i) LiAlH<sub>4</sub>/THF; (j) Boc<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub>; (k) H<sub>2</sub>, Pd–C/MeOH; (l) <b>4</b>, Et<sub>3</sub>N/DMSO; (m) Et<sub>3</sub>N/80% aqueous EtOH; (n) concentrated aqueous HCl.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) LiHMDS/THF; (b) TBAF/THF; (c) PhSO<sub>2</sub>Cl, Et<sub>3</sub>N, DMAP/CH<sub>2</sub>Cl<sub>2</sub>; (d) NaHMDS/THF; (e) TFA/CH<sub>2</sub>Cl<sub>2</sub>; (f) diphenylphosphoryl azide, Et<sub>3</sub>N/toluene; (g) 6 N aqueous HCl/1,4-dioxane; (h) sodium bis(2-methoxyethoxy)aluminum hydride/toluene; (i) Boc<sub>2</sub>O/toluene; (j) H<sub>2</sub>, Pd–C/MeOH; (k) <b>4</b>, Et<sub>3</sub>N/DMSO; (l) Et<sub>3</sub>N/80% aqueous EtOH; (m) concentrated aqueous HCl.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mechanism-based inhibition against CYP3A4 by <b>1</b>. Shown are effects of preincubation of CYP3A4 with <b>1</b> for 1′-hydroxylation of midazolam in pooled human liver microsomal system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanism-based inhibition against CYP3A4 by <b>2a</b>. Shown are effects of preincubation of CYP3A4 with <b>2a</b> for 1′-hydroxylation of midazolam in pooled human liver microsomal system.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Therapeutic effects on pneumococcal pneumonia (QR-PRSP) in mice. Animals were CBA/JNCrj mice (<i>n</i> = 4). Bacteria were <i>S. pneumoniae</i> (QR-PRSP). Test drugs were administered subcutaneously twice a day.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/medium/jm-2012-01650g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Therapeutic effects on pneumococcal pneumonia (QS-PRSP) in mice. Animals were CBA/JNCrj mice (<i>n</i> = 4). Bacteria were <i>S. pneumoniae</i> (QR-PRSP). Test drugs were administered subcutaneously twice a day.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-5/jm301650g/production/images/large/jm-2012-01650g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301650g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Komoriya, S.; Inagaki, H.; Sugimoto, Y.; Nagamochi, M.; Miyauchi, R.; Kuroyanagi, J.; Kitamura, T.; Hoshino, K.; Murakami, Y.; Tachibana, M.; Imamura, Y.; Takahashi, H.; Takemura, M.</span><span> </span><span class="NLM_article-title">DC-159a, a New Generation of Respiratory Quinolone: Design, Synthesis, and Biological Evaluation</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Society for Microbiology</span>: <span class="NLM_publisher-loc">Washington, DC</span>; Abstract F1-0477.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+Komoriya&author=H.+Inagaki&author=Y.+Sugimoto&author=M.+Nagamochi&author=R.+Miyauchi&author=J.+Kuroyanagi&author=T.+Kitamura&author=K.+Hoshino&author=Y.+Murakami&author=M.+Tachibana&author=Y.+Imamura&author=H.+Takahashi&author=M.+Takemura&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKomoriya%26aufirst%3DS.%26atitle%3DDC-159a%252C%2520a%2520New%2520Generation%2520of%2520Respiratory%2520Quinolone%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2006%26pub%3DAmerican%2520Society%2520for%2520Microbiology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Fridkin, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hageman, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanza, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Como-Sabetti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jernigan, J. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynfield, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, M. M.</span><span> </span><span class="NLM_article-title">Active bacterial core surveillance program of the emerging infections program network. Methicillin-resistant <i>Staphylococcus aureus</i> disease in three communities</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1436</span><span class="NLM_x">–</span> <span class="NLM_lpage">1444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1056%2FNEJMoa043252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=15814879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVWltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1436-1444&issue=14&author=S.+K.+Fridkinauthor=J.+C.+Hagemanauthor=M.+Morrisonauthor=L.+T.+Sanzaauthor=K.+Como-Sabettiauthor=J.+A+Jerniganauthor=K.+Harrimanauthor=L.+H.+Harrisonauthor=R.+Lynfieldauthor=M.+M.+Farley&title=Active+bacterial+core+surveillance+program+of+the+emerging+infections+program+network.+Methicillin-resistant+Staphylococcus+aureus+disease+in+three+communities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Methicillin-resistant Staphylococcus aureus disease in three communities</span></div><div class="casAuthors">Fridkin, Scott K.; Hageman, Jeffrey C.; Morrison, Melissa; Sanza, Laurie Thomson; Como-Sabetti, Kathryn; Jernigan, John A.; Harriman, Kathleen; Harrison, Lee H.; Lynfield, Ruth; Farley, Monica M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1436-1444</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in patients who do not have the established risk factors.  The national burden and clin. effect of this novel presentation of MRSA disease are unclear.  METHODS: We evaluated MRSA infections in patients identified from population-based surveillance in Baltimore and Atlanta and from hospital-lab.-based sentinel surveillance of 12 hospitals in Minnesota.  Information was obtained by interviewing patients and by reviewing their medical records.  Infections were classified as community-acquired MRSA disease if no established risk factors were identified.  RESULTS: From 2001 through 2002, 1647 cases of community-acquired MRSA infection were reported, representing between 8 and 20 percent of all MRSA isolates.  The annual disease incidence varied according to site (25.7 cases per 100,000 population in Atlanta vs. 18.0 per 100,000 in Baltimore) and was significantly higher among persons less than two years old than among those who were two years of age or older (relative risk, 1.51; 95 percent confidence interval, 1.19 to 1.92) and among blacks than among whites in Atlanta (age-adjusted relative risk, 2.74; 95 percent confidence interval, 2.44 to 3.07). Six percent of cases were invasive, and 77 percent involved skin and soft tissue.  The infecting strain of MRSA was often (73 percent) resistant to prescribed antimicrobial agents.  Among patients with skin or soft-tissue infections, therapy to which the infecting strain was resistant did not appear to be assocd. with adverse patient-reported outcomes.  Overall, 23 percent of patients were hospitalized for the MRSA infection.  CONCLUSIONS: Community-assocd. MRSA infections are now a common and serious problem.  These infections usually involve the skin, esp. among children, and hospitalization is common.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKjhK3hwB6PbVg90H21EOLACvtfcHk0ljY4SGsqnvjNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVWltr0%253D&md5=7d0e2634a3c0693cc3fc04afbdf25ac0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043252%26sid%3Dliteratum%253Aachs%26aulast%3DFridkin%26aufirst%3DS.%2BK.%26aulast%3DHageman%26aufirst%3DJ.%2BC.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DSanza%26aufirst%3DL.%2BT.%26aulast%3DComo-Sabetti%26aufirst%3DK.%26aulast%3DJernigan%26aufirst%3DJ.%2BA%26aulast%3DHarriman%26aufirst%3DK.%26aulast%3DHarrison%26aufirst%3DL.%2BH.%26aulast%3DLynfield%26aufirst%3DR.%26aulast%3DFarley%26aufirst%3DM.%2BM.%26atitle%3DActive%2520bacterial%2520core%2520surveillance%2520program%2520of%2520the%2520emerging%2520infections%2520program%2520network.%2520Methicillin-resistant%2520Staphylococcus%2520aureus%2520disease%2520in%2520three%2520communities%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D14%26spage%3D1436%26epage%3D1444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Fuller, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGeer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, D. E.</span><span> </span><span class="NLM_article-title">Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management</span> <span class="citation_source-journal">Eur. J. Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1007%2Fs10096-005-0059-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=16344922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FgsV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=780-788&author=J.+D.+Fullerauthor=A.+McGeerauthor=D.+E.+Low&title=Drug-resistant+pneumococcal+pneumonia%3A+clinical+relevance+and+approach+to+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management</span></div><div class="casAuthors">Fuller J D; McGeer A; Low D E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">780-8</span>
        ISSN:<span class="NLM_cas:issn">0934-9723</span>.
    </div><div class="casAbstract">Community-acquired pneumonia is the most common infectious disease that causes death, with Streptococcus pneumoniae remaining the leading causative pathogen.  The worldwide incidence of infections caused by pneumococci resistant to penicillin, macrolides, and other antimicrobial agents has increased at an alarming rate during the past 2 decades.  Yet, these agents are still used as first-line empirical therapy in the outpatient setting.  There are several reasons for this, including the infrequency of making a pathogen-specific diagnosis, the failure of studies to demonstrate the relevance of resistance, and the infrequency with which clinicians recognize clinical failures.  Despite this, there is mounting evidence that supports the practice of using high doses of some antimicrobial agents, a more active antimicrobial agent within a class, or switching to another class of antimicrobial agents when a patient is identified as being at an increased risk of infection with a resistant pneumococcus.  There is now information that will allow the physician to identify not only the patient at risk for infection with a resistant pneumococcus but also the antimicrobial class and, in some cases, the agent within the class to which the organism is more likely to be resistant.  This will allow clinicians to better define optimal therapy for patients with community-acquired pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgh1WC97YUkzEwO064Z95rfW6udTcc2eaNVFM0lcMDO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FgsV2isQ%253D%253D&md5=43605afe9cf317d8ef997d43b952694c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs10096-005-0059-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10096-005-0059-x%26sid%3Dliteratum%253Aachs%26aulast%3DFuller%26aufirst%3DJ.%2BD.%26aulast%3DMcGeer%26aufirst%3DA.%26aulast%3DLow%26aufirst%3DD.%2BE.%26atitle%3DDrug-resistant%2520pneumococcal%2520pneumonia%253A%2520clinical%2520relevance%2520and%2520approach%2520to%2520management%26jtitle%3DEur.%2520J.%2520Clin.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D24%26spage%3D780%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_contrib-group">Shams, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, M. E,</span><span> </span><span class="NLM_article-title">Guide to selection of fluoroquinolones in patients with lower respiratory tract infections</span> <span class="citation_source-journal">Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=949-991&issue=7&author=W.+E.+Shamsauthor=M.+E%2C+Evans&title=Guide+to+selection+of+fluoroquinolones+in+patients+with+lower+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShams%26aufirst%3DW.%2BE.%26aulast%3DEvans%26aufirst%3DM.%2BE%252C%26atitle%3DGuide%2520to%2520selection%2520of%2520fluoroquinolones%2520in%2520patients%2520with%2520lower%2520respiratory%2520tract%2520infections%26jtitle%3DDrugs.%26date%3D2005%26volume%3D65%26issue%3D7%26spage%3D949%26epage%3D991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_contrib-group">Zhanelaaa, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontaine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schurek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noreddin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoban, D. J.</span><span> </span><span class="NLM_article-title">A review of new fluoroquinolones: focus on their use in respiratory tract infections</span> <span class="citation_source-journal">Treat. Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F00151829-200605060-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=17154673" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=437-465&author=G.+G.+Zhanelaaaauthor=S.+Fontaineauthor=H.+Adamauthor=K.+Schurekauthor=M.+Mayerauthor=A.+M.+Noreddinauthor=A.+S.+Ginauthor=E.+Rubinsteinauthor=D.+J.+Hoban&title=A+review+of+new+fluoroquinolones%3A+focus+on+their+use+in+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.2165%2F00151829-200605060-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00151829-200605060-00009%26sid%3Dliteratum%253Aachs%26aulast%3DZhanelaaa%26aufirst%3DG.%2BG.%26aulast%3DFontaine%26aufirst%3DS.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DSchurek%26aufirst%3DK.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DNoreddin%26aufirst%3DA.%2BM.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DRubinstein%26aufirst%3DE.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26atitle%3DA%2520review%2520of%2520new%2520fluoroquinolones%253A%2520focus%2520on%2520their%2520use%2520in%2520respiratory%2520tract%2520infections%26jtitle%3DTreat.%2520Respir.%2520Med.%26date%3D2006%26volume%3D5%26spage%3D437%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimoto, T.</span><span> </span><span class="NLM_article-title">The history of the development and changes of quinolone antibacterial agents</span> <span class="citation_source-journal">Jpn. J. Hist. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ksFeisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=161-179&issue=2&author=H.+Takahashiauthor=I.+Hayakawaauthor=T.+Akimoto&title=The+history+of+the+development+and+changes+of+quinolone+antibacterial+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The history of the development and changes of quinolone antibacterial agents</span></div><div class="casAuthors">Takahashi Hisashi; Hayakawa Isao; Akimoto Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Yakushigaku zasshi</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-79</span>
        ISSN:<span class="NLM_cas:issn">0285-2314</span>.
    </div><div class="casAbstract">The quinolones, especially the new quinolones (the 6-fluoroquinolones), are the synthetic antibacterial agents to rival the Beta-lactam and the macrolide antibacterials for impact in clinical usage in the antibacterial therapeutic field.  They have a broad antibacterial spectrum of activity against Gram-positive, Gram-negative and mycobacterial pathogens as well as anaerobes.  Further, they show good-to-moderate oral absorption and tissue penetration with favorable pharmacokinetics in humans resulting in high clinical efficacy in the treatment of many kinds of infections.  They also exhibit excellent safety profiles as well as those of oral Beta-lactam antibiotics.  The bacterial effects of quinolones inhibit the function of bacterial DNA gyrase and topoisomerase IV.  The history of the development of the quinolones originated from nalidixic acid (NA), developed in 1962.  In addition, the breakthrough in the drug design for the scaffold and the basic side chains have allowed improvements to be made to the first new quinolone, norfloxacin (NFLX), patented in 1978.  Although currently more than 10,000 compounds have been already synthesized in the world, only two percent of them were developed and tested in clinical studies.  Furthermore, out of all these compounds, only twenty have been successfully launched into the market.  In this paper, the history of the development and changes of the quinolones are described from the first quinolone, NA, via, the first new quinolone (6-fluorinated quinolone) NFLX, to the latest extended-spectrum quinolone antibacterial agents against multi-drug resistant bacterial infections.  NA has only modest activity against Gram-negative bacteria and low oral absorption, therefore a suitable candidate for treatment of systemic infections (UTIs) is required.  Since the original discovery of NA, a series of quinolones, which are referred to as the old quinolones, have been developed leading to the first new quinolone, NFLX, with moderate improvements in over all properties starting in 1962 through and continuing throughout the 1970's.  Especially, the drug design for pipemidic acid (PPA) indicated one of the important breakthroughs that lead to NFLX.  The introduction of a piperazinyl group, which ia a basic moiety at the C7-position of the quinolone nuclei, improved activity against Gram-negative organisms broadening the spectrum to include Pseudomonas aeruginosa.  PPA also showed soem activity against Gram-positive bac teria.  The basic piperazine ring, which can form the zwitterionic natrure with the carboxylic acid at the C3-position, has subsequently been shown to increase the ability of the drugs to penetrate the bacterial cells resulting in enhanced activity.  Further, the zwitterionic forms resulted in significant tissue penetration in the pharmacokinetics.  On the other hand, the first compound with a fluorine atom at the C6-position of the related quinolone scaffold was flumequine and the compound indicated that activity against Gram-positive bacteria could be improved in the old quinolones.  The addition of a flourine atom at the C6-position is essential for the inhibition of target enzymes.  The results show the poten antibacterial activity and the penetration of the quinolone molecule into the bacterial cells and human tissue.  The real breakthrough came with the combination of these two features in NFLX, a 6-fluorinated quinolone having a piperazinyl group at the C7-position, NFLX features significant differences from the old quinolones in the activities and pharmacokinetics in humans, resulting in high clinical efficacy in the treatment of many kinds of infections including RTIs.Consequently, those great discoveries are rapidly superseded by even better compounds and NFLX proved to be just the beginning of a highly successful period of research into the modifications of the new quinolone antibacterials.  Simce the chemical structure and important features of NFLX had become apparent in 1978, many compounds were patented in the next three years, several of which reached the market.  Among the drugs, ofloxacin (OFLX) and ciprofloxacin (CPFX) are recognized as superior in several respects to the oral beta-lactam antibiotics as an antibacterial agent.  With a focus on OFLX and CPFX, numerous research groups entered the antibacterial therapeutic field, triggering intense competition in the search to find newer, more effective quinolones.  After NFLX was introduced in the market, while resulting by the end of today, eleven kinds of other new quinolones launched in Japan.  They are enoxacin (ENX), OFLX, CPFX, lomefloxacin (LFLX), fleroxacin (FRLX), tosufloxacin (TFLX), levofloxacin (LVFX), sparfloxacin (SPFX), gatifloxacin (GFLX), prulifloxacin (PULX) and also pazufloxacin (PZFX).  The advantages of these compounds, e.g., LVFX, SPFX and GFLX, are that their spectrum includes Gram-positive bacteria species as well as Gram-negative bacteria and they improve bioavailability results when a daily dose is administered for systemic infections including RTIs.  However, unexpected adverse reactions, such as the CNS reaction, the drug-drug interaction, phototoxicity, hepatotoxicity and cardiotoxicity such as the QTc interval prolongation of ECG, have been reported in the clinical evaluations or the post-marketing surveillance of several new quinolones.  Moreover, the adverse reactions of arthropathy (the joint toxicity) predicated from studies in juvenile animals have never materialized in clinical use.  Therefore, no drugs other than NFLX have yet been approved for pediatric use.  Fortunately, the newer quinolones are being developed and tested to reduce these adverse reactions on the basis of recent studies.  On the other hand, multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphycolocci (MRCNS), penicillin-resistant Streptococcus pneumoniae (PRSP) and vancomycin-resistant enterococci (VRE) have been a serious problem in the medical community.  Recently, the new quinolone antibacterials are highly successful class of antibacterial therapeutic field, however, the increased isolation of quinolone-resistant bacteria above them has become a normal outcome.  These problems of multi-drug resistance have been the driving force for the development of newer quinolones.  The next gereration of quinolone antibacterial agents will be potent against multi-drug resistant bacteria, such as MRSA, and provide a lower rate of emergence in resistance.  Further, they should have favorable safety profiles to reduce the adverse reactions.  The future of quinolones as the ultimate in pharmaceuticals must be handled cautiously if they are to realize their potential in the medical community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8vA5u365FSnT4ugvCDgnZfW6udTcc2ebPwyrlGhJ3iLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ksFeisw%253D%253D&md5=d54979b47150eb3872992253b3569850</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAkimoto%26aufirst%3DT.%26atitle%3DThe%2520history%2520of%2520the%2520development%2520and%2520changes%2520of%2520quinolone%2520antibacterial%2520agents%26jtitle%3DJpn.%2520J.%2520Hist.%2520Pharm.%26date%3D2003%26volume%3D38%26issue%3D2%26spage%3D161%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_contrib-group">Fuller, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low., D. E.</span><span> </span><span class="NLM_article-title">A review of <i>Streptococcus pneumoniae</i> infection treatment failures associated with fluoroquinolone resistance</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1086%2F430829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=15937772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ptVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=118-121&author=J.+D.+Fullerauthor=D.+E.+Low.&title=A+review+of+Streptococcus+pneumoniae+infection+treatment+failures+associated+with+fluoroquinolone+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance</span></div><div class="casAuthors">Fuller Jeffrey D; Low Donald E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We reviewed all of the published reports of cases of fluoroquinolone treatment failures for respiratory tract infection due to fluoroquinolone-resistant Streptococcus pneumoniae.  There were 20 ciprofloxacin and levofloxacin treatment failures reported.  Physicians should be aware, when treating pneumococcal respiratory tract infections in older patients with a fluoroquinolone, that clinical failures might occur, especially for patients with comorbid illnesses and a history of recent fluoroquinolone use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAcAREMijQLrqxQ2mb9Pu8fW6udTcc2ebPwyrlGhJ3iLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ptVWmsw%253D%253D&md5=f7451bde71559f2f18dea4f852afc4e1</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1086%2F430829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F430829%26sid%3Dliteratum%253Aachs%26aulast%3DFuller%26aufirst%3DJ.%2BD.%26aulast%3DLow.%26aufirst%3DD.%2BE.%26atitle%3DA%2520review%2520of%2520Streptococcus%2520pneumoniae%2520infection%2520treatment%2520failures%2520associated%2520with%2520fluoroquinolone%2520resistance%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D41%26spage%3D118%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_contrib-group">Hoffman-Roberts, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C. Babcock,  E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitropoulos, I. F.</span><span> </span><span class="NLM_article-title">Investigational new drugs for the treatment of resistant pneumococcal infections</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=973-995&issue=8&author=H.+L.+Hoffman-Robertsauthor=+E.+C.+Babcockauthor=I.+F.+Mitropoulos&title=Investigational+new+drugs+for+the+treatment+of+resistant+pneumococcal+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman-Roberts%26aufirst%3DH.%2BL.%26aulast%3DC.%2BBabcock%26aufirst%3DE.%26aulast%3DMitropoulos%26aufirst%3DI.%2BF.%26atitle%3DInvestigational%2520new%2520drugs%2520for%2520the%2520treatment%2520of%2520resistant%2520pneumococcal%2520infections%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2005%26volume%3D14%26issue%3D8%26spage%3D973%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motola, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F11531850-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=20297862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls12murk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=303-314&issue=4&author=E.+Poluzziauthor=E.+Raschiauthor=D.+Motolaauthor=U.+Morettiauthor=F.+De+Ponti&title=Antimicrobials+and+the+risk+of+torsades+de+pointes%3A+the+contribution+from+data+mining+of+the+US+FDA+Adverse+Event+Reporting+System"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System</span></div><div class="casAuthors">Poluzzi, Elisabetta; Raschi, Emanuel; Motola, Domenico; Moretti, Ugo; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-314</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">Background: Drug-induced torsades de pointes (TdP) is a complex regulatory and clin. problem due to the rarity of this sometimes fatal adverse event.  In this context, the US FDA Adverse Event Reporting System (AERS) is an important source of information, which can be applied to the anal. of TdP liability of marketed drugs.  Objective: To critically evaluate the risk of antimicrobial-induced TdP by detecting alert signals in the AERS, on the basis of both quant. and qual. analyses.  Methods: Reports of TdP from Jan. 2004 through Dec. 2008 were retrieved from the public version of the AERS.  The abs. no. of cases and reporting odds ratio as a measure of disproportionality were evaluated for each antimicrobial drug (quant. approach).  A list of drugs with suspected TdP liability (provided by the Arizona Center of Education and Research on Therapeutics [CERT]) was used as a ref. to define signals.  In a further anal., to refine signal detection, we identified TdP cases without co-medications listed by Arizona CERT (qual. approach).  Results: Over the 5-yr period, 374 reports of TdP were retrieved: 28 anti-bacterials, 8 antifungals, 1 antileprosy and 26 antivirals were involved.  Antimicrobials more frequently reported were levofloxacin (55) and moxifloxacin (37) among the antibacterials, fluconazole (47) and voriconazole (17) among the antifungals, and lamivudine (8) and nelfinavir (6) among the antivirals.  A significant disproportionality was obsd. for 17 compds., including several macrolides, fluoroquinolones, linezolid, triazole antifungals, caspofungin, indinavir and nelfinavir.  With the qual. approach, we identified the following addnl. drugs or fixed dose combinations, characterized by at least two TdP cases without co-medications listed by Arizona CERT: ceftriaxone, piperacillin/tazobactam, cotrimoxazole, metronidazole, ribavirin, lamivudine and lopinavir/ritonavir.  Discussion: Disproportionality for macrolides, fluoroquinolones and most of the azole antifungals should be viewed as 'expected' according to Arizona CERT list.  By contrast, signals were generated by linezolid, caspofungin, posaconazole, indinavir and nelfinavir.  Drugs detected only by the qual. approach should be further investigated by increasing the sensitivity of the method, e.g. by searching also for the TdP surrogate marker, prolongation of the QT interval.  Conclusions: The freely available version of the FDA AERS database represents an important source to detect signals of TdP.  In particular, our anal. generated five signals among antimicrobials for which further investigations and active surveillance are warranted.  These signals should be considered in evaluating the benefit-risk profile of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkddzQ8GgdLVg90H21EOLACvtfcHk0ljyka9z5XGqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls12murk%253D&md5=68a94e209a7f51d386fd8f202df500c0</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.2165%2F11531850-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11531850-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DMotola%26aufirst%3DD.%26aulast%3DMoretti%26aufirst%3DU.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DAntimicrobials%2520and%2520the%2520risk%2520of%2520torsades%2520de%2520pointes%253A%2520the%2520contribution%2520from%2520data%2520mining%2520of%2520the%2520US%2520FDA%2520Adverse%2520Event%2520Reporting%2520System%26jtitle%3DDrug%2520Saf.%26date%3D2010%26volume%3D33%26issue%3D4%26spage%3D303%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_contrib-group">Falagas, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafailidis, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosmarakis, E. S.</span><span> </span><span class="NLM_article-title">Arrhythmias associated with fluoroquinolone therapy</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1016%2Fj.ijantimicag.2006.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=17241772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=374-379&issue=4&author=M.+E.+Falagasauthor=P.+I.+Rafailidisauthor=E.+S.+Rosmarakis&title=Arrhythmias+associated+with+fluoroquinolone+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Arrhythmias associated with fluoroquinolone therapy</span></div><div class="casAuthors">Falagas, Matthew E.; Rafailidis, Petros I.; Rosmarakis, Evangelos S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">374-379</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fluoroquinolones are widely used and well tolerated antibacterial agents.  However, prolongation of the QT interval is an adverse effect assocd. with the use of fluoroquinolones.  According to the available case reports and clin. studies, moxifloxacin carries the greatest risk of QT prolongation from all available quinolones in clin. practice and it should be used with caution in patients with predisposing factors for Torsades de pointes (Tdp).  Although gemifloxacin, levofloxacin and ofloxacin are assocd. with a lower risk of QT prolongation compared with moxifloxacin, they should also be used with caution in patients with risk factors for QT prolongation.  Ciprofloxacin appears to be assocd. with the lowest risk for QT prolongation and the lowest rate of Tdp.  The overall risk of Tdp is small with the use of fluoroquinolones.  Clinicians can minimise that risk by avoiding prescriptions of multiple medications assocd. with QT interval prolongation, esp. in high-risk patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJyMt602Wu_7Vg90H21EOLACvtfcHk0ljyka9z5XGqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislehs7Y%253D&md5=39aab28223fa27b61898ec823b3f5771</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2006.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2006.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DFalagas%26aufirst%3DM.%2BE.%26aulast%3DRafailidis%26aufirst%3DP.%2BI.%26aulast%3DRosmarakis%26aufirst%3DE.%2BS.%26atitle%3DArrhythmias%2520associated%2520with%2520fluoroquinolone%2520therapy%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2007%26volume%3D29%26issue%3D4%26spage%3D374%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_contrib-group">Owens, R. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrose, P. G.</span><span> </span><span class="NLM_article-title">Torsades de pointes associated with fluoroquinolones</span> <span class="citation_source-journal">Pharmacotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=663-668&issue=5&author=R.+C.+Owensauthor=P.+G.+Ambrose&title=Torsades+de+pointes+associated+with+fluoroquinolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DR.%2BC.%26aulast%3DAmbrose%26aufirst%3DP.%2BG.%26atitle%3DTorsades%2520de%2520pointes%2520associated%2520with%2520fluoroquinolones%26jtitle%3DPharmacotherapy%26date%3D2002%26volume%3D22%26issue%3D5%26spage%3D663%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_contrib-group">Mehlhorn, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. A.</span><span> </span><span class="NLM_article-title">Safety concerns with fluoroquinolones</span> <span class="citation_source-journal">Ann Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1859</span><span class="NLM_x">–</span> <span class="NLM_lpage">1866</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2007&pages=1859-1866&issue=11&author=A.+J.+Mehlhornauthor=D.+A.+Brown&title=Safety+concerns+with+fluoroquinolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMehlhorn%26aufirst%3DA.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BA.%26atitle%3DSafety%2520concerns%2520with%2520fluoroquinolones%26jtitle%3DAnn%2520Pharmacother.%26date%3D2007%26volume%3D41%26issue%3D11%26spage%3D1859%26epage%3D1866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_contrib-group">Sprandel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodvold, K. A.</span><span> </span><span class="NLM_article-title">Safety and tolerability of fluoroquinolones</span> <span class="citation_source-journal">Clin Cornerstone</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S29</span><span class="NLM_x">–</span> <span class="NLM_lpage">S36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=S29-S36&issue=Suppl.+3&author=K.+A.+Sprandelauthor=K.+A.+Rodvold&title=Safety+and+tolerability+of+fluoroquinolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSprandel%26aufirst%3DK.%2BA.%26aulast%3DRodvold%26aufirst%3DK.%2BA.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520fluoroquinolones%26jtitle%3DClin%2520Cornerstone%26date%3D2003%26issue%3DSuppl.%25203%26spage%3DS29%26epage%3DS36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Kawakami, K.; Ohki, H.; Kimura, K.; Tanaka, M.; Takemura, M.; Sato, K.; Takahashi, H.; Hayakawa, I.</span><span> </span><span class="NLM_article-title">DK-507k, a New 8-Methoxyquinolones: Synthesis and Biological Evaluation of 7-[(3-Amino-4-substituted)pyrrolidine-1-yl] Derivatives</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Society for Microbiology</span>: <span class="NLM_publisher-loc">Washington, DC</span>; Abstract F-546.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=K.+Kawakami&author=H.+Ohki&author=K.+Kimura&author=M.+Tanaka&author=M.+Takemura&author=K.+Sato&author=H.+Takahashi&author=I.+Hayakawa&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKawakami%26aufirst%3DK.%26atitle%3DDK-507k%252C%2520a%2520New%25208-Methoxyquinolones%253A%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25207-%255B%25283-Amino-4-substituted%2529pyrrolidine-1-yl%255D%2520Derivatives%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2001%26pub%3DAmerican%2520Society%2520for%2520Microbiology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Dresser, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, D. G.</span><span> </span><span class="NLM_article-title">Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 #A4 inhibition</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F00003088-200038010-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=10668858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2000&pages=41-57&author=G.+K.+Dresserauthor=J.+D.+Spenceauthor=D.+G.+Bailey&title=Pharmacokinetic-pharmacodynamic+consequences+and+clinical+relevance+of+cytochrome+P450+%23A4+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition</span></div><div class="casAuthors">Dresser, George K.; Spence, J. David; Bailey, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-57</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 162 refs.  Drug interactions occur when the efficacy or toxicity of a medication is changed by administration of another substance.  Pharmacokinetic interactions often occur as a result of a change in drug metab.  Cytochrome P 450 (CYP) 3A4 oxidizes a broad spectrum of drugs by a no. of metabolic processes.  The location of CYP3A4 in the small bowel and liver permits an effect on both presystemic and systemic drug disposition.  Some interactions with CYP3A4 inhibitors may also involve inhibition of P-glycoprotein.  Clin. important CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir and grapefruit juice.  Torsades de pointes, a life-threatening ventricular arrhythmia assocd. with QT prolongation, can occur when these inhibitors are coadministered with terfenadine, astemizole, cisapride or pimozide.  Rhabdomyolysis has been assocd. with the coadministration of some 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors ("statins") and CYP3A4 inhibitors.  Symptomatic hypotension may occur when CYP3A4 inhibitors are given with some dihydropyridine calcium antagonists, as well with the phosphodiesterase inhibitor sildenafil.  Excessive sedation can result from concomitant administration of benzodiazepine (midazolam, triazolam, alprazolam or diazepam) or nonbenzodiazepine (zopiclone and buspirone) hypnosedatives with CYP3A4 inhibitors.  Ataxia can occur with carbamazepine, and ergotism with ergotamine, following the addn. of a CYP3A4 inhibitor.  Beneficial drug interactions can occur.  Administration of a CYP3A4 inhibitor with cyclosporin may allow redn. of the dosage and cost of the immunosuppressant.  Certain HIV protease inhibitors, e.g. saquinavir, have low oral bioavailability that can be profoundly increased by the addn. of ritonavir.  The clin. importance of any drug interaction depends on factors that are drug-, patient- and administration-related.  Generally, a doubling or more in plasma drug concn. has the potential for enhanced adverse or beneficial drug response.  Less pronounced pharmacokinetic interactions may still be clin. important for drugs with a steep concn.-response relation or narrow therapeutic index.  In most cases, the extent of drug interaction varies markedly among individuals; this is likely to be dependent on interindividual differences in CYP3A4 tissue content, pre-existing medical conditions and, possibly, age.  Interactions may occur under single dose conditions or only at steady state.  The pharmacodynamic consequences may or may not closely follow pharmacokinetic changes.  Drug interactions may be most apparent when patients are stabilized on the affected drug and the CYP3A4 inhibitor is then added to the regimen.  Temporal relationships between the administration of the drug and CYP3A4 inhibitor may be important in detg. the extent of the interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowhzNIdr3F67Vg90H21EOLACvtfcHk0ljIRT-qkrXVYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2kurw%253D&md5=c879e684a067e66a2c0436bdfc53cd64</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.2165%2F00003088-200038010-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200038010-00003%26sid%3Dliteratum%253Aachs%26aulast%3DDresser%26aufirst%3DG.%2BK.%26aulast%3DSpence%26aufirst%3DJ.%2BD.%26aulast%3DBailey%26aufirst%3DD.%2BG.%26atitle%3DPharmacokinetic-pharmacodynamic%2520consequences%2520and%2520clinical%2520relevance%2520of%2520cytochrome%2520P450%2520%2523A4%2520inhibition%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2000%26volume%3D38%26spage%3D41%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions</span> <span class="citation_source-journal">Curr Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2174%2F138920007780866807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=17584015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=407-447&issue=5&author=A.+S.+Kalgutkarauthor=R.+S.+Obachauthor=T.+S.+Maurer&title=Mechanism-based+inactivation+of+cytochrome+P450+enzymes%3A+chemical+mechanisms%2C+structure%E2%80%93activity+relationships+and+relationship+to+clinical+drug%E2%80%93drug+interactions+and+idiosyncratic+adverse+drug+reactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions</span></div><div class="casAuthors">Kalgutkar, Amit S.; Obach, R. Scott; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-447</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 constitute a superfamily of heme-contg. enzymes that catalyze the oxidative biotransformation of structurally diverse xenobiotics including drugs.  Inhibition of P 450 enzymes is by far the most common mechanism which can lead to DDIs.  P 450 inhibition can be categorized as reversible (competitive or non-competitive) or irreversible (mechanism-based inactivation).  Mechanism-based P 450 inactivation usually involves bioactivation of the xenobiotic to a reactive intermediate, which covalently modifies an active site amino acid residue and/or coordinates to the heme prosthetic group.  Covalent modification of P 450 enzymes can also lead to hapten formation and can in some cases trigger an autoimmune response resulting in toxicol. consequences.  Compared to reversible inhibition, irreversible inhibition more frequently results in unfavorable DDIs as the inactivated P 450 enzyme has to be replaced by newly synthesized protein.  For these reasons, most drug metab. groups within pharmaceutical companies have well-established screening paradigms to assess mechanism-based inactivation of major human P 450 enzymes by new chem. entities followed by indepth mechanistic studies to elucidate the mechanism of P 450 inactivation when a pos. finding is discerned.  A deeper understanding of the process leading to enzyme inactivation by drug candidates can lead to rational chem. intervention strategies to circumvent the P 450 inactivation/bioactivation liability.  Apart from structure-activity relationship studies, methodol. to predict the magnitude of in vivo metabolic DDIs using in vitro P 450 inactivation data and predicted human pharmacokinetics of the candidate drug also exists and can be utilized to project the extent of clin. DDIs against P 450 enzyme-specific substrates.  In this review, a comprehensive anal. of the biochem. basis and known structure-activity relationships for P 450 inactivation by xenobiotics is described.  In addn., the current state-of-the-art of the methodol. used in predicting the magnitude of DDIs using in vitro P 450 inactivation data and human pharmacokinetic parameters is discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV8akoVDkMzrVg90H21EOLACvtfcHk0ljIRT-qkrXVYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jt7Y%253D&md5=f2ee4172b6165268710c10dcc32fecb4</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.2174%2F138920007780866807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866807%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520chemical%2520mechanisms%252C%2520structure%25E2%2580%2593activity%2520relationships%2520and%2520relationship%2520to%2520clinical%2520drug%25E2%2580%2593drug%2520interactions%2520and%2520idiosyncratic%2520adverse%2520drug%2520reactions%26jtitle%3DCurr%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26issue%3D5%26spage%3D407%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_contrib-group">Thompson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidolf, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claesson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolgos, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenna, J. G.</span><span> </span><span class="NLM_article-title">Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development</span> <span class="citation_source-journal">Chem.-Biol. Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1016%2Fj.cbi.2010.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=21074519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVyiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2011&pages=65-71&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=R.+Weaverauthor=L.+Weidolfauthor=I.+Wilsonauthor=A.+Claessonauthor=K.+Pageauthor=H.+Dolgosauthor=J.+G.+Kenna&title=Risk+assessment+and+mitigation+strategies+for+reactive+metabolites+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weaver, Richard; Weidolf, Lars; Wilson, Ian; Claesson, Alf; Page, Ken; Dolgos, Hugues; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug toxicity is a leading cause of attrition of candidate drugs during drug development as well as of withdrawal of drugs post-licensing due to adverse drug reactions in man.  These adverse drug reactions cause a broad range of clin. severe conditions including both highly reproducible and dose dependent toxicities as well as relatively infrequent and idiosyncratic adverse events.  The underlying risk factors can be split into two groups: (1) drug-related and (2) patient-related.  The drug-related risk factors include metabolic factors that det. the propensity of a mol. to form toxic reactive metabolites (RMs), and the RM and non-RM mediated mechanisms which cause cell and tissue injury.  Patient related risk factors may vary markedly between individuals, and encompass genetic and non-genetic processes, e.g. environmental, that influence the disposition of drugs and their metabolites, the nature of the adverse responses elicited and the resulting biol. consequences.  We describe a new strategy, which builds upon the strategies used currently within numerous pharmaceutical companies to avoid and minimize RM formation during drug discovery, and that is intended to reduce the likelihood that candidate drugs will cause toxicity in the human population.  The new strategy addresses drug-related safety hazards, but not patient-related risk factors.  A common target organ of toxicity is the liver and to decrease the likelihood that candidate drugs will cause liver toxicity (both non-idiosyncratic and idiosyncratic), we propose use of an in vitro Hepatic Liability Panel alongside in vitro methods for the detection of RMs.  This will enable design and selection of compds. in discovery that have reduced propensity to cause liver toxicity.  In vitro Hepatic Liability is assessed using toxicity assays that quantify: CYP 450 dependent and CYP 450 independent cell toxicity; mitochondrial impairment; and inhibition of the Bile Salt Export Pump.  Prior to progression into development, a Hepatotoxicity Hazard Matrix combines data from the Hepatic Liability Panel with the Estd. RM Body Burden.  The latter is defined as the level of covalent binding of radiolabeled drug to human hepatocyte proteins in vitro adjusted for the predicted human dose.  We exemplify the potential value of this approach by consideration of the thiazolidinedione class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAv1YMcAPyUrVg90H21EOLACvtfcHk0lhNolQyRIRVzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVyiu7c%253D&md5=54ef4b6d98e18d3b7d3ae75ad0d6c114</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2010.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2010.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DClaesson%26aufirst%3DA.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DRisk%2520assessment%2520and%2520mitigation%2520strategies%2520for%2520reactive%2520metabolites%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2011%26volume%3D192%26spage%3D65%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_contrib-group">Omar, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. P.</span><span> </span><span class="NLM_article-title">FDA adverse event reports on strain-associated rhabdomyolysis</span> <span class="citation_source-journal">Anal. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1345%2Faph.1A289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=11847951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2002&pages=288-295&author=M.+A.+Omarauthor=J.+P.+Wilson&title=FDA+adverse+event+reports+on+strain-associated+rhabdomyolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">FDA adverse event reports on statin-associated rhabdomyolysis</span></div><div class="casAuthors">Omar, Mohamed A.; Wilson, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-295</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1060-0280</span>.
    
            (<span class="NLM_cas:orgname">Harvey Whitney Books Co.</span>)
        </div><div class="casAbstract">The aim of this study was to det. the no. of cases of statin-assocd. rhabdomyolysis reported to the Food and Drug Administration for 6 statins and to profile the cases.  This was a retrospective anal. of all domestic and foreign reports of statin-assocd. rhabdomyolysis between Nov. 1997 and Mar. 2000 was conducted.  Outcome measures included the total no. of reports (initial plus follow-up), the no. of unique cases, age, gender, percentages of report codes and role codes, and frequencies of concomitant interacting drugs that may have pptd. rhabdomyolysis, outcomes codes, and report source codes.  There were 871 reports of statin-assocd. rhabdomyolysis in the 29-mo time frame examd., representing 601 cases.  The following no. of cases were assocd. with each of the individual statins: simvastatin, 215 (35.8%); cerivastatin, 192 (31.9%); atorvastatin, 73 (12.2%); pravastatin, 71 (11.8%); lovastatin, 40 (6.7%); and fluvastatin, 10 (1.7%).  Drugs that may have interacted with the statins were present in the following no. of cases: mibefradil (n = 99), fibrates (n = 80), cyclosporine (n = 51), macrolide antibiotics (n = 42), warfarin (n = 33), digoxin (n = 26), and azole antifungals (n = 12).  The reports of 62.1% of cases were classified as expedited.  Statins were designated as the primary suspect in 72.0% of the cases.  Death was listed as the outcome in 38 cases.  The majority of reports (n = 556) were from health professionals.  Compared with the other statins, simvastatin and cerivastatin were implicated in a relatively higher no. of reports.  Because of the various limitations of a spontaneous reporting-system database, caution is urged when interpreting the relative no. of cases reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSlPH9OWymc7Vg90H21EOLACvtfcHk0lhNolQyRIRVzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFOjtLg%253D&md5=3822b4283e0e0fd1daeb1837afdf1e10</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1345%2Faph.1A289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1A289%26sid%3Dliteratum%253Aachs%26aulast%3DOmar%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DJ.%2BP.%26atitle%3DFDA%2520adverse%2520event%2520reports%2520on%2520strain-associated%2520rhabdomyolysis%26jtitle%3DAnal.%2520Pharmacother.%26date%3D2002%26volume%3D36%26spage%3D288%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_contrib-group">Utrehit, J.</span><span> </span><span class="NLM_article-title">Idiosyncratic drug reactions: past, present, and future</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=84-92&issue=1&author=J.+Utrehit&title=Idiosyncratic+drug+reactions%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUtrehit%26aufirst%3DJ.%26atitle%3DIdiosyncratic%2520drug%2520reactions%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26issue%3D1%26spage%3D84%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Silverman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrillo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. T.</span><span> </span><span class="NLM_article-title">Mechanism-based enzyme inactivation via a diactivated cyclopropane intermediate</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2982</span><span class="NLM_x">–</span> <span class="NLM_lpage">2983</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00060a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=2982-2983&author=R.+B.+Silvermanauthor=C.+Z.+Dingauthor=J.+L.+Borrilloauthor=J.+T.+Chang&title=Mechanism-based+enzyme+inactivation+via+a+diactivated+cyclopropane+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fja00060a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00060a059%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26aulast%3DBorrillo%26aufirst%3DJ.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BT.%26atitle%3DMechanism-based%2520enzyme%2520inactivation%2520via%2520a%2520diactivated%2520cyclopropane%2520intermediate%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D2982%26epage%3D2983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Borlak, J.</span><span> </span><span class="NLM_article-title">Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity—molecular mechanisms and lessons for pharmacotoxicity</span> <span class="citation_source-journal">Hum. Exp. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">2–3</span><span class="NLM_x">) </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1177%2F0960327109105767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=19713375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kitb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=119-121&issue=2%E2%80%933&author=J.+Borlak&title=Trovafloxacin%3A+a+case+study+of+idiosyncratic+or+iatrogenic+liver+toxicity%E2%80%94molecular+mechanisms+and+lessons+for+pharmacotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity molecular mechanisms and lessons for pharmacotoxicity</span></div><div class="casAuthors">Borlak, J.</div><div class="citationInfo"><span class="NLM_cas:title">Human & Experimental Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">119-121</span>CODEN:
                <span class="NLM_cas:coden">HETOEA</span>;
        ISSN:<span class="NLM_cas:issn">0960-3271</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">The genomic responses to hepatocyte toxicity assocd. with trovafloxacin, and which kinds of metabolic pathways are perturbed were examd. using DNA microarrays.  It was shown that the drug inhibits mammalian and bacterial topoisomerases.  In addn., hepatic nuclear factor-4α expression was severely reduced by this drug.  It can be concluded that primary human hepatocyte culture studies supplied significant data on a mechanism of idiosyncratic liver toxicity, and may have been used to predict the excessive hepatotoxicity of trovafloxacin, and of other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJdB41P7edpbVg90H21EOLACvtfcHk0lhNolQyRIRVzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kitb3E&md5=c4c20158bf7ba99186b48d174a334bd1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F0960327109105767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0960327109105767%26sid%3Dliteratum%253Aachs%26aulast%3DBorlak%26aufirst%3DJ.%26atitle%3DTrovafloxacin%253A%2520a%2520case%2520study%2520of%2520idiosyncratic%2520or%2520iatrogenic%2520liver%2520toxicity%25E2%2580%2594molecular%2520mechanisms%2520and%2520lessons%2520for%2520pharmacotoxicity%26jtitle%3DHum.%2520Exp.%2520Toxicol.%26date%3D2009%26volume%3D28%26issue%3D2%25E2%2580%25933%26spage%3D119%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kawakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemura, M.</span><span> </span><span class="NLM_article-title">Studies on 8-methoxyquinolones: synthesis and antibacterial activity of 7-(3-amino-4-substituted)pyrrolidinyl derivatives</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1667</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2000&pages=1667-1672&issue=11&author=K.+Kawakamiauthor=H.+Takahashiauthor=H.+Ohkiauthor=K.+Kimuraauthor=S.+Miyauchiauthor=R.+Miyauchiauthor=M.+Takemura&title=Studies+on+8-methoxyquinolones%3A+synthesis+and+antibacterial+activity+of+7-%283-amino-4-substituted%29pyrrolidinyl+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKawakami%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DOhki%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DMiyauchi%26aufirst%3DS.%26aulast%3DMiyauchi%26aufirst%3DR.%26aulast%3DTakemura%26aufirst%3DM.%26atitle%3DStudies%2520on%25208-methoxyquinolones%253A%2520synthesis%2520and%2520antibacterial%2520activity%2520of%25207-%25283-amino-4-substituted%2529pyrrolidinyl%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2000%26volume%3D48%26issue%3D11%26spage%3D1667%26epage%3D1672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cornforth, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornforth, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, K. K.</span> <span class="citation_source-journal">J. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_fpage">2539</span><span class="NLM_x">–</span> <span class="NLM_lpage">2547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cornforth%2C+J.+W.%3B+Cornforth%2C+R.+H.%3B+Mathew%2C+K.+K.J.+Chem.+Soc.+1959%2C+2539%E2%80%932547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCornforth%26aufirst%3DJ.%2BW.%26aulast%3DCornforth%26aufirst%3DR.%2BH.%26aulast%3DMathew%26aufirst%3DK.%2BK.%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1959%26spage%3D2539%26epage%3D2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="note"><p class="first last">Compound <b>11</b> (or starting material) was prepared by our method described in PCT Int. Appl. WO2006123792 A1, <span class="NLM_year">2006</span>. <sup>1</sup>H NMR (CDCl<sub>3</sub>), δ ppm: 1.34 (12H, s), 1.52 (3H, d, <i>J</i> = 7.10 Hz), 2.27 (1H, d, <i>J</i> = 17.0 Hz), 2.93 (1H, d, <i>J</i> = 17.0 Hz), 3.05 (1H, d, <i>J</i> = 10.1 Hz), 3.32 (1H, d, <i>J</i> = 10.1 Hz), 5.50 (1H, q, <i>J</i> = 7.1 Hz), 7.23–7.38 (5H, m).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_contrib-group">Murayama, N.; Tachibana, M.; Takao, A.; Okazaki, O.; Sudo, K.</span><span> </span><span class="NLM_article-title">DC-159a, a New Generation Respiratory Quinolone: Pharmacokinetics in Rats and Monkeys</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Society for Microbiology</span>: <span class="NLM_publisher-loc">Washington, DC</span>; Abstract F1-0477.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=N.+Murayama&author=M.+Tachibana&author=A.+Takao&author=O.+Okazaki&author=K.+Sudo&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurayama%26aufirst%3DN.%26atitle%3DDC-159a%252C%2520a%2520New%2520Generation%2520Respiratory%2520Quinolone%253A%2520Pharmacokinetics%2520in%2520Rats%2520and%2520Monkeys%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2006%26pub%3DAmerican%2520Society%2520for%2520Microbiology" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><div class="note"><p class="first last">Experimental reference of mechanism-based inhibition is as follows: </p></div><span class="NLM_contrib-group">Madan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usuki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs</span> <span class="citation_source-journal">Drugs Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot1Ortb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2002&pages=217-294&author=A.+Madanauthor=E.+Usukiauthor=L.+A.+Burtonauthor=B.+W.+Ogilvieauthor=A.+Parkinson&title=In+vitro+approaches+for+studying+the+inhibition+of+drug-metabolizing+enzymes+and+identifying+the+drug-metabolizing+enzymes+responsible+for+the+metabolism+of+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs</span></div><div class="casAuthors">Madan, Ajay; Usuki, Etsuko; Burton, L. Alayne; Ogilvie, Brian W.; Parkinson, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drugs and the Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">Drug-Drug Interactions</span>),
    <span class="NLM_cas:pages">217-294</span>CODEN:
                <span class="NLM_cas:coden">DPHSDS</span>;
        ISSN:<span class="NLM_cas:issn">0360-2583</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review on the in vitro systems for studying the inhibition of drug-metabolizing enzymes and the identification of drug-metabolizing enzymes involved in the metab. of a drug.  Various exptl. designs, their advantages and pitfalls, and extrapolation of in vitro data to the clin. situation are also discussed.  Particular focus is given to cytochrome P 450 enzymes, because most of the clin. relevant pharmacokinetic drug interactions are, in one way or another, related to P 450 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopsTSmwbgSYLVg90H21EOLACvtfcHk0lhnPLdqKpdVmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot1Ortb0%253D&md5=07f2d67ac696ad5a6607bd483c307732</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DUsuki%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%2BA.%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520approaches%2520for%2520studying%2520the%2520inhibition%2520of%2520drug-metabolizing%2520enzymes%2520and%2520identifying%2520the%2520drug-metabolizing%2520enzymes%2520responsible%2520for%2520the%2520metabolism%2520of%2520drugs%26jtitle%3DDrugs%2520Pharm.%2520Sci.%26date%3D2002%26volume%3D116%26spage%3D217%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_contrib-group">Ponte, M. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Girolamo, G.</span><span> </span><span class="NLM_article-title">Mechanisms of drug induced QT interval prolongation</span> <span class="citation_source-journal">Curr Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2174%2F157488610789869247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=20210718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFeqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=44-53&issue=1&author=M.+L+Ponteauthor=G.+A.+Kellerauthor=G.+Di+Girolamo&title=Mechanisms+of+drug+induced+QT+interval+prolongation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug induced QT interval prolongation</span></div><div class="casAuthors">Ponte, Marcelo Luis; Keller, Guillermo Alberto; Di Girolamo, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-53</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The long QT syndrome (LQTS) is characterized by a prolonged QT interval, as well as a propensity to develop syncope and sudden cardiac death caused by the malignant polymorphic ventricular arrhythmia called torsades de pointes (TdP).  The QT interval is measured from the onset of the QRS complex to the end of the T wave and can be affected by both ventricular conduction velocities as well as by the velocity of repolarization.  In most cases, QT prolongation is caused by factors that prolong the duration of the action potential, mainly by delaying the repolarization phase 3.  The mol. mechanism is partially known.  There are two well described mechanisms: blocking of the ion channel cavity of HERG; or causing an abnormal protein trafficking required for the location of HERG subunits in cell membrane.  Both of them impair the IKr current.  However the blockade of ion channels is not the only condition to generate TdP.  Other factors may play an important role, e.g. myocardium heterogeneity, drug-drug interaction, genetic polymorphism, and electrolyte disturbances.  Several drugs had been subject of withdrawal because QT-prolongation and arrhythmia.  Understanding of processes involved in drug-induced QT prolongation is needed for the study and prevention of life-threatening arrhythmias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqey6q8MXCoe7Vg90H21EOLACvtfcHk0lhnPLdqKpdVmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFeqtbg%253D&md5=2e7a05d5105cb97776197407fe09996a</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.2174%2F157488610789869247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488610789869247%26sid%3Dliteratum%253Aachs%26aulast%3DPonte%26aufirst%3DM.%2BL%26aulast%3DKeller%26aufirst%3DG.%2BA.%26aulast%3DDi%2BGirolamo%26aufirst%3DG.%26atitle%3DMechanisms%2520of%2520drug%2520induced%2520QT%2520interval%2520prolongation%26jtitle%3DCurr%2520Drug%2520Saf.%26date%3D2010%26volume%3D5%26issue%3D1%26spage%3D44%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_contrib-group">Lagrutta, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepakova, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1102</span><span class="NLM_x">–</span> <span class="NLM_lpage">1112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2174%2F156802608785700016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=18782006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1102-1112&issue=13&author=A.+A.+Lagruttaauthor=E.+S.+Trepakovaauthor=J.+J.+Salata&title=The+hERG+channel+and+risk+of+drug-acquired+cardiac+arrhythmia%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview</span></div><div class="casAuthors">Lagrutta, Armando A.; Trepakova, Elena S.; Salata, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1102-1112</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the assocd. risk of ventricular arrhythmia and fibrillation.  The mol. characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation.  The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to det. structure-activity relations (SAR) within chem. series.  More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chem. series is a viable strategy to reduce or eliminate hERG activity.  Despite a crit. need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoixN90Myu6bVg90H21EOLACvtfcHk0lhshK-PP8r3wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsrjK&md5=31c03ae1d1c67bf8f85d804c7b2fe2d2</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.2174%2F156802608785700016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608785700016%26sid%3Dliteratum%253Aachs%26aulast%3DLagrutta%26aufirst%3DA.%2BA.%26aulast%3DTrepakova%26aufirst%3DE.%2BS.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520hERG%2520channel%2520and%2520risk%2520of%2520drug-acquired%2520cardiac%2520arrhythmia%253A%2520an%2520overview%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D13%26spage%3D1102%26epage%3D1112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_contrib-group">Liu, H. H.</span><span> </span><span class="NLM_article-title">Safety profile of the fluoroquinolones: focus on levofloxacin</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.2165%2F11536360-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=20397737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslejt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=353-369&issue=5&author=H.+H.+Liu&title=Safety+profile+of+the+fluoroquinolones%3A+focus+on+levofloxacin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of the fluoroquinolones: focus on levofloxacin</span></div><div class="casAuthors">Liu, Hans H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-369</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  The fluoroquinolone class of antibacterial agents are among the most frequently prescribed drugs, with utility in a broad range of bacterial infections.  Although very useful agents, the fluoroquinolones as a class are assocd. with a no. of adverse events, some with considerable clin. significance.  In the past 15-20 years, tolerability concerns have led to restrictions on the use of the fluoroquinolones and, in some instances, the withdrawal of agents from the market.  This review focuses on the safety and tolerability of levofloxacin, a third-generation fluoroquinolone, relative to other fluoroquinolones.  A literature search was performed of the MEDLINE database encompassing the dates 1980-2009, using as keywords the drug names levofloxacin and concurrently marketed fluoroquinolones combined with the words 'safety', 'adverse effect' or 'adverse drug reaction', or the name of the specific adverse effect.  Adverse events commonly assocd. with the fluoroquinolones include gastrointestinal and CNS toxicity (most frequently headache and dizziness), as well as other adverse events including ECG abnormalities (for example QT interval prolongation), disrupted glucose metab., phototoxicity, tendon and joint disorders, hypersensitivity and skin disorders, and hepatic toxicity.  Package inserts for the fluoroquinolones in Europe and the US contain warnings regarding these risks.  US package inserts also carry 'black-box' warnings regarding the risk of tendon rupture and joint disorders with these agents; however, there is a substantial body of evidence to indicate that there are marked differences in the tolerability profiles of the individual agents within the fluoroquinolone class.  These differences may be explained, at least in part, by structural differences: all fluoroquinolones share a basic quinolone core, with differences in specific side chains underlying the adverse event relationships.  Furthermore, many of the fluoroquinolone-assocd. adverse effects and toxicities occur more frequently in patients with pre-existing risk factors, or in certain subpopulations.  Notably, package inserts for the fluoroquinolones carry warnings regarding use in the elderly, paediatric patients and patients with preexisting, or factors predisposing to, seizure disorders.  Because of this, many adverse reactions with these agents could be prevented by improving patient screening and education.  The recent withdrawal of gatifloxacin due to dysglycemia makes it timely to review the safety and tolerability of the individual agents in this class.  Overall, it appears that levofloxacin is relatively well tolerated, with low rates of clin. important adverse events such as CNS toxicity, cardiovascular toxicity and dysglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgeZYFPvQVk7Vg90H21EOLACvtfcHk0lhshK-PP8r3wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslejt7k%253D&md5=6832db269b694276ba5fd46d1ace7d72</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.2165%2F11536360-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11536360-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%2BH.%26atitle%3DSafety%2520profile%2520of%2520the%2520fluoroquinolones%253A%2520focus%2520on%2520levofloxacin%26jtitle%3DDrug%2520Saf.%26date%3D2010%26volume%3D33%26issue%3D5%26spage%3D353%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><div class="note"><p class="first last">Experimental reference of hERG patch clamp assay is as follows:</p></div><span class="NLM_contrib-group">Bischoff, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Netzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongs, O.</span><span> </span><span class="NLM_article-title">Effects of fluoroquinolones on HERG currents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1016%2FS0014-2999%2800%2900693-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm301650g&amp;key=11040340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm301650g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlKjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=341-343&author=U.+Bischoffauthor=C.+Schmidtauthor=R.+Netzerauthor=O.+Pongs&title=Effects+of+fluoroquinolones+on+HERG+currents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fluoroquinolones on HERG currents</span></div><div class="casAuthors">Bischoff, U.; Schmidt, C.; Netzer, R.; Pongs, O.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-343</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">We have investigated the effects of four fluoroquinolones on the human ether-a-go-go-related gene (HERG) mediated K+ currents to evaluate their potential to induce QT-prolongation.  HERG currents were measured from stably transfected Chinese hamster ovary (CHO) cells by means of the patch-clamp technique.  Bath application of sparfloxacin, moxifloxacin and grepafloxacin produced an inhibition of HERG outward currents at -40 mV with EC50 of 13.5±0.8, 41.2±2.0 and 37.5±3.3 μg/mL, resp.  Current inhibitions were reversible after washout of the compds.  By contrast, ciprofloxacin at concns. of up to 100 μg/mL did not effect HERG outward currents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou4sWoRGGOsrVg90H21EOLACvtfcHk0lhshK-PP8r3wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlKjtbg%253D&md5=205d18afe8d9b1d9bba4873fc7913e41</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2800%2900693-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252800%252900693-2%26sid%3Dliteratum%253Aachs%26aulast%3DBischoff%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DNetzer%26aufirst%3DR.%26aulast%3DPongs%26aufirst%3DO.%26atitle%3DEffects%2520of%2520fluoroquinolones%2520on%2520HERG%2520currents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D406%26spage%3D341%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Atarashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span> </span><span class="NLM_article-title">Fluorocyclopropyl quinolones. 1. Synthesis and Structure–ctivity Relationships of 1-(2-fluorocyclopropyl)-3-pyridonecarboxylic acid antibacterial agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3444</span><span class="NLM_x">–</span> <span class="NLM_lpage">3448</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00074a027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3444-3448&author=S.+Atarashiauthor=M.+Imamuraauthor=Y.+Kimuraauthor=A.+Yoshidaauthor=I.+Hayakawa&title=Fluorocyclopropyl+quinolones.+1.+Synthesis+and+Structure%E2%80%93ctivity+Relationships+of+1-%282-fluorocyclopropyl%29-3-pyridonecarboxylic+acid+antibacterial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm00074a027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00074a027%26sid%3Dliteratum%253Aachs%26aulast%3DAtarashi%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DA.%26aulast%3DHayakawa%26aufirst%3DI.%26atitle%3DFluorocyclopropyl%2520quinolones.%25201.%2520Synthesis%2520and%2520Structure%25E2%2580%2593ctivity%2520Relationships%2520of%25201-%25282-fluorocyclopropyl%2529-3-pyridonecarboxylic%2520acid%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3444%26epage%3D3448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atarashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsuhiro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span> </span><span class="NLM_article-title">Fluorocyclopropyl quinolones. 2. Synthesis and stereochemical structure–activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">3344</span><span class="NLM_x">–</span> <span class="NLM_lpage">3352</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00046a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=3344-3352&author=Y.+Kimuraauthor=S.+Atarashiauthor=K.+Katsuhiroauthor=K.+Satoauthor=I.+Hayakawa&title=Fluorocyclopropyl+quinolones.+2.+Synthesis+and+stereochemical+structure%E2%80%93activity+relationships+of+chiral+7-%287-amino-5-azaspiro%5B2.4%5Dheptan-5-yl%29-1-%282-fluorocyclopropyl%29quinolone+antibacterial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm00046a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00046a019%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DAtarashi%26aufirst%3DS.%26aulast%3DKatsuhiro%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DHayakawa%26aufirst%3DI.%26atitle%3DFluorocyclopropyl%2520quinolones.%25202.%2520Synthesis%2520and%2520stereochemical%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520chiral%25207-%25287-amino-5-azaspiro%255B2.4%255Dheptan-5-yl%2529-1-%25282-fluorocyclopropyl%2529quinolone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D3344%26epage%3D3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Hoshino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okumura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otani, T.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=65-76&issue=1&author=K.+Hoshinoauthor=K.+Inoueauthor=Y.+Murakamiauthor=Y.+Kurosakaauthor=K.+Nambaauthor=Y.+Kashimotoauthor=S.+Uoyamaauthor=R.+Okumuraauthor=S.+Higuchiauthor=T.+Otani&title=In+vitro+and+in+vivo+antibacterial+activities+of+DC-159a%2C+a+new+fluoroquinolone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DKurosaka%26aufirst%3DY.%26aulast%3DNamba%26aufirst%3DK.%26aulast%3DKashimoto%26aufirst%3DY.%26aulast%3DUoyama%26aufirst%3DS.%26aulast%3DOkumura%26aufirst%3DR.%26aulast%3DHiguchi%26aufirst%3DS.%26aulast%3DOtani%26aufirst%3DT.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antibacterial%2520activities%2520of%2520DC-159a%252C%2520a%2520new%2520fluoroquinolone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26issue%3D1%26spage%3D65%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><div class="note"><p class="first last">SIR92: </p></div><span class="NLM_contrib-group">Altomare, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burla, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascarano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacovazzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagliard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polidori, G.</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301650g&amp;key=10.1107%2FS002188989400021X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SIR92%3A+Altomare%2C+A.%3B+Burla%2C+M.+C.%3B+Camalli%2C+M.%3B+Cascarano%2C+M.%3B+Giacovazzo%2C+C.%3B+Guagliard%2C+A.%3B+Polidori%2C+G.J.+Appl.+Crystallogr.+1994%2C+27%2C+435%E2%80%93435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS002188989400021X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS002188989400021X%26sid%3Dliteratum%253Aachs%26aulast%3DAltomare%26aufirst%3DA.%26aulast%3DBurla%26aufirst%3DM.%2BC.%26aulast%3DCamalli%26aufirst%3DM.%26aulast%3DCascarano%26aufirst%3DM.%26aulast%3DGiacovazzo%26aufirst%3DC.%26aulast%3DGuagliard%26aufirst%3DA.%26aulast%3DPolidori%26aufirst%3DG.%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1994%26volume%3D27%26spage%3D435%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a href="/doi/suppl/10.1021/jm301650g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_02181"></div></div></div></div></div><hr /></hr><p class="last">Crystallographic details for <b>14</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301650g/suppl_file/jm301650g_si_001.pdf">jm301650g_si_001.pdf (46.92 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301650g&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm301650g%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301650g" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                818KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a2bc16bb8d93a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
